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Introduction and outline of this thesis
Congenital heart defects (CHD) are the most common of all congenital defects and affect 
approximately 7-9 per 1000 live born children1. The  collective term CHD is used for a 
combined group of different cardiac lesions that can be anatomically heterogeneous. 
CHD contribute significantly to neonatal mortality, causing a higher infant death rate than 
chromosomal aberrations, sudden infant death syndrome or accidents. In the Netherlands, 
approximately half to 75% of all CHD are detected prenatally, as shown in a large cohort 
from 2002-20122;3. Future parents are increasingly confronted with a (suspected) fetal 
CHD, since the 20 weeks anomaly scan was introduced in 2007. The four-chamber view 
and outflow tracts of the fetal heart are systematically evaluated in this scan to detect 
abnormalities. The defects that are most frequently detected prenatally are severe 
CHD; severe is internationally defined as requiring percutaneous intervention or surgery 
in the first year of life. Examples are hypoplastic left heart syndrome (HLHS; figure A), 
transposition of the great arteries (TGA; figure B), double outlet right ventricle (DORV) 
and Tetralogy of Fallot (TOF; figure C), but the spectrum of (severe) CHD is very wide. In 
general, a prenatal diagnosis of CHD means that future parents can anticipate, but more 
importantly, that adequate medical measures can be taken once the baby is born. Especially 
in cases of TGA and HLHS it has been proven that prenatal detection is associated with 
lower postnatal mortality and morbidity4. A prenatal diagnosis of severe CHD might also 
prevent neurological injury due to acute severe hypoxia after birth in undetected cases5.
COUNSELING
In the prenatal setting, the estimation of the severity and impact of the CHD is based 
on the nature of the defect and the presence of associated extracardiac and/or 
chromosomal abnormalities. Future parents receive comprehensive tailored counseling, 
including what can be expected postnatally with respect to surgery, survival chances, 
admission to the neonatal intensive care unit, administered medication and the possible 
necessity of emergency interventions like balloon atrial septostomy. Of course, there are 
levels of uncertainty in this prognosis, as the postnatal course can vary from case to case. 
In some cases parents opt for termination of pregnancy, which is chosen in approximately 
25% of prenatally detected severe CHD. Termination of pregnancy is performed most 
frequently when there is a suspicion of a coinciding syndromic abnormality or when the 
CHD is in the severest spectrum such as HLHS and other univentricular heart defects. 
Approximately 5% of CHD will lead to intrauterine death, which is sometimes the 
result of cardiac decompensation with hydrops, but it can also occur unexpectedly2. 
Depending on the severity of the CHD, postnatal death in the first year of life occurs in 
approximately 6-20% of severe CHD6. The mortality rates depend on the type of CHD; 
12
1
INTRODUCTION AND OUTLINE OF THIS THESIS
Figure A: hypoplastic left heart syndrome
Figure B: transposition of the great arteries
Figure C: tetralogy of Fallot
Figures A-C are reprinted from the American Heart Association
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in HLHS the highest mortality occurs. When a child with HLHS survives pregnancy and 
the first week of life to undergo the first stage of a three-step surgical repair process, 
approximately 70% will be alive at the age of 1 year old7. The long-term outcome of CHD 
is partly uncertain, because cardio-surgical techniques continue to evolve. In the last 
decades there has been a trend of improving survival of children with severe CHD. The 
focus for innovation in the care for infants with CHD is therefore shifting to quality of 
life, neurodevelopment and (cardiovascular) complications at adolescence or older age. 
 
ISOLATED VERSUS SYNDROMIC
Based on postnatal studies it is know that in approximately 30% the CHD is part of a 
genetic syndrome8. The most common genetic abnormalities associated with CHD are 
Down syndrome (trisomy 21) and Di George syndrome (22q11 microdeletion). However, 
many more genetic abnormalities are associated with CHD, such as other aneuploidies 
like Turner syndrome (monosomy X), microdeletion/-duplication syndromes like Williams-
Beuren, and monogenetic syndromes like Noonan, Kabuki, Holt-Oram and CHARGE. To 
illustrate the magnitude and the diversity of the subject, the scientific statement “the 
genetic basis of CHD” issued by the American Heart Association and updated in 2018 
comprises as many as 60 pages. In cases with genetic syndromes usually extracardiac 
abnormalities are present, such as renal dysplasia, hemivertebra, abnormal extremities, 
dysmorphic facial features and neurodevelopmental (ND) delay. If a fetal CHD is 
accompanied by a genetic abnormality, an additional extracardiac abnormality is seen on 
prenatal ultrasound in approximately 60-65% of cases2. In CHD children without genetic 
abnormality, however, extracardiac abnormalities can also be present, as Egbe reported 
11% additional abnormalities in children with CHD born without a genetic syndrome9. In 
the antenatal phase, the presence of additional extracardiac abnormalities is therefore 
highly suspicious for genetic syndromes, but not pathognomic. It is important to realize 
that prenatal ultrasound cannot detect (mild) dysmorphic facial features or neurological 
developmental disorders, and genetic syndromes can still be present in the absence of 
extracardiac abnormalities.
The presence of a genetic syndrome influences the postnatal prognosis. For example, in 
children with 22q11 microdeletion syndrome perioperative complication, such as airway 
problems and infections,  are more common and long-term survival is lower10;11. Thus, 
genetic testing is important in the prenatal phase, to be able to provide proper risk 
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There are several diagnostic genetic tests available, with varying resolutions and 
detection rates. The traditional karyogram is suitable to detect aneuploidies (trisomy/
monosomy) and large deletions or duplications (size 5-10.000.000 base pairs). Until a 
few years back, karyotyping was the only option for prenatal genetic analysis. However, 
the molecular cytogenetic tests available nowadays enable us to study the genome 
in a higher resolution: array comparative genomic hybridization (array CGH, also 
known as micro-array) has evolved from bacterial artificial chromosome (BAC) array 
(resolution 1.000.000 base pairs), to oligonucleotide (resolution 30-50 base pairs) to 
even single nucleotide polymorphisms (SNP) array and next generation, whole exome 
or whole genome sequencing (NGS/WES/WGS) (resolution 1 base pair). These new 
tests can yield many copy number variants (CNVs) or point mutations, enabling accurate 
and comprehensive diagnosis of known syndromes and diseases such as Di George or 
Noonan syndrome. However, these more detailed genetic examinations have certain 
disadvantages as well. CNVs or smaller mutations also frequently occur in apparently 
healthy individuals, and some are considered ‘variants of unknown significance’ (VUS), 
indicating that its pathogenicity is unknown. This complicates the interpretation of the 
found genetic profile and makes counseling difficult, especially in the prenatal phase in 
which the phenotype can be incomplete. Counseling by a clinical geneticist is therefore 
of great importance in the event of an abnormal genetic profile - or any suspected 
syndromic disorder based on extracardiac abnormalities - because different syndromes 
may exhibit different penetrance, phenotypes and neurological development. 
Currently, most prenatal centers in the Netherlands offer micro-array with a (reported) 
resolution up to 150.000 base pair. Whole exome sequencing (WES) is possible and 
performed incidentally, because the time window to generate and interpret the results 
has been reduced drastically the last few years, but it is not routinely performed 
prenatally yet. This is changing rapidly with the evolution of new laboratory techniques 
and the accelerating amount of knowledge and experience that has been acquired. 
Targeted testing for point mutations such as Noonan syndrome or CHARGE is possible, 
but rarely done because specific signs of these syndromes often lack prenatally. 
 
NEUROLOGICAL OUTCOME
With the improving survival of children with CHD, the focus of research has shifted 
to the long-term and neurodevelopmental (ND) outcome. Even in the absence of 
chromosomal or syndromic abnormalities, ND delay may occur, especially in severe 
CHD cases. Large follow-up studies show that global ND delay occurs in 23% of children 
15
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with severe ‘isolated’ CHD, and 25% exhibit some kind of behavioral problem12. These 
ND impairments in CHD children are considered the result of cerebral injury, mostly 
sustained in the perioperative  period. ND delay is associated with the cardiopulmonary 
bypass time, the type of surgery and the method of anesthesia. Two causative mechanism 
contributing to the cerebral injury are hypoxia and thrombo-embolic events in the 
brain13. The risk for ND delay can therefore roughly be predicted by the severity of the 
CHD and the complexity and number of the operation(s). Additional research, however, 
has shown that in certain patients some level of ND delay and cerebral ‘damage’ is 
already detectable before surgery, indicating that the ND impairments might have their 
origin in the prenatal or perinatal period14. This theory is supported by reports of small 
head circumference at birth (below the 10th percentile) in 25-36% of neonates with 
severe CHD. It was found that 40-55% of neonates show abnormalities at neurological 
examination (such as abnormal tonus, absent sucking reflex) prior to surgery15. Imaging 
studies also reported abnormalities before surgery, such as cerebral atrophy on 
ultrasound in 27% of the infants, and ischemic lesions on MRI in 21-41% of cases. These 
studies unfortunately rarely report whether the CHD was detected antenatally or not, 
and no studies are performed in prenatally detected CHD only. Nonetheless, one of 
the postulated theories is that altered blood flow in the heart and vessels in fetuses 
with severe CHD, results in a reduced amount of oxygen-rich blood in the fetal brain, 
resulting in chronic brain hypoxia16. See figure D for illustration. The assumption is that 
in the normal fetal circulation (left) the oxygen-rich blood from the inferior caval vein is 
shunted to the left side to reach the brain first. Subsequently, fetuses with TGA (second 
from the left) are hypothesized to receive blood with the lowest level of oxygenation in 
the brain, as result from the abnormal connection to the ventricles (the shunted blood 
reaches the pulmonary system first). Fetuses with univentricular heart defects (such as 
HLHS, third from the left)) or large ventricular defects (such as DORV and TOF, right) are 
considered to receive mixed oxygenated blood in the brain due to ventricular mixing of 
the shunted blood with the low-oxygen blood. In cases of reversed aortic arch flow (left 
ventricle obstruction such as HLHS) the restriction of flow to the carotid arteries would 
additionally lead to cerebral oxygen deficiency. As a result of this ‘altered hemodynamics 
theory’, it is hypothesized that the brain development and growth is restricted in CHD, 
which results in prenatally altered development of the brain or reduced head size, in 
some cases even fetal microcephaly. 
16
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Figure D: Illustration of the altered hemodynamics theory in a normal heart, TGA, HLHS and 
TOF. Reprinted from Sun et al.17
Research in this area - altered cerebral development in fetal CHD - seems to be biased 
towards the severest types of CHD, consisting of inhomogeneous groups and varying 
definitions of heart defects, which makes comparison difficult. Also, the association of 
prenatal cerebral abnormalities and variations with long-term ND outcome is difficult to 
investigate and has rarely been reported on. ND outcome can only be assessed reliably 
once the child is 2-4 years old and is majorly influenced by perioperative factors. Also, 
there are many confounders like parental socio-economic status, need for additional 
cardiac interventions, etcetera, and cohorts would need to be immense to correct for 
this. Thus, in the absence of genetic syndromes, there are no known prenatal predictors 
for postnatal ND outcome. 
It is known that parents of children with CHD worry about the (neurological) development 
of their child, and a vast amount of these children receive additional care such as 
remedial teaching, physical or logopedic therapy12. Future parents also worry about this, 
and usually ask the perinatologist and fetal cardiologist how his/her child will do in later 
life. Currently, the International Society for Ultrasound in Obstetrics and Gynecology 
(ISUOG) advices to counsel future parents on this topic as follows18: ‘…the majority of 
fetuses/neonates with isolated CHD do well. However, there is evidence that some 
have a degree of ND delay, which cannot be predicted antenatally. The severity of this 
impairment varies from individual to individual, and the likely incidence varies with the 
type of CHD, being highest (up to 40–45% in some studies) in lesions with univentricular 
heart hemodynamics such as HLHS. We advise genetic investigations, including array‐
CGH to rule out associated and syndromic forms of CHD.’ 
17
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CHD are associated with chromosomal and syndromic abnormalities, as well as ND delay. 
In the prenatal phase however, the prevalence of genetic syndromes or risks of being 
affected by cerebral maldevelopment is still largely unknown. In many cases, when a 
CHD appears to be isolated, it is often assumed to be isolated. The aim of this thesis 
was to explore whether prenatally appearing isolated CHD are really isolated – without a 
genetic syndrome or a maldeveloped brain.
Part I explores the additional value of a array CGH and WES, two methods of genetic 
analysis with notable higher resolution than conventional karyotyping. In chapter 2, 
a systematic review and meta-analysis of the literature on array CGH in fetal CHD is 
presented. In chapter 3 the additional value of array CGH is assessed in a subgroup 
of CHD, left sided CHD, historically assumed to have a low prevalence of syndromic 
anomalies - when Turner syndrome is excluded. Chapter 4 describes an unusual case of 
a fetus with a small ventricular septal defect (VSD) and additional abnormalities. VSDs 
occur frequently and are usually innocent. However, in this case, additional abnormalities 
were found and indicated an underlying mitochondrial disease – identified with WES.
The second part of this thesis assesses prenatal and early postnatal brain development 
in CHD. In chapter 5, a systematic review and meta-analysis of prenatal cerebral 
development and cerebral variations in CHD is presented. Chapter 6 shows the results 
of a retrospective analysis of head circumference growth in a large cohort of fetal 
CHD, with a referee commentary on our study by the reviewing editor of the journal 
in which the paper was published. Chapters 7 and 8 describe analyses of a prospective 
cohort of isolated CHD cases compared to healthy controls, in which we performed 
extensive monthly neurosonography (the Heart And NeuroDevelopment (HAND) study). 
In chapter 7  the results of the volume measurements of the brain between 18 and 32 
weeks of gestation are shown, exploring the prenatal cerebral growth and evolution 
of the extracerebral fluid compartments. Chapter 8 describes early postnatal cranial 
ultrasound findings and measurements, comparing prenatally detected CHD cases with 
healthy controls. 
Chapter 9 presents a general discussion of the combined results of these studies, and 
chapter 10 is a general summary.
18
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Additional remarks on ethical and legal aspects
In the Netherlands, there are several laws and guidelines regulating medical research; 
the most important being the WMO (‘law on medical research’). When fetal samples are 
taken - to analyze the genetic material for example - there might be left over material. 
This left over material can be used in medical research exempt from the WMO. Patients 
can object to the use in medical research when the sample is gathered, but they have to 
actively opt out themselves. This implicates that there is no need to request permission 
from the individual patients, as long as the patient has not objected, outcomes are not 
retraceable to individual patient data, and the additional analyses are performed on 
anonymized material. This was the case in chapter 3.
Observational studies with fetuses are prohibited by the ‘embryowet’ (2002). Therefore 
all fetal data analyzed in this thesis (chapters 6, 7, 8) were collected in the routine care 
for fetuses with CHD, and were therefore exempt from the WMO. The prospective 
inclusion of the healthy control group (chapters 7, 8) was only possible after a slight 
liberalization of the ‘embryowet’ in 2014, making it possible to perform observational 
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heart disease: impact on prenatal counseling. 






Genetic anomalies in fetal congenital 
heart disease: beyond fetal karyotype

CHAPTER 2
Array Comparative Genomic 
Hybridization and Fetal Congenital 
Heart Defects - A systematic 
review and meta-analysis










Array comparative genomic hybridization (aCGH) is a molecular cytogenetic technique 
that is able to detect the presence of copy number variants (CNVs) within the genome. 
The detection rate of imbalances of aCGH compared to the standard karyotype and FISH 
22q11 in the setting of prenatally diagnosed cardiac malformations has been reported 
in several studies. The objective of our study was to perform a systematic literature 
review and meta-analysis to document the additional diagnostic gain of aCGH in cases 
of congenital heart disease (CHD) diagnosed on prenatal ultrasound, in order to assist 
clinicians to determine whether aCGH analysis is warranted when ultrasonographic 
diagnosis of CHD is made, and to guide counseling in this setting.
Methods
All articles in the PubMed, Embase and Web of Science database from January 2007 to 
September 2014 describing CNVs in prenatal cases of CHD were included. Search terms 
were: array comparative genomic hybridization, copy number variants, fetal congenital 
heart defects. Articles regarding karyotyping or 22q11 deletion only were excluded.
Results
Thirteen publications met the inclusion criteria for the analysis. Meta-analysis indicates 
an incremental yield of 7.0% (95% CI 5.3; 8.6) by aCGH, after exclusion of aneuploidy and 
22q11 microdeletion. Subgroup results show 3.4% (95% CI 0.3; 6.6) incremental yield in 
isolated CHD and 9.3% (95% CI 6.6; 12) when extracardiac malformations are present. 
Overall incremental yield of 12% (95%CI 7.6; 16) was found including 22q11 deletion. 
There was an additional yield of 3.4% (95%CI 2.1; 4.6) of variants of unknown significance 
(VOUS).
Discussion
In this review, we provide an overview of published data and discuss benefits and 
limitations of aCGH. If karyotyping and 22q11 microdeletion analysis by FISH are 
normal, aCGH has an additional value, detecting pathogenic CNVs in 7.0% of prenatally 
encountered CHD, with a 3.4% additional yield of detecting VOUS.
2
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INTRODUCTION
Congenital heart disease (CHD) is the leading cause of non-infectious neonatal mortality, 
affecting up to 1% of newborns. For most CHD, surgical repair or palliation is now possible 
with good outcome1. In some cases, however, the prognosis is dominated by the presence 
of chromosomal or extra-cardiac malformations2-4. In the prenatal setting the incidence 
of chromosomal anomalies is reported to be as high as 18-22% of all CHD, most being 
trisomy 21, trisomy 18, and 22q11 microdeletion5-7. Furthermore, fetuses with CHD carry 
a residual risk of additional genetic anomalies including microdeletion or –duplication 
syndromes such as Williams-Beuren and Potocki-Lupski or monogenetic anomalies such 
as Noonan syndrome.8;9 
Providing information about the association of CHD with additional anomalies is 
important when counseling future parents.  Assessing the presence of a pathogenic 
copy number variant (CNV) is crucial for prognostic purposes, given that the risk of 
non-iatrogenic neurological impairment is increased even in apparently isolated CHD10. 
Prenatal diagnosis of genetic conditions can also influence treatment plans2;4. In certain 
types of severe CHD, the interval between delivery and the necessary surgical procedure 
can be short, highlighting the importance of prenatal testing.
Cytogenetic fetal karyotyping used to be the gold standard of prenatal genetic testing. 
Karyotyping is able to detect aneuploidy and large chromosomal rearrangements up to 
5-10 Mb. Array comparative genomic hybridization (aCGH) is a cytogenetic molecular 
technique that detects the presence of CNVs within the genome with increased 
resolution, a much higher resolution then conventional karyotyping, depending on the 
probe spacing and platform used. 
Reports detailing the incremental yield of aCGH in the prenatal setting are rapidly 
emerging11-22. Most published reports include large cohorts, but describe the incremental 
yield for a variety of indications. Subgroup analysis of (different types of) CHD, the most 
common structural abnormality detected in the prenatal setting, is rarely reported. In 
this review, we describe the incremental yield of aCGH in prenatally diagnosed CHD.  Our 
goal was to assist clinicians in determining whether aCGH is warranted once the diagnosis 
of a fetal CHD is made, and to guide them as they counsel future patients in this setting. 
27
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Figure 1: Flow-chart showing inclusion of studies in the review. CHD, congenital heart defects; 
MLPA, multiplex ligation-dependent probe amplification.
METHODS
A literature review was performed conforming to the Database of Abstracts of Reviews of 
Effects (DARE) criteria23. We conducted a systematic search of the PubMed, Embase and 
Web of Science databases from January 2007 to September 2014, using search terms array 
comparative genomic hybridization, copy number variants, prenatal or fetal malformations 
and congenital heart defects, with related search terms (complete search string available 
in Appendix S1). There was no language restriction to our search. The extracted articles 
were evaluated for relevance by two  independent researchers (FJ and MH). Eligible titles 
were identified and further screened based on the abstract. Non-English abstracts were 
assessed by a relevant native speaker. Only original research articles discussing the yield 
of array analysis in the prenatal setting were reviewed for the full text. If a (sub) group 
of CHD could be identified in the published data, the article was included. Genetic locus 
association studies in familial occurrence of CHD and case reports were excluded. We 
analyzed references of eligible articles for further inclusions. Data on inclusion criteria, 
patient characteristics (type of defect, presence of multiple malformations), array 
resolution, methods of CNV interpretation, and postnatal confirmation of the heart defect 
were extracted from the publications. Details of all reported aCGH anomalies were assessed 
by two authors independently (FJ and JC) to evaluate clinical significance. Raw data of one 
publication16 was provided by AF. Incremental yield of aCGH was defined as the yield over 
28
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karyotyping only, or over karyotyping and FISH 22q11 combined. The incremental yields from 
each study were pooled to estimate an overall and subgroup incremental yield of aCGH 
using RevMan version 5.3.4 (Review Manager, The Cochrane Collaboration, Copenhagen, 
Denmark) and 95% CIs were computed. Studies with fewer than 20 cases were excluded 
from the meta-analysis. Statistical heterogeneity was examined using Higgins I2 (quantitative) 
test. To take into account the low statistical power of tests of heterogeneity, we considered 
statistically significant heterogeneity as Cochran’s Q test with a P<0.1 or I2 greater than 30%. 
A random effects model was used when there was significant heterogeneity. We assessed 
publication bias graphically using funnel plots. We assessed study quality based on the 
factors we considered most likely to threaten study validity (Table S1).
RESULTS
The search revealed 751 studies, of which 13 primary articles (including 1131 CHD cases) 
met the final inclusion criteria (figure 1)7;12-16;24-30. We encountered no overlapping 
populations among the studies selected. The funnel plot suggesting publication bias is 
showed in figure 2. Table 1 displays characteristics of the studies, including study design, 
resolution of array and number of assessed cases. 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PART I: GENETIC ANOMALIES
Details of included studies and the meta-analysis are shown in tables 2-4 and figures 3 
and 4. There were 120 aCGH anomalies and these varied between 0.85kb29 and 14.9Mb7 
in size and are listed in Table S2. The pooled results from the  seven studies that included 
>20 cases (Table 2) indicate that the incremental yield of aCGH after karyotyping and 
FISH 22q11 is 7.0% (95% CI 5.3; 8.6) (figure 3). The incremental yield over karyotyping 
alone, including the yield of 22q11 microdeletions, is also summarized in table 2. Pooled 
results of five studies indicate an incremental yield of 12% (95%CI 7.6; 16) for isolated 
and non-isolated CHD combined. One study was excluded from this sub-group analysis 
owing to small sample size13. The additional yield of aCGH detecting variants of unknown 
significance (VOUS) was 3.4% (95% CI 2.1; 4.6).
The incremental yield of aCGH varied depending on the presence or absence of 
extracardiac malformations and/or soft markers. Most authors reported on subgroups 
of isolated and non-isolated CHD. However, whether additional minor malformations and 
soft markers were included in the isolated or non-isolated groups varied. For isolated 
CHD pooled results from six studies that included >20 cases (table 3) indicate that the 
incremental yield of aCGH after karyotyping and FISH 22q11 was 3.4% (95% CI 0.3; 6.6) 
(figure 4). Two studies were excluded from this sub-group analysis owing to small sample 
size14;30. Statistical tests for variation in outcomes between studies showed significant 
heterogeneity. For non-isolated CHD, summarized and pooled results are shown in table 
4. Forest plots of all subgroups are shown in figure S1.




Table 2: Results of aCGH in fetuses with CHD (no aneuploidy)
























Tyreman 2009 1/32 0.03 (-0.05; 0.11) 5/34*
0.15 
(0.02; 0.27) 3/32 a
2 HLHS, 
1 VSD 1/3
Shaffer 2012 19/569 0.03 (0.02; 0.05) 46/580
0.08 






Lee 2012 0/45 0.00 (-0.04; 0.04) 6/49+
0.12 
(0.03; 0.22) 2/45+ a
1 TOF, 
1 VSD 1/2
Schmid 2012 3/12°  0.25†(-0.01; 0.51) - - 3/12 a
2 VSD, 
1 CAT 3/3















+ a 2 TOF 0/2
Donnelly 2014 5/146 0.03 (0.00; 0.07) 19/154
0.12 
(0.07; 0.18) 11/146 a
2 VSD, 
2 CoA, 




Chen 2014 n.s. - - - 3/8§ a 1 TOF, 1 TGA, 1 iAA n.s.
Liao 2014 5/94 0.05(0.00; 0.10) 17/99‡
0.17 











+ MA, 1 VSD 
+ PLVCS, 
1 PS + VSD
2/5
Pooled result           0.03 (0.00; 0.07)=
                                           I2 0%
0.12 (0.08; 0.16)×
I2 53% a
a plotted in forest plot figure 3, * in some cases 22q11 microdeletion was already excluded by FISH, 
+ abnormal karyotype not completely excluded in this CHD group, † not included in pooling, ° at 
resolution 50-200kb, § conotruncal malformations only, ‡ minor cardiac malformations also included as 
CHD, = fixed effects model; x random effects model
Numbers indicate patients, as multiple array malformations can occur within one patient
VOUS variants of unknown significance, CNV copy number variants, n.s. not stated, HLHS hypoplastic left 
heart syndrome, VSD ventricular septum defect, TOF tetralogy of Fallot, AVSD atrioventricular septum 
defect, DORV double outlet right ventricle, PS pulmonary stenosis, TGA transposition of the great arteries, 
CoA coarctation of the aorta, sv single ventricle, iAA interrupted aortic arch, PLVCS persistent left vena 
cava superior, MA mitral atresia, CAT common arterial trunk
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Figure 4: Pooled results of yield over karyotyping and FISH 22q11, isolated CHD only













CHD in cases with 
pathol. CNV
Shaffer 2012 9/236 6/237§ 0.03 (0.00; 0.05) 5/236§ b 4 HLHS, 1 n.s.
Schmid 2012 1/7 - - 0 / 7 b -
Faas 2012 0/9 1/10 0.10+ (-0.14; 0.34) 0/9 b -
Hillman 2013 1/37 4/41 0.10 (0.00; 0.20) 0/37 b -
Mademont-Soler 2013 n.s. - - 0 / 28† b -
Donnelly 2014 1/64 6/66 0.09 (0.02; 0.16) 4/64 b 1 VSD, 1 CoA, 2 n.s.
Liao 2014 n.s. 10/69 0.14 (0.06; 0.23) 7 / 66 b
2 VSD, 1 AVSD,  
1 sv+TGA, 1 iAA, 
2 minor CHD
Yan 2014 3/49 - - 3/49 b







b plotted in forest plot figure 4, § 44 cases included with additional non-structural defects, + not included in 
pooling
† including unknown no of cases with cardiac markers , ° random effects model, Numbers indicate patients, as 
multiple array malformations can occur within one patient.
VOUS variants of unknown significance, CNV copy number variants, n.s. not stated, n.a. not applicable, HLHS 
hypoplastic left heart syndrome, DORV double outlet right ventricle, MA mitral atresia, VSD ventricular septum 
defect, PS pulmonary stenosis, TOF tetralogy of Fallot, sv single ventricle, TGA transposition of the great arteries, 
iAA interrupted aortic arch, CoA coarctation of the aorta, HRHS hypoplastic right heart syndrome
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yield excl. 22q11 
(95%CI)
CHD in cases 
with pathol. 
CNV
Schmid 2012 2/5 - - 3/5+ 0.60 (-0.15; 1.05) 2 VSD, 1 CAT
Shaffer 2012 10/343 40/343 0.12 (0.08; 0.15) 30/333 0.09 (0.06; 0.12)
7 HLHS, 5 TOF, 14 
VSD,  4 other
Mademont-Soler 
2013
n.s. - - 2/23†‡ 0.09 (-0.05; 0.22)
1 TOF, 1 unbal-
anced AVSD
Yan 2014 1/27 - - 2/27 0.07 (-0.04; 0.19)
1 HLHS, 
1 VSD+PLVCS
Liao 2014 n.s. 7/30*‡ 0.23 (0.08; 0.39) 5/28*‡ 0.18 (0.03; 0.33)
1 CoA, 1 PS, 
1 VSD, 1 PLVCSS
Donnelly 2014 4/82 13/88‡ 0.15 (0.07; 0.22) 7/82‡ 0.09 (0.02; 0.15)
1 VSD, 1 CoA, 







       I2 0% 
§ with additional, extracardiac defects,  + not included in pooling, † including unknown no of cases with 
cardiac markers, * minor cardiac malformations also included as CHD, ‡ fetuses with additional soft markers 
included in non-isolated group, ° fixed effects model
Numbers indicate patients, as multiple array malformations can occur within one patient.
VOUS variants of unknown significance, CNV copy number variants, n.a. not applicable, VSD ventricular 
septum defect, CAT common arterial trunk , HLHS hypoplastic left heart syndrome, TOF tetralogy of Fallot, 
PLVCS persistent left vena cava superior, CoA coarctation of the aorta, PS pulmonary stenosis, AVSD atrio-
ventricular septum defect
Two studies reported on subgroups of specific cardiac lesions. Combined results from 
these two studies are not eligible for meta-analysis. Shaffer et al.16 reported separately on 
groups with n>20 in their cohort: hypoplastic left heart syndrome (HLHS), tetralogy of Fallot 
(TOF), ventricular septal defect (VSD) and dextrocardia/situs inversus (d/SI). In 42 isolated 
HLHS cases, aCGH had a yield of 10% (n=4), and all anomalies were <10Mb in size. No aCGH 
anomalies were detected in 18 fetuses with isolated TOF, 38 fetuses with isolated VSDs or 21 
fetuses with isolated d/SI.  In the subgroup of fetuses with multiple structural malformations 
the yield of clinically significant CNVs was higher, but this also included anomalies >10Mb in 
size. Significant findings were found in 7/26 non-isolated HLHS (27%), 5/25 non-isolated 
TOF (20%), 14/94 non-isolated VSD (15%) and 1/27 non-isolated d/SI (3.7%). 
Donnelly et al.24 analysed subgroups of four-chamber view malformations, outflow tract 
malformations, TOF and heterotaxia. The authors however did not elaborate on the 
specific method of subgrouping. In the category of isolated outflow tract malformations 
(aortic stenosis, coarctation or interruption, transposition of the great arteries, common 
arterial trunk) an incremental yield of 30% (n=3/10) was found; 22q11 deletions were not 
among these three CNVs. The incremental yield excluding 22q11 deletion in the other 
subgroups could not be extracted. 
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DISCUSSION
Considering the association of genetic anomalies with CHD, and the implications on both 
prenatal and postnatal management, obtaining the most accurate and detailed genetic 
information in the prenatal setting is important for both patients and providers. 
In this systematic review, aCGH yielded additional clinically valuable information in 7.0% 
(95% CI 5.3; 8.6) of fetal CHD cases, even after karyotyping and FISH 22q11 analysis were 
normal. This includes both causative aCGH anomalies as well as incidental but clinical 
relevant findings, such as high risk for neurodevelopmental delay. The additional yield of 
VOUS was 3.4% (95%CI 2.1; 4.6). 
In particular, there were more pathogenic CNV when extracardiac defects were 
present; estimated 9.3% (95% CI 6.6; 12). This yield appears lower when compared with 
published reports of aCGH in the postnatal setting, which describe yields of 17-53% 
in CHD with extracardiac malformations, neurodevelopmental delay and/or dysmorphic 
features32-39. This discrepancy can be attributed to non-comparable cohorts. There may 
be an ascertainment bias of cases in the postnatal groups that already present with 
neurodevelopmental delay or dysmorphic features. 
When analyzing isolated CHD an incremental yield of 3.4% (95% CI 0.3; 6.6) was found. 
In postnatal cohorts of isolated CHD with normal karyotype and 22q11 analysis, the yield 
appears to be somewhat lower, 0-4%35;40-44. This small difference may be due to the 
limitation of prenatal ultrasound in detecting dysmorphic features and other subtle 
expressions of syndromic anomalies45.
It seems that VSDs (mainly perimembranous46) with extracardiac malformations, 
conotruncal malformations (TOF, interrupted arch) and left ventricle outflow tract 
malformations are common in prenatal cases which yield pathogenic aCGH results. Even 
transposition of the great arteries and heterotaxia, which are not considered to be 
associated with chromosomal anomalies by karyotyping, were found to have pathogenic 
aCGH results. However, the reported CHD with aCGH anomalies are very heterogeneous, 
and subgroups of different types of CHD are not large enough to analyse separately. 
Moreover, the categorisation of CHD is not consistent in the different reports, which 
inhibits calculation of the yield per specific CHD.  Our recommendation therefore is to 
offer aCGH in all types of CHD.
In addition to submicroscopic anomalies <5-10 Mb in size, aCGH also yields anomalies 
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>10Mb. For example, karyotype failed to detect a large 14.9 Mb deletion, detected 
subsequently by aCGH7. Shaffer et al. reported the yield >10Mb separately. This 
emphasizes that karyotyping does not detect 100% of anomalies >10Mb in size, and 
aCGH may be a more reliable method of detecting these mutations47.
The possibility of aCGH replacing FISH 22q11 analysis in the prenatal setting of CHD merit 
consideration. The reported prevalence of 22q11 microdeletion in fetal CHD is as high as 
7%7 ,with aortic arch and conotruncal malformations having the highest yields9;48. FISH 
22q11 analysis is therefore already an important part of the diagnostic genetic work up in 
cases of isolated and non-isolated CHD. An important benefit of aCGH over FISH analysis 
for 22q11 microdeletions was noted by Chen29, reporting on 2 deletions in the 22q11 
region which were not detected by FISH.
The limitation of our review is that pooled results are predominantly influenced by 
the report from Shaffer16, which has considerable uncertainty regarding confirmation 
of diagnosis. Furthermore, publications show large variability in the size of the cohort, 
platforms used, patient characteristics, and classification of extracardiac malformations. 
This results in high rates of statistical heterogeneity, especially in the isolated CHD 
subgroup. The process of interpreting CNV as pathogenic or benign is not always described 
and seems to vary significantly between the different groups. Larger prospective 
cohorts, focusing further on different types of CHD, are therefore warranted. Questions 
regarding the optimal probe spacing, platform and resolution, as well as the method of 
CNV categorization into benign and pathogenic, remain important. 
There are some limitations of aCGH to be considered. First of all, the detection of VOUS 
could lead to challenges in counseling and parental anxiety. Combining data from large 
cohorts and linking certain aCGH anomalies with specific anatomic malformations could, 
however, increasingly reduce the frequency and clinical ambiguity of VOUS, for providers 
and their patients. Also, comparison with parental aCGH results can aid in detecting 
VOUS which are inherited from presumably healthy parents, therefore being less likely to 
be pathogenic. From our review it appears  that studies that routinely performed aCGH 
of both parents, encountered a lower frequency of VOUS.  
Secondly, clinicians should also be aware that single-gene disorders are also associated 
with CHD and they will not be detected by aCGH. These remain to be screened for 
individually on a case-by-case indication, until whole genome sequencing is available 
in the prenatal setting. Moreover, triploidies, chromosomal inversions and balanced 
translocations will not be detected by aCGH. Considerations for karyotype replacement 
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by aCGH should therefore include an additional rapid method of aneuploidy/triploidy 
detection (RAD) such as quantitative fluorescent polymerase chain reaction17. Detection 
of balanced translocations and inversions does not seem a solid reason to perform 
complete karyotyping, as those chromosomal rearrangements will be detected if 
accompanied by a small deletion. Furthermore, if they are truly balanced, they are most 
probably not causative for CHD.
For pre-test counseling purposes results can be summarized as follows: the chance 
of finding an aCGH anomaly in prenatal CHD (including 22q11) is approximately 14% in 
total; 3% VOUS, 4% microdeletion 22q11 and 7% other pathogenic CNVs. In cases of 
isolated CHD with normal karyotype and 22q11 microdeletion analysis by FISH, the yield 
of additional aCGH has not yet been firmly established, but may be approximately 3%. 
In non-isolated cases, this yield is more evident, approximately 9%. In our opinion, 
given the available data, aCGH should be considered in cases of prenatally diagnosed 
fetal cardiovascular malformations, even if the lesion is apparently isolated based on 
prenatal imaging. As the common aneuploidies are most frequently associated with CHD, 
especially in cases of additional extra-cardiac malformations, aCGH can be considered 
if RAD results are normal, in order to reduce healthcare utilization and costs. However, 
local practices, the gestational age of the pregnancy, and regulations on pregnancy 
termination may lead providers to consider RAD and aCGH concurrently.  
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CHAPTER 3
Chromosomal abnormalities and copy 
number variations in fetal left sided 
congenital heart defects
Prenatal Diagnosis 2016; 36: 177–185
ABSTRACT
Objectives
To demonstrate the spectrum of copy number variants (CNVs) in fetuses with isolated 
left sided congenital heart defects (CHDs), and analyze genetic content. 
Methods
Between 2003 and 2012, 200 fetuses were identified with left sided CHD. Exclusion 
criteria were chromosomal rearrangements, 22q11.2 microdeletion and/or extra-cardiac 
malformations (n=64). We included cases with additional minor anomalies (n=39), such 
as single umbilical artery. In 54 of 136 eligible cases, stored material was available for 
array analysis. CNVs were categorized as either (likely) benign, (likely) pathogenic or of 
unknown significance.
Results
In 18 of the 54 isolated left sided CHDs we found 28 rare CNVs (prevalence 33%, average 
1.6 CNV per person size 10.6kb – 2.2Mb). Our interpretation yielded clinically significant 
CNVs in two of 54 cases (4%) and variants of unknown significance in three other cases 
(6%).
Conclusions
In left sided CHDs that appear isolated, with normal chromosome analysis and 22q11.2 
FISH analysis, array analysis detects clinically significant CNVs. When counselling parents 
of a fetus with a left sided CHD it must be taken into consideration that aside from the 
cardiac characteristics, the presence of extra-cardiac malformations and chromosomal 
abnormalities influence the treatment plan and prognosis. 
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INTRODUCTION
Congenital heart defects (CHDs) are the most prevalent congenital malformations and 
occur in 6-8 per 1000 neonates1. The  collective term CHD is used for a combined group 
of different cardiac lesions that can be anatomically heterogeneous. Abnormalities of 
the left ventricular outflow tract constitute roughly 10% of all neonatal CHDs and 20% 
of all CHDs detected prior to birth2. The spectrum of left sided CHDs varies from a 
bicuspid aortic valve, without clinical symptoms, to hypoplastic left heart syndrome 
(HLHS), leading to neonatal death if left untreated. Children with HLHS require a single 
ventricle palliation associated with considerable mortality and long-term morbidity3. 
Other left sided CHDs, like critical aortic valve stenosis or coarctation of the aorta, call 
for immediate postnatal intervention but, if treated in time, have a better prognosis.
CHDs in general present as either an isolated anomaly or as part of a malformation 
syndrome with chromosomal and/or extra-cardiac malformations. The rates of 
association with genetic syndromes vary, depending on the type of CHD. In children 
with HLHS it has been described that 5-12% of cases are associated with chromosomal 
or syndromic abnormalities3;4, including Turner syndrome (monosomy X), 22q11.2 
microdeletion syndrome and Jacobsen syndrome (11q deletion). Providing information 
about the association of CHDs with these syndromes is important when counselling 
future parents, given the influence of genetic conditions on surgical success and long-
term outcome5;6. Most syndromes are detectable after birth and/or display multiple 
malformations. However, prenatal ultrasound cannot identify all signs of syndromes 
such as dysmorphic features, nor can it predict developmental delay. Therefore, 
prenatal genetic assessment by amniocentesis is routinely offered in cases with a fetal 
CHD. Chromosome analysis (karyotyping) using fetal cells can detect aneuploidy and 
chromosome rearrangements. However, it has a limited resolution (5-10 Mb), requires 
operator dependent microscopic analysis, and has a relatively slow turn-around time. 
Chromosome analysis can be supplemented by FISH analysis of the 22q11.2 region. 
Recent studies suggest that instead of chromosome analysis, detection of copy 
number variants (CNVs) by array analysis could be more informative7;8. Array analysis 
has a much higher resolution and it is an automated molecular technique that detects 
chromosomal imbalances throughout the whole genome. It has proven to be clinically 
valuable in the pediatric population, especially in the setting of multiple malformations 
or developmental delay9. Experience gained from postnatal cohorts has encouraged the 
use of this diagnostic tool for prenatal diagnosis and it is increasingly performed if fetal 
abnormalities are diagnosed by ultrasound10. Nowadays, array analysis has become the 
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standard procedure for prenatal genetic analysis, and it is commonly preceded by rapid 
aneuploidy detection (RAD) to exclude common aneuploidies first11-13.
The prevalence of clinically significant CNVs in prenatal CHDs is described in a few 
cohorts14-20. As mentioned, CHD are a very heterogeneous group of lesions. The prenatal 
cohorts that have been published in recent years, focus on CHDs in general, but not at 
the level of the specific defect. These cohorts are not large enough, have significant 
selection bias, had no postnatal confirmation of the CHDs, or are otherwise unsuitable 
to extract the prevalence on the level of specific heart defects21. Thus, from a clinical 
point-of-view, our aim was to assess the presence and spectrum of clinically significant 
CNVs or variants of unknown significance (VOUS) by performing array analysis in a group 
of isolated fetal left sided CHDs.
MATERIALS AND METHODS
Cases with a prenatal diagnosis of a left sided CHD were selected from the CAHAL 
database. This is a regional cohort of fetuses with severe CHD born between 2002 
and 2012 in the northwest region of the Netherlands. Methods of data collection are 
previously reported2. We extracted left sided CHD from this cohort, and subsequently 
excluded cases with additional CHD such as abnormal positioning of the great vessels. 
Ultrasound data were reviewed and cases were grouped as either ‘isolated’ or ‘non-
isolated’ (defined as the presence of significant extra-cardiac malformations, hydrops or 
hygroma colli). Soft markers, minor additional findings, growth restriction, amniotic fluid 
pathology and/or single umbilical artery were not considered as significant extracardiac 
abnormalities. These cases are included in the ‘isolated’ group (see table S3). The 
presence and outcome of genetic analysis was assessed.
Cases with a prenatal diagnosis of an isolated left sided CHD, with a normal karyotype 
or rapid aneuploidy detection (RAD) result and absence of 22q11.2 microdeletion were 
eligible for array analysis Array was performed if frozen amniocytes, chorionic mesoderm, 
or isolated DNA was available in storage. Samples were anonymously processed. Affymetrix 
Cytoscan HD array or Agilent CGH 180K oligo array (Amadid 023363) was used as array 
platform and performed according to manufacturer’s instructions. Data analysis was 
performed using Chromosome Analysis Suite (ChAS) 2011 version CytoB-N1 2.0.232 (r4280), 
Nexus Copy Number versions 5.0, 6.1 and 7.0 or Genomic Workbench 6.5, and interpreted 
using Cartagenia BENCH 4.0 Feb-2012 (genome build hg19). Standard settings for SNPs in 
ChAS were adjusted: gain- size of 20 kb, marker count of 10, and a confidence of >85 and 
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for loss-size of 10 kb, marker count of 10 and a confidence of >85. Standard settings for 
CNVs in Nexus were adjusted: threshold for probe median: gain 0.3 and loss -0.3. Minimal 
probes for a call: 20 per segment. Only samples meeting the quality criteria, i.e. QC >15, 
MapD <0.25 and a WavinessSD <0.12, were analyzed. For the oligo arrays analyzed with 
genomic workbench an aberration was defined as at least 3 consecutive probes with log2 
ratio ≤ -0.4 or ≥0.4. The interpretation of CNVs has been done according the criteria as 
described by Gijsbers et al22. If parental material was available, we analyzed trios to assess 
whether rare CNVs were de novo or inherited. Various available online platforms were 
used, including the UCSC Genome Browser, Ensembl Genome Browser, the Toronto DB of 
Genomic Variants (DGV) and Decipher. Common polymorphic CNVs were considered as 
benign, with the exception of CNVs that are known as (possible) susceptibility factors, such 
as 15q11.2 BP1-BP2 microdeletions23;24 and Xp22.31 microduplications25;26, and maternally 
inherited CNVs on the X chromosome in male fetuses. The remaining variants were 
included for consideration for clinical significance. Inherited CNVs from parents were also 
considered as rare CNVs to account for CNVs with a possible reduced penetrance. To 
assess the function of the genes involved, we consulted PubMed and the OMIM database, 
as well as genecards.org (consulted between July and November 2015). Statistical analysis 
was performed using SPSS version 20.0.0. 
RESULTS
The database contained 200 cases of prenatally diagnosed left sided CHDs. In table 1 
the anatomic subgroups of the CHD, the rates of invasive testing, and rates of residual 
material available are summarized. A significant extra-cardiac malformation, detected 
by prenatal ultrasound, was present in 55 fetuses (27.5%), such as multiple soft markers, 
cerebral malformations, abdominal wall defects, or severe hydrops/hygroma colli. In 145 
fetuses (72.5%) no significant extra-cardiac defects were present; 11 of these (7.6%) had a 
single umbilical artery and 28 (19%) had a single soft marker, minor malformation, growth 
abnormality and/or amniotic fluid pathology. In 67 of 145 cases (46%) with an ‘isolated’ 
left sided CHD the child was live born; in 67 cases (46%) a termination of pregnancy was 
performed (table S1). The CHD was confirmed by either postnatal ultrasound or post-
mortem analysis in 100 of 145 ‘isolated’ cases (69%). In 45 cases (31%), the diagnosis 
was only ascertained by prenatal ultrasound. Further details on survival in both groups 
are summarized in the supplemental table S1. Rates of chromosome abnormalities and 
22q11.2 microdeletions, of the isolated and non-isolated groups, are summarized in table 
S2. Large chromosomal abnormalities or 22q11 microdeletion were present in 8% (95% 
CI 3-14%) of ‘isolated’ left sided CHDs. 
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Table 1: Rates of invasive testing, genetic analysis in total and number of arrays performed in fetuses 
with isolated and non-isolated left sided CHDs






cases with left 
over material (array 
performed)
Isolated left sided CHD
HLHS 104 73   (70%) 8 81   (78%) 43
Coarctation of the aorta 22 11   (50%) 4 15   (68%) 7
Aortic stenosis 10 5     (50%) - 5     (50%) 2
other left sided CHD*) 9 5     (56%) - 5     (56%) 2
TOTAL isolated 145 94   (65%) 12 106  (73%) 54
Non-isolated left sided CHD
HLHS 40 34   (85%) 1 35   (88%)
Coarctation of the aorta 5 5     (100%) - 5     (100%)
Aortic stenosis 4 3     (75%) - 3     (75%)
other left sided CHD*) 6 5     (83%) 1 6     (100%)
TOTAL non-isolated 55 47   (85%) 2 49   (89%)
TOTAL overall 200 141 (71%) 14 155 (78%)
*) includes cases with Shone syndrome, aortic arch hypoplasia and small left ventricle not otherwise 
specifiedAbbreviations: CHD congenital heart defect; PND prenatal invasive procedure; HLHS hypoplastic left 
heart syndrome;
The inclusion process for array analysis is displayed in figure 1, resulting in 54 inclusions 
of 136 eligible cases (40%) for array analysis. Details of these 54 cases are available in 
table S3. Of the 54 cases, 36 (67%) were performed on the Affymetrix Cytoscan and 18 
(33%) were performed on the Agilent CGH. 
FIGURE 1: Inclusion for array analysis
Abbreviations: CHD congenital heart defect; MCA multiple congenital anomalies; karyo karyogram; RAD rapid 
aneuploidy detection; 22q11.2 microdeletion
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Table 2 lists the encountered rare CNVs, the clinical implications, the locus on the 
chromosome, and the corresponding genes pertaining to that locus. We found 28 rare 
CNVs in 18 cases accounting for a prevalence of 33% with an average of 1.6 rare CNVs 
per person. The size of the CNVs ranged between 10.6 kb and 2.2 Mb. Our analysis 
and interpretation yielded clinically significant CNVs in 2 of 54 cases (4%; 95%CI 0 - 
9%). In case 7 we found a ~10% mosaicism for trisomy 2, which remained undetected 
by previous chromosome analysis because at that time not enough cells (n=16) were 
analysed to detect the very low mosaicism. Because amniocytes were the cells used 
for the initial diagnosis, this result was not caused by a confined placental mosaicism. 
This aberration is known to be associated with cardiac defects and multiple congenital 
malformations27;28. Follow-up is unavailable because the pregnancy was terminated 
without post-mortem analysis. In case 48 we identified a 2.2Mb de novo 10q25 deletion, 
associated with multiple congenital malformations29;30. Genes include: DUSP5, associated 
with susceptibility to vascular anomalies, SMC3, associated with mild Cornelia de Lange 
syndrome 3, RBM20, associated with dilated cardiomyopathy, SHOC2, associated with 
Noonan-like disease, and ADRA2A, associated with cardiac hypertrophy and diminished 
contractility. Currently three years old, the child has dysmorphic features, a horseshoe 
kidney (missed antenatally), and appears to be developing normally compared to peers. 
In the above mentioned two cases, as well as the 16 other cases, we also found 26 smaller 
CNVs. Most of these are unlikely to be clinically relevant or possibly causative, because 
the genetic involvement appears to be unrelated to critical developmental processes. 
Parental samples were not available for comparison in 14 of the 18 cases, therefore it 
is uncertain if 20 of the 26 found rare CNVs were inherited or de novo. Analysis of the 
involved genes demonstrated genes possibly related to abnormal cardiac development 
in only 1 case: In case 5 array analysis demonstrated a duplication including the 3’part 
of the AAK1 gene; this gene interacts with the activated form of NOTCH1a31. The clinical 
implications of this duplication are uncertain (VOUS). The parents were not tested, and 
the pregnancy was terminated without post-mortem analysis. 
In case 38 we found a maternally inherited 4q21.23 deletion in a region including the 
WDFY3 gene. This deletion has previously been reported as a possible risk factor for 
autism spectrum pathology32. This child died 3 weeks after birth due to cardiovascular 
complications.
In case 43 we found a maternally inherited Xp22.31 duplication in a region including 
the STS gene in a male fetus. This gain has been reported as a possible risk factor for 














































































































































































































































































































































































































































































































































































































































































































































































   









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































As deduced from table S3, minor additional findings were present in 17 of 54 ‘isolated’ 
cases (35%), including enlarged nuchal translucency/neck cysts (n=4), ascites/pericardial 
effusion (n=6), single umbilical artery (n=4), and other minor findings (n=3). Additionally, 
two fetuses were postnatally identified with extra-cardiac malformations (horseshoe 
kidney in cases 23 and 48), where one had a clinically significant CNV (case 48). These 19 
fetuses with prenatally detectable (although missed in 2 cases) additional malformations 
did not differ in the frequency of rare CNVs from fetuses that are ‘truly’ isolated, without 
additional findings (both 31%). Furthermore, one child with normal array results currently 
displays neurodevelopmental delay (case 3). Another child with a normal array result 
developed hydrocephalus of an unknown cause (case 52). Both fetuses with a clinically 
significant CNV had an additional finding (cases 7 and 48), however in case 48 the extra-
cardiac anomaly was only detected after birth. This results in 1/17 (6%) clinically significant 
array findings in fetuses with additional findings and 1/37 (3%) clinically significant array 
findings in prenatal isolated appearing cases (independent samples T test p=0.6). 
DISCUSSION
Congenital heart defects (CHDs) are known to be associated with chromosomal 
abnormalities and 22q11.2 microdeletion4. This is confirmed by our study (table 
S2). Furthermore, our study shows that array analysis can yield clinically significant 
abnormalities in 4% of euploid fetuses without a 22q11.2 microdeletion. Thus, in the 
absence of ultrasonographically detected significant extra-cardiac malformations, and 
with a normal karyotype/FISH 22q11.2 result, array can in some cases predict if fetuses 
with a left sided CHD are at risk for a more severe phenotype. In our study, the risk of array 
abnormalities appears to be unrelated to the presence of minor additional malformations 
such as enlarged nuchal translucency. In two cases additional malformations (horseshoe 
kidney) remained undetected prior to birth. 
Previous reports on the incidence of submicroscopic chromosomal abnormalities 
in fetal CHDs focus on CHDs in general, or analyze postnatal cohorts21;33-35, which is 
impractical in prenatal counselling. As the diagnostic accuracy of prenatal ultrasound 
increases, targeted information concerning the specific diagnosis will also need to 
emerge. The current study determines the specific incidence of genetic abnormalities in 
the subgroups of isolated and non-isolated left sided CHDs. Left sided CHD are generally 
considered not to be associated with genetic syndromes, if they appear isolated on 
prenatal ultrasound. Compared to other CHD, tetralogy of Fallot for example, which 
is highly associated with syndromic and chromosomal anomalies, physicians may be 
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more reluctant to stress the need for fetal genetic sampling in absence of other fetal 
abnormalities. Thus, with our data, physicians are able to counsel parents more tailored 
to this specific condition. A great strength in our study is the large rate of postnatal 
confirmation (69% in isolated cases), thus analyzing a sharply defined phenotype of left 
sided CHD only. 
Our array data confirms a previously reported additional yield of 6% with clinically 
significant submicroscopic chromosomal abnormalities in two large cohorts of euploid 
fetuses with isolated malformations in general36;37. When focusing on left sided CHD only, 
our findings are in concordance with Shaffer, who reported a subgroup with isolated 
HLHS in a large cohort of fetuses with various ultrasound abnormalities14. Shaffer found 
4 (9.5%) significant findings (all < 10Mb) in 42 isolated HLHS fetuses. This study, however, 
does not provide follow-up data to validate the prenatal findings with regard to postnatal 
outcome, nor does it elaborate on the details of the array abnormalities and inheritance. 
Hitz et al. stated that in 10% of left sided CHDs, CNVs play a causative or contributing 
role38. Though this study included a well-focused phenotype, Hitz studied families with 
postnatally proven isolated left sided CHDs, excluding known syndromes and dysmorphic 
features. As this information is not available in the prenatal setting, the data of Hitz are 
not applicable for parental counselling in a fetal diagnosis.  
Our study is the first to report the detection of rare CNVs, in a prenatal cohort. Our data 
demonstrate an average of 1.6 rare CNVs per person in 33% of fetuses with left sided 
CHDs. Our data coincide with findings in postnatal similar patient groups with similar 
array resolution: Hitz found 1.35 rare CNVs per person in 31% of children with left sided 
CHD (n= 54/174) with a resolution of 10kb, and Iascone found 1.32 rare CNVs per person, 
in 47% of postnatal HLHS cases (n= 25/53), with an average resolution of 20kb38;39. Payne 
reported on the frequency of small CNVs (<60kb), not likely to be disease-causing in 43 
postnatal isolated and non-isolated cases of HLHS. Their found average (1.49 CNVs per 
person) was significantly higher when compared to 16 healthy controls39. In comparison 
to Hitz38 and Iascone39, the availability of parental material is somewhat lower in our 
dataset. Considering the fact that we found a similar number, or fewer, patients with 
rare CNVs, we do not expect this to have resulted in a high number of false CNVs calls.
The interpretation of CNVs remains controversial and prone to differences between 
centers. The identification of clinically significant CNVs is subject to variations in the 
used platform and the consulted genomic databases. The clinical (in)significance of 
variants of unknown significance (VOUS) are increasingly unveiled. Our interpretation 
of the CNVs yielded two array anomalies with clinical significance. Both anomalies are 
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known to be associated with cardiac defects and multiple congenital malformations27-30. 
However, these findings include some ambiguity. The degree of mosaicism trisomy 2 and 
affected tissues cannot be predicted (case 7). However, it would trigger suspicion of 
additional fetal congenital abnormalities.  Interestingly, the 10q25 deletion case (case 48) 
did present with an additional structural abnormality, but neurodevelopment is normal. 
Three VOUS were identified that were of interest. In the duplication of chromosome 2 in 
case 5, AAK1 appears to be an interesting gene due to its interaction with the activated 
form of NOTCH131. However only the 3’part of the gene is duplicated; further investigation 
is needed to determine whether this duplication will disrupt this gene and subsequently 
has an effect on the gene function . The second and third VOUS are maternally inherited 
variants. The Xp22.31 duplication in case 43, including the STS gene is a variant that is 
present at a low frequency in the population, but is still considered clinically significant 
because it is found at higher frequency in affected individuals.   Although this variant 
will not explain the HLHS, it could be a risk factor for neurodevelopmental delay25. The 
4q21.23 deletion in case 38, including the WDFY3 gene, has been correlated to cerebral 
changes in mice that could be characteristic for autism spectrum disorders and epilepsy. 
The implications of both variants are unclear, and both children died at very young age 
due to cardiac complications. As our study was done on banked samples, it is unclear 
how these findings would have influenced the prenatal counselling.  
Previous studies have implicated several loci and genes in left sided CHDs (mainly HLHS), 
including NOTCH1, NKX2.5, NKX2.6, HAND1, HAND2, SNAI2, GATA6, GJA1, FGF8, FOXC1, 
FOXC2, FOXH1 and FOXL140-45. Identifying a new candidate gene or combination of genes 
responsible, however, remains difficult, mainly due to variable penetrance41. In isolated 
left sided CHDs, there appears to be no single genetic cause. Familial recurrence does 
occur, but left sided CHDs are considered to be genetically heterogeneous. Embryological 
blood flow alterations also seem to play an important role in the etiology46;47. The 
reported genes were not found in any of the CNV regions we identified. However, the 
platforms we used either lacked or had few probes specific for the following genes: 
HAND1, HAND2, SNAI2, NKX2.5 FOXC1 NKX2.6 FOXH1 and FGF8;  intragenic insertions or 
deletions could have been missed.
Our study has some limitations. Due to the retrospective nature of our study, segmental 
analysis of the development of the CHDs was not available in all cases. It is complicated 
to provide a link between a CNV or a candidate gene and the observed phenotype39;48. 
In left sided CHDs it is even more difficult because the anomaly itself displays high 
rates of anatomic variation49. Clinical classifications of left sided CHDs are focused on 
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a functional outcome. In HLHS, as an end stage development product, it is not always 
possible to identify the developmental cause of the observed anomaly. In our cohort, 
segmental developmental analysis was only possible in a small group, mainly in those that 
underwent postmortem dissection after termination of pregnancy. In the live born cases 
specific developmental details, regarding the presence of mitral or aortic valve hypo- or 
aplasia, as cause of HLHS were not always identifiable.
Furthermore, only 22% of our samples were analysed as trios, so information regarding 
the presence or absence of identified CNVs in parents is lacking in the remaining 42 
cases. The importance of information regarding inheritance  is evidenced by the findings 
of Warburton, where de novo rare CNVs occurred in 12.7% of their 71 postnatal HLHS 
cases versus 2% in their cohort of healthy controls50. The history of familial occurrence 
of cardiac defects was not always available in our cohort, and parents were generally not 
tested for the presence of mild left sided CHDs such as a bicuspid aortic valve. Familial 
segregation analysis (linkage studies) and subsequent speculation on other potentially 
contributing CNVs, labelled in our study as clinically not significant, is therefore not 
possible. Thus, we are unable to rule out a possible influence of a yet unknown, common 
CNV as a susceptibility factor. Known susceptibility factors, such as 15q11.2 BP1-BP2 
microdeletions, were not found in our study. Furthermore, the resolution of the used 
array method is restricted to 10kb in deletions and 20 kb in duplications; smaller 
intragenic deletions or duplications could not have been detected by this test.
Also, genetic material was not available in all eligible cases. As we have demonstrated in 
table 1, parents typically opted for an invasive procedure when additional malformations 
were present. Also, in 53 cases, genetic material was unavailable due to logistic challenges, 
absence of stored material and failure of cell culture. Therefore a selection bias cannot 
be ruled out.
Despite the limitations, our data serves as guide in focused prenatal counselling when 
genetic analysis is offered in left sided CHDs. Considering the fact that the long-term 
outcome may also be dominated by non-iatrogenic neurological impairment, even in 
apparently isolated CHDs, attempting to identify beforehand which cases are at highest 
risk for a more severe phenotype is important51,52.  As mentioned, our data also confirm 
reports that left sided CHDs are associated with chromosome abnormalities and 22q11.2 
microdeletion syndrome4, detecting these aberrations in as many as 57% of fetuses with 
left sided CHDs in the presence of significant extra-cardiac malformations in this study. 
Left sided CHDs which seem to be isolated on prenatal ultrasound also carry a 7% risk of 
clinical significant chromosome abnormalities and 22q11.2 microdeletions in our cohort. 
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Together with clinically significant CNVs found in 4%, the yield of genetic analysis could 
be as high as 11% when using karyotyping and array analysis combined. However, all of 
the significant chromosome abnormalities found in our study with karyotyping (table S2) 
are also identifiable by array. It is advisable therefore to perform array analysis as a 
first tier test. Depending on local policies and costs deliberations, array analysis can be 
preceded by RAD to exclude common aneuploidies first. However, our study also shows 
that array analysis cannot predict all cases that display adverse (neurodevelopmental) 
outcome. Furthermore, as discussed, the significant array findings include some 
ambiguity. Therefore, while array analysis would have identified individual cases where 
the search for additional phenotypic abnormalities would be warranted, counselling 
may still involve some uncertainty.  In the future, if whole exome or genome sequencing 
becomes widely available in the prenatal setting, this effect might even be stronger. To 
attach consequences to subtle array abnormalities, such as refusal of certain palliative 
interventions, has to be avoided until evidence of adverse outcome can be ascertained.
In conclusion, our data show that performing array analysis in a high resolution in cases of 
prenatal left sided CHD could aid parental counselling. It could identify some fetuses that 
are at high risk for a more severe phenotype, because of its capability to demonstrate 
unbalanced submicroscopic chromosome abnormalities and low mosaic aneuploidies. 
As the first to explore this in a prenatal setting, our research supports the use of array 
analysis as a first tier diagnostic test in isolated left sided CHD53. Left sided CHD are 
usually considered to have a low risk for genetic anomalies, if not accompanied by 
additional congenital anomalies, leading to lower rates of invasive procedure performed. 
This study however confirms that fetal ultrasound misses certain additional lesions, thus 
emphasizing the importance of fetal genetic analysis. Because array analysis is also able 
to detect 22q11.2 microdeletion, it can be performed instead of FISH analysis, preceded 
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SUPPLEMENTARY FILES
Table S1: Details of survival and postnatal confirmation of the CHD in fetuses with isolated and 
non-isolated left sided CHD




Live born Currently alive†
Isolated left sided CHD§
HLHS 104 64 62% 61 4 2 37 36% 17 47%
Coarctation of the aorta 22 21 95% 2 - 1 19 90% 17 89%
Aortic stenosis 10 7 70% 3 1 1 5 56% 5 100%
other left sided CHD* 9 8 89% 1 2 - 6 67% 3 50%
TOTAL isolated 145 100 69% 67 7 4 67 46% 42 63%
Non-isolated left sided CHD§
HLHS 40 10 25% 27 8 1 4 10% 0
Coarctation of the aorta 5 2 40% 3 1 - 1 20% 1
Aortic stenosis 4 3 75% 1 - - 3 75% 0
other left sided CHD* 6 5 83% 5 - - 1 17% 0
TOTAL non-isolated 55 20 36% 36 9 1 9 16% 1
TOTAL overall 200 120 60% 103 16 4 76 39% 43 57%
* includes cases with Shone syndrome, aortic arch hypoplasia, absent left AV-connection, and small left ventricle 
not otherwise specified
ǂ by either post-mortem analysis or postnatal ultrasound 
† percentage of live born cases
§ please note that non-isolated is defined as no extracardiac anomalies present on fetal ultrasound; some of the 
aneuploidies are therefore included in the isolated group, if presented by only a CHD before birth. 
Abbreviations: CHD congenital heart defect; HLHS hypoplastic left heart syndrome; TOP termination of pregnancy; 
IUFD intra uterine fetal demise
Data available online:
Table S2: prevalence of large chromosomal abnormalities and 22q11 microdeletion in 
fetuses with isolated and non-isolated left sided CHD.















* Both authors contributed equally
CHAPTER 4
Polyhydramnion and cerebellar 
atrophy: a prenatal presentation 
of mitochondrial encephalomyopathy 
caused by mutations in the FBXL4 gene 
Clinical Case Reports 2016; 4(4): 425–428
KEY CLINICAL MESSAGE
Severe recessive mitochondrial myopathy caused by FBXL4 gene mutations may present 
prenatally with polyhydramnios and cerebellar hypoplasia. Characteristic dysmorphic 
features are: high and arched eyebrows, triangular face, a slight upslant of palpebral 
fissures, and a prominent pointed chin. Metabolic investigations invariably show increased 
serum lactate and pyruvate levels.
CASE DESCRIPTION
Polyhydramnios in the second and third trimester of pregnancy is defined by 
(semiquantative) measurements such as a maximum vertical pocket (MVP) >8cm, or 
an amniotic fluid index (AFI) >24 cm. Approximately 90% of cases are idiopathic or 
caused by gestational diabetes (GDM)1. However, 10% of cases are associated with fetal 
structural abnormalities2. Most frequent causes are impaired swallowing from any cause 
(gastro-intestinal, facial, musculoskeletal or brain abnormalities), cardiac failure, hydrops 
and renal abnormalities. Metabolic diseases, such as congenital disorders of glycogen 
storage, are also incidentally reported to present with polyhydramnios in pregnancy3. 
The usual diagnostic work-up of polyhydramnios is to exclude GDM and maternal 
infections, and to perform an extensive structural assessment to rule out fetal anomalies. 
The presence of structural anomalies involves increased risk of aneuploidy or other 
chromosomal and syndromic disorders. In isolated polyhydramnios, the risk of perinatal 
adverse outcome is, however, still increased when compared to uneventful pregnancies4. 
A 30-year old primigravid woman, with a so far uneventful pregnancy, was referred to 
our clinic with polyhydramnios. Aside from a spontaneously closed ventricular septal 
defect (VSD) in her own infancy, both parents were healthy. A maternal uncle of the 
mother had died postnatally of an unknown cause. 
First-trimester combined test revealed a low risk for trisomies (NT 1.1 mm). The anomaly 
scan was performed at 20 weeks GA and showed no abnormalities. Transverse cerebellar 
diameter was normal at p50. At 25+5 weeks of gestation she presented with signs of 
polyhydramnios (uterine size that outpaced gestational age) and premature contractions. 
She received tocolytics and corticosteroids for fetal lung maturation. Ultrasound 
showed polyhydramnios (MVP 9.9 cm, AFI 27.5 cm) with normal fluid-filled stomach 
and mild dilatation of both lateral ventricles (11mm). Amniotic fluid drainage (1.8 liter) 
was performed in an attempt to cease the premature contractions. More detailed fetal 
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intracranial assessment was possible afterwards, showing an enlarged cisterna magna 
(12mm) and a dysplastic and small cerebellum. The transcerebellar diameter measured 
25.4 mm (slightly below p3, Figure 1A, with head circumference p50). Further intracranial 
assessment was not possible due to maternal habitus, fetal position and uterine 
contractions. The myocardium was hypertrophic with a small perimembraneous VSD. 
QF PCR and a CytoScan HD Array were performed, showing a small de novo duplication 
on chromosome 11 (11q22.1), including exon 1 of the contactine 5 (CNTN5) gene. This 
variant is not reported as genomic variant in the normal population, neither known to 
be associated with a genetic disorder or malformation. A relation with the clinical signs 
appears unlikely. Maternal serum infection testing (TORCHES) was also normal.
Two days later (26+0) she spontaneously delivered a boy of 835 g (-0.5 SDS), Apgar scores 
were 4/4/7 after 1.5 and 10 minutes respectively. At birth he was started on CPAP and 
transported to the neonatal intensive care unit. Physical examination showed a hypotonic 
infant with a lack of subcutaneous fat. The muscles and bones were clearly visible. He had 
mild dysmorphic features with high and arched eyebrows, a hairy forehead, triangular face, 
a slight upslant of palpebral fissures, down turned corners of the mouth, mild hypoplastic 
alae nasi, prominent pointed chin, deep incisura between tragus and antitragus providing 
a clear view into the external meatus (Figure 1B). 
Figure 1. 
(A) Fetal cerebral ultrasound at GA 25 + 5 showed cerebellar hypoplasia (*) and borderline dilatation 
of the ventricles. In retrospect, the outlines of some of the periventricular cysts are also discernible 
(see arrows). 
(B) shows the postmortem facial features. Note the prominent eyebrows and the triangular face 
with pointed chin. The bruises around the nose and philtrum, and the asymmetry of the nostrils are 
the effect of ventilation.
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He had relatively long and slender arms and legs, large hands, long fingers, small fingernails 
and somewhat broad distal phalanges. The lower extremities showed bilateral pes cavus 
with broad metatarsals and prominent heels. Testes were not palpable in the scrotum. 
Postnatal cardiac ultrasound confirmed the presence of a small VSD. Cranial ultrasound 
on first postnatal day showed bilateral peri- and intraventricular haemorrhages with 
dilatation of the ventricles, periventricular pseudocysts, and confirmed the presence of 
cerebellar atrophy.
A few hours after birth the neonate required mechanical ventilation and surfactant 
treatment for respiratory distress syndrome. He developed hypotension and was treated 
with fluid boluses and inotropic support and antibiotics. Despite stabilisation of blood 
pressure and systemic circulation he developed a progressive lactate acidosis with 
extremely high plasma lactate: 19.1 mmol/L (normal range 0.5-2.2)and high pyruvate: 
269 µmol/L (normal range 40-140). The L/P (lactate/pyruvate) ratio was 71, which is 
strongly increased (normal <20). Organic acid analysis in urine showed a strong increase 
of lactate (56540 µmol/mmol creatinine) and increases of 3-OH-butyrate, pyruvate, 
fumarate, malate, and 4-OH-phenyllactate. The amino acids proline and lysine were 
increased in both urine and plasma. Oligosaccharides in urine and acylcarnitines and 
very-long-chain fatty acids in plasma were normal. In the absence of secondary causes, 
these findings are consistent with primary lactic acidosis, caused by a disorder of the 
pyruvate metabolism or a mitochondrial respiratory chain defect. 
Due to the severity of the cumulative problems the neonate died 2 days after birth. 
Post-mortem cranial MRI confirmed the findings on ultrasound, showing extensive 
bilateral intra-, and periventricular haemorrhage with adjacent cyst (Figure 1C), vermian 
and cerebellar hypoplasia with a retrocerebellar pseudocyst (Figure 1D). 
DNA analysis of the PDHA1-gene (most frequent genetic cause of pyruvate-dehydrogenase 
complex deficiency) showed no pathogenic mutations. Large deletions, point mutations 
and small insertions/deletions in mitochondrial DNA (mtDNA) derived from blood were 
excluded by next generation sequencing (NGS) using the Illumina MiSeq platform and a 
dedicated bioinformatics pipeline (available on request).
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Figure 1. 
(C) shows an axial view of the postmortal MRI (T2 weighted images) showing dilated ventricles with 
bilateral peri- and intraventricular hemorrhages and cysts adjacent to the right ventricle (arrows). 
(D) shows the vermian and cerebellar hypoplasia with enlarged cisterna magna or pseudocyst 
(arrow).
For whole exome sequencing, exome enrichment was performed by the Agilent 
SureSelectXT exome enrichment kit version 4, including the UTR regions. Sequencing was 
performed by an Illumina HiSeq2000 using a 2x100 bp paired-end recipe. Basecalling, 
and demultiplexing was done using bcl2fastq 1.8.4., reads were aligned onto the human 
reference genome (hg19) using BWA 0.5.9., duplicates marked using the PICARD software 
suite 1.77, and variants were called using GATK 2.1-8. Annotations were added using an in-
house build annotation database, according to UCSC RefGene track, dbSNP137 and the 
dbNSFP (v2.0). Targeted exome analyses of a panel of 447 nuclear genes was performed, 
containing known mitochondrial disease genes and functionally or clinically related genes. 
Two heterozygous mutations in the FBXL4 gene were detected and confirmed by Sanger 
sequencing: c.292C>T (p.(Arg98*))and  c.1303C>T (p.(Arg435*)). Both are nonsense 
mutations resulting in a premature stop codon at position p.98 and p.435 of the FBXL4 
protein, respectively. The location  of these mutations on different alleles (compound 
heterozygosity) was confirmed by testing the parents. 
Missense and stop mutations in the FBXL4 gene were reported recently to be associated 
with severe autosomal recessively inherited mitochondrial encephalomyopathy5-8. 
Our case is the first case demonstrating a premature prenatal onset of symptoms of 
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FBXL4-related mitochondrial encephalomyopathy. The polyhydramnios was the primary 
sign, leading to the detection of brain abnormalities on more detailed fetal ultrasound 
examination. This early presentation of polyhydramnios is most likely caused by hypotonia 
and diminished fetal movements. 
The cases of FBXL4-related encephalopathy reported so far are characterised by 
increased serum lactate level, psychomotor delay, hypotonia, failure to thrive, swallowing 
difficulty and muscle wasting6. Onset of symptoms varied from neonatal onset after 
term birth, to the age of 14 months5,6,8. Other reported cases were born at term or 
premature due to medical intervention for intrauterine growth retardation or reduced 
fetal movements5,6. 
The  FBXL4  gene is situated on nuclear DNA on chromosome 6q16.1. The FBXL4 
mitochondrial protein contains an F box in its N-terminal half, followed by 11 leucine-rich 
repeats9, and is expressed in heart, kidney, liver, lung, pancreas, and placenta10. Evidence 
of the pathogenetic effect of FBXL4 mutations was provided by skeletal muscle biopsies 
and fibroblasts showing defects in mitochondrial respiratory chain enzyme activities, 
loss of mitochondrial membrane potential, a disturbance of the dynamic mitochondrial 
network, and mtDNA depletion5. 
The nonsense mutation p.Arg435* in the FBXL4 gene, present in our patient, was earlier 
reported in homozygous form in a child of consanguineous parents with early onset 
mitochondrial encephalopathy, severe hypotonia, cardiomyopathy, MRI abnormalities, 
increased serum lactate and premature death5. The second mutation detected in our 
patient (p.Arg98* mutation) has not been reported previously. However, like the other 
mutation reported, this nonsense mutation leads to nonsense-mediated decay (NMD, 
RNA degradation) or a  truncated protein5,6. As a result our patient would have been 
unable to produce a normal FBXL4 gene product. 
The mother was pregnant again before exome sequencing had started. Within the prenatal 
timeframe, exome sequencing lead to the diagnosis of the first child, consequently 
enabling prenatal diagnosis for the second child. Amniocentesis with sequence analysis 
of the FBXL4 gene confirmed that the fetus was unaffected. The pregnancy resulted in 
the birth of a healthy child. The VSD in our patient is considered to be a separate finding 
(familial trait) which is not related to the syndrome.
Our case demonstrated a prenatal onset mitochondrial encephalomyopathy presenting 
with polyhydramnios, causing premature delivery, and cerebellar atrophy. The neonate 
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was hypotonic and in a poor condition with need for mechanical ventilation, inotropic 
support, and persistent  lactate acidosis. Targeted  exome sequencing using a mitochondrial 
gene panel proved its benefit by revealing compound heterozygous mutations in the 
FBXL4 gene. Prenatal testing was successfully carried out in the subsequent pregnancy. 
Direct testing for mutations in the FBXL4 gene should be considered in patients with 
severe encephalomyopathy with high levels of serum lactate. 
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ABSTRACT
Congenital heart defects (CHD) are associated with neurodevelopmental (ND) delay. This 
study aims to assess evidence for impaired prenatal brain development, in fetuses with 
CHD. A systematical search was performed and 34 studies evaluating the fetal brain 
(MRI or ultrasound) in isolated CHD were included (1990-2015). Data regarding cerebral 
abnormalities, head circumference (HC) growth and middle cerebral artery (MCA) flow 
were extracted. Antenatal MRI was studied in 10 articles (445 fetuses), resulting in a 
pooled prevalence of 18% (95%CI -6% to 42%) for combined structural and acquired 
cerebral abnormalities. Prenatal HC was studied in 13 articles (753 fetuses), resulting in 
a pooled z-score of -0.51 (95%CI -0.84;-0.18). Doppler was studied in 21 articles (1412 
fetuses), resulting in a lower MCA pulsatility index (z-score -0.70, 95%CI -0.99;-0.41) in 
left sided CHD only. We conclude that prenatal MRI and ultrasound demonstrate brain 
abnormalities, delay in head growth and brainsparing in subgroups of CHD. However, 
large MRI studies are scarce and ultrasound data are biased towards severe and left-
sided CHD. Long term follow-up studies correlating prenatal findings with postnatal ND 
outcome are limited and data is lacking to support counseling families regarding ND 
outcome based on prenatal findings suggestive of altered brain development.
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BACKGROUND
Congenital heart disease (CHD) is the most common congenital malformation, affecting six 
to eight per 1000 newborns. Although the survival rates of these children have increased 
over the last decades, there is a significant risk for adverse neurodevelopmental (ND) 
outcome, even in the absence of associated chromosomal or syndromic abnormalities1-4. 
ND sequelae, like developmental delay and low IQ, are mainly encountered in children 
with severe CHD, who require surgery in the first year of life5. Until recently, these ND 
sequelae were assumed to be the result of perioperative conditions resulting in cerebral 
hypoxia and thrombo-embolic events6.
Recent studies demonstrated signs of abnormal neurological development already 
present at birth, prior to surgery. These studies demonstrated abnormal results of 
early neurological examination and abnormal imaging findings such as periventricular 
leukomalacia, white matter injury and cerebral atrophy7;8. Some studies related these 
findings to a poor neurological development later in life9;10. The characteristics of 
certain pre-operative neurological abnormalities, such as cerebral atrophy and delayed 
maturation, suggest that these abnormalities originate in utero. A second finding 
indicating towards a fetal origin is a smaller head circumference (HC), found in neonates 
with severe isolated CHD. Smaller HC is mainly reported in neonates with transposition 
of the great arteries (TGA), tetralogy of Fallot (TOF) and hypoplastic left heart syndrome 
(HLHS)11-14 and is associated with a higher risk for ND outcome15.When a CHD is identified 
before birth, basic fetal ultrasound (US) can be used to identify delayed fetal head 
growth and abnormal cerebral flow. Dedicated fetal neurosonography or fetal brain 
magnetic resonance imaging (MRI) can be used to identify more subtle signs impaired 
fetal cerebral development16;17;18.The aim of this study was to systematically review 
existing evidence for impaired brain development in utero, in fetuses with isolated CHD. 
More specifically, we aimed to objectify the presence of fetal hemodynamic brainsparing 
effects, delay in fetal brain growth or fetal brain abnormalities in general, in these cases. 
Furthermore we attempted to stratify the findings to the type of CHD.
METHODS
Search strategy
A systematic search was conducted in PubMed, Embase, Web of Science and Cochrane 
databases in October 2015. Publications from 1 January 1990 to 28 October 2015, 
containing the search terms imaging (ultrasonography or MRI), fetology, congenital heart 
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disease and neurodevelopment were included. The complete search string is available 
in Supplement 1. Studies on genetic syndromes associated with CHD, such as Trisomy 
21, Noonan syndrome and 22q11.2 microdeletion syndrome were excluded, as well 
as functional CHD, arrhythmias and lethal abnormalities. The extracted articles were 
evaluated for relevance by 3 independent researchers (FJ, SE, MH). Studies were eligible 
for inclusion if MRI and/or US  was performed before birth, assessing cerebral maturation, 
brain volume or growth, measuring Doppler flow patterns in the middle cerebral artery 
(MCA), and/or measuring head biometry, in fetuses with isolated CHD. To maximize the 
sample size, selected articles were cross-referenced. We assessed study quality and risk 
of bias by rating the articles based on the Strobe criteria19. Disagreement was resolved 
by consensus. Low methodological quality was not an exclusion criterion. The consensus 
statement on reporting in meta-analysis of observational studies in epidemiology 
(MOOSE-statement), was followed when possible and appropriate20.
Data extraction and processing
The number and type of identified cerebral abnormalities were extracted from the 
MRI studies. Reported abnormalities were assessed by a pediatric neurologist (CP) and 
subdivided into four categories: 1) structural malformations, such as callosal agenesis, 
2) cystiform anomalies including arachnoid, subependymal and germinolytic cysts, 3) 
ventricular anomalies including asymmetrical appearing ventricles and intraventricular 
hemorrhage, and 4) lesions possibly caused by hemodynamic changes, such as cerebral 
atrophy, white matter injury and delay in maturation. The prevalence of the abnormalities 
was pooled per category, based on the available data.
Biometrical values of head circumference (HC) and MCA-pulsatility indices (MCA PIs) 
were extracted from the US studies, as mean or median z-scores, percentiles or absolute 
values. . If z-scores or percentiles were reported, the used reference population was 
noted. Reported percentiles, absolute values or median PI z-scores with range intervals 
were transformed to mean z-scores to correct for differences in gestational age (GA) 
at sampling (Supplement 2). To transform the HC outcome measures into z-scores, 
the population parameters by Hadlock were used21. To transform the MCA-PI outcome 
measures into z-scores, the population parameters by Arduini were used22. Furthermore, 
we extracted the gestational age of assessment, the type of included CHD, the used 
exclusion criteria and the centers and time span of data-collection. Also, if included, the 
used control group was noted, as well as the method of postnatal neurodevelopmental 
assessment, if performed. An e-mail request was sent to authors if data were not 
extractable from the original article. 
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Meta-analysis models
The metafor package (Viechtbauer 2010, version 1.9-4) for the statistical program R (R 
Development Core Team 2010), was used to conduct the meta-analyses. For the HC and 
MCA PI measurements, meta-analysis models were constructed for all CHD combined 
(mixed types of CHD). For the MCA PI measurements meta-analysis models were also 
constructed for the following subgroups: 1) left sided obstructive lesions (LSOL) such as 
hypoplastic left heart syndrome and coarctation of the aorta, 2) right sided obstructive 
lesions (RSOL), such as tricuspid atresia, pulmonary stenosis, Ebstein’s anomaly and 
tetralogy of Fallot, and 3) transposition of great arteries (TGA). If combined effect sizes 
for a mixture of CHDs were not reported in a study, missing combined effect sizes were 
calculated from documented subgroup effect sizes (Supplement 2).
For each meta-analysis model the following parameters were calculated using a random 
effect model: the estimated overall effect size with its standard error, the statistical 
significance of the estimated effect and several parameters describing the heterogeneity 
(between studies variance (tau2), Cochran’s Q-test and I2). The variance between studies 
was calculated with the restricted maximum likelihood method. A forest plot and a funnel 
plot were created additionally for each fitted model. Sensitivity analyses were performed 
to check whether the meta-analysis models should be corrected for two possible origins 
of estimation biases: bias related to overlapping cohorts between studies (duplicate/
secondary publication) and missing effect sizes of control groups. 
RESULTS
The search resulted in 34 included articles (1983 fetuses, Figure 1). The study 
characteristics are summarized in Tables 1a (MRI studies) and 1b (US studies). Quality 
assessment is summarized in Figures 2a (MRI studies) and 2b (US studies). The included 
types of CHD per cohort are delineated in Tables 1a and 1b. CHD characteristics were not 
always described thoroughly. Several authors divided the cohort into LSOL, RSOL and 
mixed lesions. Others only included certain types of CHD (TGA, TOF, HLHS). Variation was 
found in the description of HLHS and LSOL: some only included those with retrograde 
aortic arch flow, others included cases of aortic stenosis, coarctatio of the aorta and/or 
interrupted arch as well in the LSOL group. In this meta-analysis, all types of LSOL were 
combined in one group.
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Figure 1: Flow diagram of search and inclusion process 
Figure 2a: Quality of included MRI studies
US, ultrasound; MRI, magnetic resonance imaging
Search result: 1044 titles
- PubMed: 505
- Embase: 602 (453 unique)
- Web of Science: 175 (82 unique)
- COCHRANE: 8 (4 unique)
34 articles included - 1983 fetuses 
- 8 addressing correlation of US variables with ND-outcome - 331 fetuses 
- 21 addressing Doppler flow in middle cerebral artery (US) - 1412 fetuses 
- 13 addressing biometrical values (US) - 753 fetuses 
 (of which 9 addressed Doppler flow as well)
- 10 addressing various aspects of MRI - 445 fetuses 
 1 also including US measurements
Excluded 980 based on title/abstract
Included 1
Identified from reference lists (Szwast 2012)
Excluded 31
- 7 review / opinion
- 12 addressing other (Doppler flow) 
 measurements only
- 4 congress abstracts
- 6 addressing neonates
64 full article reviewed
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center* Patients Type of CHD†










P S 30 AS, CoA, DORV, 
Ebstein, TA, TGA, 
TOF
36 30 Fetal brain size, 
oxygen satu-






P S 38 CoA, DORV, HLHS, 
TGA, TOF other 
















P S 58 AVSD, AS, CoA, 
complex CHD, 
Ebstein, HLHS, 
PA, TA,  TGA, TOF, 
truncus, 









P M 144 AVSD, DORV, 
















12 Brain weight 
(MRI), CMR 











bral spinal fluid 









P M 18 HLHS 25-37 
(mean 
30.8±3.8)
30 Brain volume, 
cortical surface 
















P S 55 AS, DORV, Ebstein 
, HLHS, PA, PS, TA, 









ity, total brain, 
fluid. 
- 17
* P, prospective; R, retrospective; S, single center; M, multicenter, n/a not applicable
† Ao hypoplasia, aortic arch hypoplasia; AS, Aorta Stenose; AVSD, Atrioventricular Septum Defect; CoA, Coarctatio 
Aortae; DORV, Double Outlet Right Ventricle; Ebstein, Ebstein’s anomaly; FO, Foramen Ovale; tumor, intracardiac 
tumor; HLHS, hypoplastic left heart syndrome ; other, other non-chromosomal extracardiac malformations; PA 
Pulmonary Atresia; PS, Pulmonary Stenosis; TA,Tricuspid atresia; TI, Tricuspid Insufficiency; TGA, Transposition of the 
Great Arteries; TOF, Tetralogy of Fallot; Truncus, Truncus Arteriosus; RSOL, Right Sided Obstructive Lesions;
‡ HC, Head Circumference; BPD, Biparietal Diameter; MCA, Middle Cerebral Artery;  PI, Pulsatility Index; CPR, 
Cerebral-Placental Ratio; VOCAL, Virtual Organ Computer-aided AnaLysis; UA, Umbilical Artery; AC, Abdominal 




Table 1b: overview of included Ultrasound studies
Author (year) / 
country Design*
Multi-/






analysis** Used normal values
Williams (2015) USA/
Canada
P S 66 HLHS, TGA ,TOF F1 (mean 23.6±2), F2 
(mean30.6±1.6), F3 
(mean 36.4±1) 
41 BPD, HC + 15 HC   Hadlock 1984
Hahn (2015) USA R M 133 single 
ventricle
20-34 (mean 27.2±5.3) - Biometry(n=133), MCA 
PI(n=119)
+ 18 mix; HC Arduini 1990; Hadlock 
1984
Masoller (2015) Spain P S 58 AS, AVSD, CoA, complex 
CHD, Ebstein, HLHS, PA, TA, 
TGA,  TOF, truncus 
20-24 (mean 22.3±0.9) 58 BPD, CPR, composite score, 
correlation with MRI, HC, 
MCA PI, 




Zeng 3d Flow (2015) 
China
P S 112 HLHS, LSOL, RSOL, TGA 19+6-30+3 (mean 
25.7±2.74)
112 3D flow , MCA PI + 20 mix; lsol; rsol; 
tga  
Arduini 1990
Zeng 3d Volume 
(2015) China
P S 73 Ao hypoplasia, AVSD,  HLHS, 
PA, PS, TA, TGA, TOF, truncus 
20+4–36+4  (mean 28.2 
± 4.4)
168 cerebral volume(VOCAL), HC, 
MCA PI
- 18 mix (n) n/a 
Miller (2014) USA R S 43 AS, HLHS mean 33+5 - Biometry - 19 n/a Olsen 2010
Masoller (2014) Spain P S 95 Group 1: AS, CoA, HLHS, TGA 
Group 2: AVSD, complex 
CHD, DORV, TOF, truncus 
arteriosus
Group 3: Ebstein, PA, PS, TA
20-23+5 (mean 22+3) 95 Biometry, CPR, fractional mov-
ing blood volume, MCA PI




R M 119 single ventricle(79% HLHS) 18-38 (mean 27) - MCA PI, neonatal HC + 18 mix (n); lsol (n) Arduini 1990
Hangge (2013) USA R S 38 HLHS mean 26.6±5 - Biometry, MCA PI, neonatal HC + 19 lsol (n); HC (n) Olsen 2010
Cnota (2013) USA R S 33 HLHS 19-37 (median 27) - Biometry, UA flow, neonatal 
HC




R S 89 CoA, HLHS, HLHS + CoA, 
PA , TGA
closest to term (mean 
32±5)
89 CPR, MCA PI, neonatal HC - 17 mix; lsol; rsol; 
tga  
Ebbing 2007
Szwast (2012) USA R S 131 single ventricle (RSOL/LSOL) LSOL mean 28.0±5.4; 
RSOL mean 24.4±4.0
92 CPR, MCA PI - 15 mix (n); lsol; 
rsol  
Arduini 1990
Williams (2012) USA pilot S 16 HLHS, TGA, TOF 18-24 (mean 22.8±2.8) - CPR, MCA PI, + 16 mix; lsol; tga Arduini 1990
Arduini (2011) Italy R S 60 AS, AVSD, CoA, HLHS, PA, PS, 
TGA, TOF, other
30-35 (mean 34.1±1.9) 65 Biometry, CPR , MCA PI - 15 mix; HC   n/a 
Itsukaichi (2011) 
Japan
R S 44 CoA, DORV, Ebstein,  HLHS, 
HRHS, PA, PS, single ven-
tricle, TA, TGA, TOF, tumor, 
truncus, VSD
28-34 140 Biometry(AC, BPD, FL), CPR, 
MCA PI
- 18 n/a n/a 
McElhinney (2010) 
USA




P S 45 AS, CoA, completed en-
docardial cushion defect, 
DORV,   Ebstein, HLHS, PA, 
PS, single ventricle, TA, TGA, 
TOF, truncus, 
20-40 275 CPR, MCA PI - 15 mix; lsol; rsol  not reported
Chen (2009) China R S 11 Ebstein 23-37 44 MCA PI - 16 rsol (n) n/a 





R S 28 HLHS/AS 17-36 - HC pre -and postnatal - 15 HC (n) Hadlock 1984
Modena (2006) USA R S 71 AS, AVSD, CoA, DORV, HLHS, 
HRHS, PA, TA, TGA, TOF, 
Truncus, tumor, VSD
‘closest to mid second 
trimester’
71 CPR, MCA PI - 16 mix   Arduini 1990
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Table 1b: overview of included Ultrasound studies
Author (year) / 
country Design*
Multi-/






analysis** Used normal values
Williams (2015) USA/
Canada
P S 66 HLHS, TGA ,TOF F1 (mean 23.6±2), F2 
(mean30.6±1.6), F3 
(mean 36.4±1) 
41 BPD, HC + 15 HC   Hadlock 1984
Hahn (2015) USA R M 133 single 
ventricle
20-34 (mean 27.2±5.3) - Biometry(n=133), MCA 
PI(n=119)
+ 18 mix; HC Arduini 1990; Hadlock 
1984
Masoller (2015) Spain P S 58 AS, AVSD, CoA, complex 
CHD, Ebstein, HLHS, PA, TA, 
TGA,  TOF, truncus 
20-24 (mean 22.3±0.9) 58 BPD, CPR, composite score, 
correlation with MRI, HC, 
MCA PI, 




Zeng 3d Flow (2015) 
China
P S 112 HLHS, LSOL, RSOL, TGA 19+6-30+3 (mean 
25.7±2.74)
112 3D flow , MCA PI + 20 mix; lsol; rsol; 
tga  
Arduini 1990
Zeng 3d Volume 
(2015) China
P S 73 Ao hypoplasia, AVSD,  HLHS, 
PA, PS, TA, TGA, TOF, truncus 
20+4–36+4  (mean 28.2 
± 4.4)
168 cerebral volume(VOCAL), HC, 
MCA PI
- 18 mix (n) n/a 
Miller (2014) USA R S 43 AS, HLHS mean 33+5 - Biometry - 19 n/a Olsen 2010
Masoller (2014) Spain P S 95 Group 1: AS, CoA, HLHS, TGA 
Group 2: AVSD, complex 
CHD, DORV, TOF, truncus 
arteriosus
Group 3: Ebstein, PA, PS, TA
20-23+5 (mean 22+3) 95 Biometry, CPR, fractional mov-
ing blood volume, MCA PI




R M 119 single ventricle(79% HLHS) 18-38 (mean 27) - MCA PI, neonatal HC + 18 mix (n); lsol (n) Arduini 1990
Hangge (2013) USA R S 38 HLHS mean 26.6±5 - Biometry, MCA PI, neonatal HC + 19 lsol (n); HC (n) Olsen 2010
Cnota (2013) USA R S 33 HLHS 19-37 (median 27) - Biometry, UA flow, neonatal 
HC




R S 89 CoA, HLHS, HLHS + CoA, 
PA , TGA
closest to term (mean 
32±5)
89 CPR, MCA PI, neonatal HC - 17 mix; lsol; rsol; 
tga  
Ebbing 2007
Szwast (2012) USA R S 131 single ventricle (RSOL/LSOL) LSOL mean 28.0±5.4; 
RSOL mean 24.4±4.0
92 CPR, MCA PI - 15 mix (n); lsol; 
rsol  
Arduini 1990
Williams (2012) USA pilot S 16 HLHS, TGA, TOF 18-24 (mean 22.8±2.8) - CPR, MCA PI, + 16 mix; lsol; tga Arduini 1990
Arduini (2011) Italy R S 60 AS, AVSD, CoA, HLHS, PA, PS, 
TGA, TOF, other
30-35 (mean 34.1±1.9) 65 Biometry, CPR , MCA PI - 15 mix; HC   n/a 
Itsukaichi (2011) 
Japan
R S 44 CoA, DORV, Ebstein,  HLHS, 
HRHS, PA, PS, single ven-
tricle, TA, TGA, TOF, tumor, 
truncus, VSD
28-34 140 Biometry(AC, BPD, FL), CPR, 
MCA PI
- 18 n/a n/a 
McElhinney (2010) 
USA




P S 45 AS, CoA, completed en-
docardial cushion defect, 
DORV,   Ebstein, HLHS, PA, 
PS, single ventricle, TA, TGA, 
TOF, truncus, 
20-40 275 CPR, MCA PI - 15 mix; lsol; rsol  not reported
Chen (2009) China R S 11 Ebstein 23-37 44 MCA PI - 16 rsol (n) n/a 





R S 28 HLHS/AS 17-36 - HC pre -and postnatal - 15 HC (n) Hadlock 1984
Modena (2006) USA R S 71 AS, AVSD, CoA, DORV, HLHS, 
HRHS, PA, TA, TGA, TOF, 
Truncus, tumor, VSD
‘closest to mid second 
trimester’




Author (year) / 
country Design*
Multi-/






analysis** Used normal values
Kaltman (2005) USA P S 58 arch interruption, AS, CoA,  
Ebstein, PA, PS, TA, TOF
20-39 114 CPR, MCA PI - 19 mix; lsol; rsol  Arduini 1990
Donofrio (2003) USA P M 36 HLHS, HRHS, TGA, LVOTO, 
TOF 
23-29 (mean 26.5±3.8) 21 CPR, HC, MCA RI - 20 n/a n/a 
Jouannic (2002) 
France
P S 23 TGA (+/- VSD) 36-38 (mean 36.7) 40 MCA PI, UA PI - 15 tga n/a 
Meise (2001) 
Germany
P S 115 AS, ASD, AVSD, CoA, DORV, 
Ebstein, HLHS, PA, PS, TA, 
TOF, truncus, VSD, other
19-41 (mean 30.8) 100 MCA PI, UA PI - 14 mix not reported
* P, prospective; R, retrospective; S, single center; M, multicenter
† Ao hypoplasia, aortic arch hypoplasia; AS, Aorta Stenose; AVSD, Atrioventricular Septum Defect;  CoA, Coarctatio 
Aortae; DORV, Double Outlet Right Ventricle; Ebstein, Ebstein’s anomaly; FO, Foramen Ovale; tumor, intracardiac
tumor; HLHS, hypoplastic left heart syndrome ; other, other non-chromosomal extracardiac malformations; 
PA Pulmonary Atresia; PS, Pulmonary Stenosis; TA,Tricuspid atresia; TI, Tricuspid Insufficiency; TGA, Transposition 
of the Great Arteries; TOF, Tetralogy of Fallot; Truncus, Truncus Arteriosus; RSOL, Right Sided Obstructive Lesions;
‡ AC, Abdominal Circumference;  BPD, Biparietal Diameter; CMR, Cardiac Magnetic Resonance;  
CRP, Cerebral-Placental Ratio; CSF, Cerebro-spinal fluid;  FL, Femur Length; HC, Head Circumference; 
MCA, Middle Cerebral Artery;  PI, Pulsatility Index; RI, Resistance Index; UA, Umbilical Artery; VOCAL, 
Virtual Organ Computer-aided AnaLysis; n/a not applicable
** in which meta-analyses are data included: mix, all/mixed types of CHD combined (MCA); lsol, 
left sided obstructive defects (MCA); rsol, rightsided obstructive defects (MCA); tga, transposition of the great 
arteries (MCA); HC, head circumference; (n) not included in the final model, overlapping publication
Table 2: Overview of MRI anomalies

















Sun 2015 CHD: lower umbilical vein oxygen content and lower cerebral oxygen delivery. Reduced fetal 
brain size correlated with these findings
1 in 30 1 n/a n/a  n/a n/a in 30
Andescavage 2015 CHD: smaller brain volume and cerebral volume but larger brainstem volumes, than control 
fetuses. Placental volumes were not associated with the differences in brain volumes.
4 in 38* 0* 1* 1* 2* 0 in 94
Schellen 2015 TOF: abnormally low total brain volumes and enlarged CSF spaces as early as 20 weeks of 
gestation
5 in 24** 0** n/a 5** n/a 0 in 24
Masoller 2015 CHD: smaller brain volumes, also decreased depths for several fissures and metabolic chang-
es, when compared with controls
0 in 58‡ 0‡ n/a n/a n/a 0 in 58
Brossard 2013 CHD: Brain abnormalities in 23% versus 1.5% of normal controls. Subgroup analyses compar-
ing the type and frequency of brain abnormalities based on cardiac physiology did not reveal 
significant associations, suggesting that the brain abnormalities were not limited to those 
with the most severe CHD
33 in 144* 3* 2 13 15 3 in 194
al Nafisi 2013 CHD: 6/22 fetuses showed brain weights at or below the 5th centile for gestational age 
(controls 0/12). No correlation found between brain weight and flow in the SVC, AAo or CVO. 
No correlation found between SVC flow or brain weight with Doppler flows or aortic isthmus 
size or Doppler gradient.
n/a n/a n/a n/a n/a n/a in 12
Mcllzoch 2012 ‘Congenital brain disease’ was found in 39% of fetuses with CHD 21 in 53** 7** 4 9** 1 n/a
Clouchoux 2012 HLHS fetuses demonstrate diminishing brain volumes in third trimester, as well as delay in 
cortical gyrification as early as 25 weeks.
5 in 18* 0* n/a 5* n/a 0 in 30
Berman 2011 3 fetuses with CHD demonstrated abnormally high water diffusion in the thalamus and 
periventricular white matter
1 in 3 1 n/a n/a n/a n/a in 33
Limperopoulos 
2010 Third-trimester fetuses with some forms of CHD have smaller total brain volumes than nor-
mal fetuses and display impaired neuroaxonal development and metabolism.
6 in 52* 2* 2* 4* n/a 0 in 55















* overlapping publications Andescavage / Brossard /Clouchoux / Limperopoulos 
** overlapping publications Mlczoch /Schellen
‡ overlapping publications Masoller 2015 and 2016
† includes cerebellar hypoplasia; corpus callosum agenesis; holoprosencephaly; other cerebral malformations; 
microcephaly; macrocephaly
n/a - not applicable/or stated
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Table 1b continued.
Author (year) / 
country Design*
Multi-/






analysis** Used normal values
Kaltman (2005) USA P S 58 arch interruption, AS, CoA,  
Ebstein, PA, PS, TA, TOF
20-39 114 CPR, MCA PI - 19 mix; lsol; rsol  Arduini 1990
Donofrio (2003) USA P M 36 HLHS, HRHS, TGA, LVOTO, 
TOF 
23-29 (mean 26.5±3.8) 21 CPR, HC, MCA RI - 20 n/a n/a 
Jouannic (2002) 
France
P S 23 TGA (+/- VSD) 36-38 (mean 36.7) 40 MCA PI, UA PI - 15 tga n/a 
Meise (2001) 
Germany
P S 115 AS, ASD, AVSD, CoA, DORV, 
Ebstein, HLHS, PA, PS, TA, 
TOF, truncus, VSD, other
19-41 (mean 30.8) 100 MCA PI, UA PI - 14 mix not reported
* P, prospective; R, retrospective; S, single center; M, multicenter
† Ao hypoplasia, aortic arch hypoplasia; AS, Aorta Stenose; AVSD, Atrioventricular Septum Defect;  CoA, Coarctatio 
Aortae; DORV, Double Outlet Right Ventricle; Ebstein, Ebstein’s anomaly; FO, Foramen Ovale; tumor, intracardiac
tumor; HLHS, hypoplastic left heart syndrome ; other, other non-chromosomal extracardiac malformations; 
PA Pulmonary Atresia; PS, Pulmonary Stenosis; TA,Tricuspid atresia; TI, Tricuspid Insufficiency; TGA, Transposition 
of the Great Arteries; TOF, Tetralogy of Fallot; Truncus, Truncus Arteriosus; RSOL, Right Sided Obstructive Lesions;
‡ AC, Abdominal Circumference;  BPD, Biparietal Diameter; CMR, Cardiac Magnetic Resonance;  
CRP, Cerebral-Placental Ratio; CSF, Cerebro-spinal fluid;  FL, Femur Length; HC, Head Circumference; 
MCA, Middle Cerebral Artery;  PI, Pulsatility Index; RI, Resistance Index; UA, Umbilical Artery; VOCAL, 
Virtual Organ Computer-aided AnaLysis; n/a not applicable
** in which meta-analyses are data included: mix, all/mixed types of CHD combined (MCA); lsol, 
left sided obstructive defects (MCA); rsol, rightsided obstructive defects (MCA); tga, transposition of the great 
arteries (MCA); HC, head circumference; (n) not included in the final model, overlapping publication
Table 2: Overview of MRI anomalies

















Sun 2015 CHD: lower umbilical vein oxygen content and lower cerebral oxygen delivery. Reduced fetal 
brain size correlated with these findings
1 in 30 1 n/a n/a  n/a n/a in 30
Andescavage 2015 CHD: smaller brain volume and cerebral volume but larger brainstem volumes, than control 
fetuses. Placental volumes were not associated with the differences in brain volumes.
4 in 38* 0* 1* 1* 2* 0 in 94
Schellen 2015 TOF: abnormally low total brain volumes and enlarged CSF spaces as early as 20 weeks of 
gestation
5 in 24** 0** n/a 5** n/a 0 in 24
Masoller 2015 CHD: smaller brain volumes, also decreased depths for several fissures and metabolic chang-
es, when compared with controls
0 in 58‡ 0‡ n/a n/a n/a 0 in 58
Brossard 2013 CHD: Brain abnormalities in 23% versus 1.5% of normal controls. Subgroup analyses compar-
ing the type and frequency of brain abnormalities based on cardiac physiology did not reveal 
significant associations, suggesting that the brain abnormalities were not limited to those 
with the most severe CHD
33 in 144* 3* 2 13 15 3 in 194
al Nafisi 2013 CHD: 6/22 fetuses showed brain weights at or below the 5th centile for gestational age 
(controls 0/12). No correlation found between brain weight and flow in the SVC, AAo or CVO. 
No correlation found between SVC flow or brain weight with Doppler flows or aortic isthmus 
size or Doppler gradient.
n/a n/a n/a n/a n/a n/a in 12
Mcllzoch 2012 ‘Congenital brain disease’ was found in 39% of fetuses with CHD 21 in 53** 7** 4 9** 1 n/a
Clouchoux 2012 HLHS fetuses demonstrate diminishing brain volumes in third trimester, as well as delay in 
cortical gyrification as early as 25 weeks.
5 in 18* 0* n/a 5* n/a 0 in 30
Berman 2011 3 fetuses with CHD demonstrated abnormally high water diffusion in the thalamus and 
periventricular white matter
1 in 3 1 n/a n/a n/a n/a in 33
Limperopoulos 
2010 Third-trimester fetuses with some forms of CHD have smaller total brain volumes than nor-
mal fetuses and display impaired neuroaxonal development and metabolism.
6 in 52* 2* 2* 4* n/a 0 in 55















* overlapping publications Andescavage / Brossard /Clouchoux / Limperopoulos 
** overlapping publications Mlczoch /Schellen
‡ overlapping publications Masoller 2015 and 2016
† includes cerebellar hypoplasia; corpus callosum agenesis; holoprosencephaly; other cerebral malformations; 
microcephaly; macrocephaly




The search resulted in ten studies (445 fetuses) addressing fetal cerebral MRI. In 
Table 2 the main conclusions and extracted data regarding cerebral abnormalities are 
summarized. We noted variation in reported cerebral data: some studies reported fetal 
brain volumes or brain weights, but the methods to calculate the variables differed23-28. 
Others reported on metabolic aspects23;28;29, cerebral maturation indices27;28 or 
derived cerebral oxygenation parameters24;26. Most authors also described cerebral 
malformations or acquired cerebral lesions. Possible duplicate cohorts were identified 
in three publications23;25;27. The data of five articles (duplicate cohorts not included) 
were summarized to a prevalence estimate of cerebral abnormalities of 18% (95% CI -6; 
42)28-32. Structural brain anomalies were present in 3% (95% CI -1; 8). The subdivision 
in the three other categories was feasible in two articles without possible overlap; the 
estimated prevalence is displayed in Table 2 (cystiform abnormalities 4%, ventricular 
abnormalities 12% and other (acquired) lesions 6%)30;31. The data were reported as mixed 
CHD group, however most authors included severe CHD only. The data did not allow 
further subdivision into specific CHD.
Figure 2b: Quality of included ultrasound studies
ULTRTASOUND STUDIES
Head circumference
The search resulted in 13 studies (753 fetuses) addressing fetal head biometry values. 
Eight studies included larger groups of mixed CHD28;33-39 and five only included HLHS40-44. 
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Eight studies calculated z-scores or percentiles to correct for the effect of gestational 
age, using various normal reference populations (Table 1b)28;33-36;40-42. One study reported 
absolute values at 34 weeks of gestation37. Data from five articles were excluded from 
the meta-analysis because of incomparable data (BPD36 or head/weight ratio38;43), or 
because data were not displayed39;44. Four meta-analysis models were fitted, including 
three models for sensitivity analysis (Supplement 3). Three articles contained possible 
duplicates and were excluded from the final meta-analysis model28;41;42. The final model 
(Figure 3) includes the data of five articles, of which three  included a control group34;35;37. 
The results were analyzed as data of a mixed CHD group, but LSOL and single ventricle 
defects cases are overrepresented. The HC has a pooled z-score of -0.51 (95% CI -0.84; 
-0.18), indicating a smaller HC in CHD fetuses of 0.5 SD below the population mean. The 
data did not allow further subdivision into in specific CHD, because of small numbers in 
each category.  Funnel plots and information on statistical heterogeneity are available in 
Supplement 4.
Figure 3: Pooled head circumference z-score – fetuses with mixed types of CHD
Suspected duplicate cohorts are excluded; the effect sizes are corrected for gestational age using 
population parameters of reference studies (no control groups).
Several authors reported the percentage of fetuses with “abnormal” HC values, meaning 
cases with a HC below the third percentile or a z-score below -2, at various gestational 
ages28;41;42. Only a few studies explored the HC/abdominal circumference or HC/fetal 
weight ratio as well37;38;41;43, but the data were not suitable for pooling.
Doppler flow
Data regarding middle cerebral artery (MCA) flow were available in 21 articles (1412 
fetuses). Most studies  (n=14) calculated z-scores or percentiles to correct for the effect 
of the gestational age, using various normal reference populations (Table 1b)28;33;35;40;45-54. 
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Seven studies reported absolute values at a specific gestational age36-39;42;55;56.  Three 
articles were excluded from the meta-analysis because the pulsatility indices (PIs) 
were not available23;36;38. In three studies the combined effect size for a group of mixed 
CHDs was not reported, but could be calculated from documented subgroup effect 
sizes46;52;53(Supplement 2). Sixteen meta-analysis models were fitted, including twelve 
models for sensitivity analyses (Supplement 3). Several studies were identified to report 
overlapping populations28;39;42;52;54;56, and 13 studies included a control group. Only the 
largest and/or the most recent cohorts, including a control group, were used in the final 
meta-analyses displayed in Figures 4a-d; either as a mixed CHD group (nine articles, 
Figure 4a) or for specific CHD: LSOL (six articles, Figure 4b); RSOL (seven articles, Figure 
4c) or TGA (four articles, Figure 4d). A significant lower MCA PI z-score was found in 
the mixed CHD group (-0.33; 95% CI -0.50 to -0.16) and the LSOL group (-0.70; 95% 
CI -0.99 to -0.41). Only two studies reported a subgroup with TOF49;50. These numbers 
were too small for a subgroup meta-analysis. Funnel plots and information on statistical 
heterogeneity are available in Supplement 4.
Several authors reported the percentage of fetuses with “abnormal” values. The 
definitions of abnormal varied (MCA PI, or RI, below the fifth or 2.3rd percentile or a 
z-score below -2, at least once in pregnancy or at a certain gestational age)27;34-37;40;42;46-
48;50;52;56. Reports on the prevalence of CPR below 1.0 (labeled as “brainsparing”) varied, 
ranging from 11% (in the third trimester) to 56% (in the second trimester) and 44% at 
any time in pregnancy36;38;49. A higher prevalence of CPR below the fifth percentile was 
reported in CHD fetuses47, and CPR z-scores below -2 were reported more frequently 
in HLHS fetuses50. These data were not suitable for pooling.
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Figure 4b: Pooled middle cerebral artery pulsatility index z-score – fetuses with left sided 
obstructive lesions
Figure 4c: Pooled middle cerebral artery pulsatility index z-score – fetuses with right sided 
obstructive lesions
Figure 4d: Pooled middle cerebral artery pulsatility index z-score – fetuses with transposition 
of the great arteries




CORRELATION WITH NEURODEVELOPMENTAL OUTCOME
In eight articles (331 fetuses, Table 3), postnatal ND outcome was assessed. The correlation 
with fetal data was studied in seven articles28;33;34;42;49;53;54. One study was identified 
as a possible duplicate54. Results varied between studies. Three articles focused on 
correlating ND outcome to fetal cerebral flows, but had conflicting results49;53;54. The 
largest of the studies correlated brainsparing with a favourable ND outcome54. Three 
articles focused on correlating ND outcome to fetal biometry, possibly showing a trend 
towards worse ND outcome in fetuses with lower age-adjusted weight in general33;34;42. 
Relative small fetal HC compared to weight (small HC/weight or HC/abdomen ratio) was 
not unanimously identified as a predictor for adverse ND outcome.
DISCUSSION 
This review and meta-analysis show that fetuses with CHD demonstrate signs of impaired 
brain development, identified either with fetal US or MRI. The most studied parameter is 
the middle cerebral artery (MCA), which demonstrates a slightly increased end-diastolic 
blood flow in CHD fetuses. This effect appears to be predominantly present in LSOL. The 
MCA-flow appears not to be altered in TGA or RSOL. Although one of the larger studies 
focusing solely on TGA showed a significant lower MCA PI55, this effect is contradicted by 
the three other studies that included a TGA subgroup. 
Combining all types of CHD, a smaller HC throughout gestation is encountered 21;57;58, but 
pre-selected CHD cases, mainly LSOL, are overrepresented in these data. In postnatal 
studies, neonates with HLHS, TGA and TOF have been associated with a smaller HC and 
subsequent adverse ND outcome12-15. Recently, a large population-based study reported 
a smaller neonatal HC in less severe CHD such as ventricular septal defects59, but this 
has not been confirmed in prenatal studies yet.
Reported US data are limited to the measurement of flows or biometry at specific 
gestational ages. The effect of growth throughout gestation has not been investigated 
thoroughly, thus the timing of (ND) deterioration is difficult to determine. The small HC 
might already be present at midgestation in specific types of CHD35. The MCA PI appears 
to diminish with advancing GA52. 
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Table 3: Articles assessing neurodevelopmental outcome















Biometry BSID-III at 18 
months
46 of 68 After multivariate correction: 
Low BSID-III cognitive score 
correlated with low  HC/AC ratio 
at midgestation. Low BSID-III 
language score was predicted by 
FL/BPD at beginning 3rd trimester
Hahn (2015) USA * single 
ventricle
Biometry BSID-II at 14 
months
82 of 133 Low BSID-II mental score fetal 
correlated with low AC z-score 
at > 34 weeks. Low BSID-II 
psychomotor score correlated 
with high mean HC/AC ratio, low 
EFW z-score and low AC z-score 
at 24-29 weeks. 






38 of 104 Early adverse ND outcome 







the first 6 
months of 
life
MRI BSID-III at 4-6 
months
17 of 58 BSID-III average score correlated 
with fetal MRI brain volume, fissure 
depth and metabolic aspects. 
“Abnormal brain development 
“(MRI composite score) 
correlated with HC and MCA PI at 
midgestation




Flows BSID-II at 12 
months
41 of 112 No significant correlation between 
MCA-PI and BSID-II score. Low 
BSID mental and psychomotor 
score fetal correlated with several 







Flows BSID-II at 14 
months
72 of 119 High BSID-II psychomotor score 
was associated with low MCA PI 
z-score
Williams (2012) USA HLHS, TGA, 
TOF
Flows BSID-III at 18 
months and 
neonatal EEG
13 of 16 Low BSID-III cognitive score 
correlated with low MCA PI 
z-score and CPR z score <-1 










22 of 53 3/8 (37.5%) children with fetal 
brain abnormalities and 3/14 
(21.4%) children with no fetal brain 
abnormality exhibited 
developmental problems. Because 
of the small groups, no statistics 
were performed.
ND, neurodevelopment; BSID, Bayley’s Scale of Infant Development; EEG electro encephalogram; CPR, 
cerebroplacental ratio; MCA PI, middle cerebral artery pulsatility index 
† AS, Aorta Stenose; AVSD, Atrioventricular Septum Defect; CoA, Coarctatio Aortae; Ebstein, Ebstein’s anomaly; 
HLHS, hypoplastic left heart syndrome; other, other non-chromosomal extracardiac malformations; PA Pulmonary 
Atresia; RSOL, Right Sided Obstructive Lesions; TA,Tricuspid atresia; TOF, Tetralogy of Fallot; TGA, Transposition of 
the Great Arteries; Truncus, Truncus Arteriosus; 
* overlapping publications: Hahn 2015 and Williams 2013
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We did not encounter any fetal US studies assessing detailed cerebral characteristics, 
such as cortical thickness, cerebral maturation or spinal fluid amount, even though 
neonatal studies report delayed brain maturation and cerebral atrophy in newborns with 
CHD7;8 and dedicated neurosonography has the capacity to detect most of the reported 
anomalies16. Fetal brain volume was addressed in one ultrasound study, showing reduced 
cerebral volume growth in fetuses with HLHS, TGA, aortic arch hypoplasia and TOF39. 
As demonstrated in our review, ND details and cerebral metabolism are increasingly 
being studied in CHD using fetal MRI. The reported variables in the included MRI 
studies are however very heterogeneous and were assessed at different gestational 
ages. Normal values are not available for comparison, and methods of data reporting 
vary between studies, hampering meta-analysis. Studies including a control group do 
consistently report smaller fetal brain volumes in different types of CHD23-25;27;28;32;60. 
Reports on this topic are emerging rapidly, but the analysis of fetal cerebral volume, 
metabolism and maturation appears to be limited to research settings and have not 
permeated to daily clinical practice yet. Also, the definition of (the pathogenicity of) 
MRI lesions varies between studies. For example, subependymal cysts are generally 
considered to be physiological variants61,  but are reported as abnormalities by some 
authors23;30;60. Furthermore, genetic abnormalities and severe structural lesions, such as 
holoprosencephaly, were not excluded in certain studies26;30, resulting in an overrating 
of found anomalies.
Several theories were postulated to explain the correlation of CHD with prenatal cerebral 
findings, but exact pathophysiologic mechanisms remain unclear. A high prevalence of 
children small for gestational age in CHD62-64 prompted several authors to investigate the 
relationship between fetal CHD and placental development26;60;65. Placental insufficiency 
and subsequent growth restriction usually presents with a relative large HC/abdomen 
ratio in fetuses without CHD66. Most of the fetal biometry reports addressing HC growth 
in CHD fetuses did, however, not include the abdominal growth, fetal weight or HC/
abdomen ratios. Therefore, we are unable to determine a possible correlation between 
the found smaller HC and fetal weight. Postnatal studies have indicated that most of the 
neonates with CHD and smaller HC are also small for gestational age at birth; but HC/
weight ratios have not been extensively investigated11;14.
Secondly, a correlation between cerebral hemodynamics and fetal neurodevelopment in 
CHD has been suggested38. It seems plausible that the restriction of flow to the carotid 
arteries, in cases of reversed aortic arch flow, can induce vasodilatation in the cerebral 
circulatory system to facilitate and secure transport of oxygen and nutrients. This is 
not proven in an in-vivo setting yet. In this review, heterogeneity in the reported data 
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resulted in an impossibility to pool the data on the cerebroplacental ratio, hampering a 
definite conclusion regarding a possible brainsparing effect in CHD. Moreover, research 
concerning the brainsparing effect has mainly been performed in placental insufficiency, 
in which it is considered a mechanism to prevent fetal brain hypoxia rather than a sign 
of impending brain damage67. Because of the totally different pathophysiological and 
hemodynamic circumstances in CHD versus growth restriction, conclusions are not 
interchangeable. Brainsparing is correlated with worse ND outcome in growth restricted 
fetuses68. Even though available data suggests that brainsparing correlates with altered 
brain development in CHD27;28, a correlation with long-term outcome has not been 
established. On the contrary, it has even been suggested that brainsparing is associated 
with more favorable ND outcome in CHD54. 
Another explanation for the cerebral variations in neonates with CHD could be a 
common genetic pathway, causing fetal CHD and ND delay69;70. The fact that fetuses and 
neonates with types of CHD that do not have a significant effect on fetal hemodynamics 
(minor CHD), also demonstrate cerebral anomalies, a smaller HC and low birth weight59 
supports this theory. The development of the fetal brain in less severe CHD, such 
as ventricular septal defects, has however not been reported separately. In future 
research, the inclusion of minor CHD will be necessary to investigate this. Furthermore, 
a thorough genetic assessment in fetal CHD studies is necessary to exclude the effect 
of confounding genetic factors. Prenatal genetic testing is generally limited to array CGH 
with a reasonable resolution71, but it is known that smaller (point)mutations can play a 
role in CHD or neurodevelopment72-74. 
To our knowledge, this review and meta-analysis is the first to perform a meta-analysis of 
fetal cerebral flow abnormalities in fetuses with (severe) CHD. A narrative review published 
in 2010 and a recent systematic review on MRI findings are available75;76. Certain included 
publications overlap, but our study includes a larger sample size with regard to cerebral 
flow, facilitating meta-analyses and subgroup assessment. Furthermore, exclusion of 
certain duplicate MRI cohorts results in a lower prevalence of MRI abnormalities in our 
review, which did not reach statistical significance. Two reviews focusing on postnatal 
findings are available for comparison, reporting high rates of cerebral damage in fetuses 
with CHD prior to surgery7;8. However, these reviews probably included children with 
CHD that were undetected prior to birth, thus possibly including postnatally developed 
abnormalities, possibly due to asphyxia because of a delayed diagnosis. 
In our meta-analyses we compared z-scores. A z-score is a statistical tool to compare 
the results from cases with a standardized population, eliminating the influence of 
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gestational age. We have tried to maximize our sample size by transforming divergent 
outcome measures to mean z-scores, which also has some drawbacks. Grouped effect 
sizes would have been more accurate when individual measurements were corrected for 
individual gestational age, but these data are not available and assumptions on a higher 
data aggregation level are made. Another source of bias can be the various used normal 
values, which causes difficulty comparing the studies with each other. In the sensitivity 
analyses we determined that the use of population references, compared to the use of a 
control group, leads to a different outcome. In most studies it lead to a larger difference 
in effect size. To eliminate the effect of the various used standard populations we have 
chosen to use the studies reported control group as reference value. 
Conclusion
This meta-analysis shows that fetuses with isolated, severe CHD demonstrate signs of 
impaired fetal cerebral development, demonstrated by fetal ultrasound or MRI. Our 
findings underline the importance of fetal neurological evaluation in CHD. However, 
reports correlating postnatal ND outcome to fetal findings remain inconclusive. 
Therefore, it is too early to conclude that aberrations revealed by neuroimaging involve 
a high risk of ND delay. To define the clinical meaning of prenatal cerebral variations in 
CHD, prospective large and long-term cohort studies are required, combining pre- and 
postnatal data. Such studies should include thorough genetic assessment and compare 
the findings to healthy controls.  Parents should be counselled about the correlation 
of (specific types of) CHD with ND delay77, but until a correlation with ND outcome has 
been ascertained, there is insufficient data to support counseling families regarding ND 
outcome, or as a rationale for fetal therapy, based on prenatal findings suggestive of 
altered brain development.
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congenital heart defects: lack of 
influence of aortic arch flow and 
ascending aorta oxygen saturation
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Congenital heart defects (CHD) are reported to be associated with smaller head 
circumferences (HC) and neurodevelopmental delay. Recent studies suggest that altered 
intra-uterine brain hemodynamics may explain these findings. 
Methods 
Singleton fetuses with isolated CHD were selected in three fetal medicine units 
(n=436). Cases with placental insufficiency or genetic syndromes were excluded. CHD 
were clustered based on the flow and oxygen saturation in the aorta. HC at different 
gestational ages was evaluated and univariate and multivariate mixed regression analysis 
was performed to examine the patterns of prenatal HC growth.
Results
Fetuses with severe and less severe types of CHD demonstrate HC growth restriction 
with advancing gestation (slope -0.017/ day), but a statistically significant effect of 
fetal hemodynamics clustering was absent. Even CHD with normal brain oxygenation 
and normal aortic flow showed a significant decrease in HC growth (slope -0.024/day). 
Furthermore, only Tetralogy of Fallot demonstrated a smaller HC z-score at 20 weeks of 
gestation (-0.67; 95% CI -1.16; -0.18).
Conclusions
The HC growth decline in prenatally detected isolated CHD was still within the normal HC 
range, raising the question of its clinical significance. Furthermore, in contrast to other 
studies, this large cohort did not establish a significant correlation between aortic flow 
or oxygen saturation and HC growth. Factors other than altered cerebral hemodynamics 
may contribute to HC restriction with advancing gestation, such as (epi)genetic or 
placental factors. 
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INTRODUCTION 
Severe congenital heart defects (CHD) occur in 2-3 per 1000 live births and are 
responsible for significant morbidity and mortality. New methods of neonatal support 
and advanced surgical techniques have improved the survival rate significantly over the 
last decades. As a result, the focus of attention has shifted from survival to irreversible 
morbidity and long-term outcome1. Children with severe CHD frequently show cerebral 
impairments and neurodevelopmental delay (ND)2-4. Major causes of ND are hypoxia, 
thrombo-embolic insults and other surgical factors5-8. However, more than half of the 
newborns with CHD have signs of neurological abnormalities prior to surgery, raising the 
question whether CHD might cause prenatal cerebral damage9-11. It has been hypothesized 
that intrauterine hypoxic central nervous system damage or altered cerebral arterial 
hemodynamics induce delayed brain maturation and growth12-16. Various studies found 
significantly smaller head circumference (HC) in non-syndromic CHD, mainly in children 
with transposition of the great arteries (TGA), tetralogy of Fallot (TOF) and hypoplastic 
left heart syndrome (HLHS)17-20. However, the published cohorts attempting to validate 
the prenatal hemodynamics hypothesis are small and focus only on specifically severe 
CHD12-16;21;22. 
If the HC is smaller at birth, then it  should be detectable prior to birth. If cerebral 
flow and oxygen delivery play an important role, the relationship between the type of 
CHD and the HC should be apparent. As the presence of reduced head growth might 
be associated with ND after birth23, its presence may be  predictive and could have an 
impact on parental counselling. Few studies, however, have focused on the prenatal HC 
growth in CHD13;16;23-28. 
Our aim was to evaluate patterns of HC growth in a large cohort of fetuses with various 
CHD, and to analyze these patterns per type of CHD, to estimate the effect of cerebral 
hemodynamics (aortic arch flow and ascending aorta oxygen saturation) with advancing 
gestation in the second and third trimester . Our hypothesis was that, in the presence of 
a normal abdominal growth, HC growth is diminished in fetuses with CHD with reduced 
ascending aorta oxygen saturation and/or reduced aortic arch flow.
METHODS
This study was performed in the Leiden University Medical Center (LUMC), VU Medical 
center (VUmc) and Amsterdam Medical Center (AMC) over a 12.5 year period. These 
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three university medical centers collaborate in the care for children with CHD (center 
for congenital heart defects Amsterdam Leiden, CAHAL). All children with CHD, born 
between January 2002 and January 2012 were entered in the CAHAL database. The 
cases and methods of data collection were previously described29. The CAHAL database 
was supplemented with consecutive CHD cases, born in the LUMC between January 
2012 and July 2014. From this combined database, prenatally diagnosed structural CHD 
were extracted. Functional CHD such as cardiomyopathy and primary arrhythmias were 
not eligible for inclusion. Cases with co-existing significant extracardiac malformations, 
severe hydrops, genetic anomalies and/or postnatal appearing syndromic abnormalities 
were excluded from further analysis. Minor additional findings, such as soft markers 
(e.g. echogenic focus and echogenic bowel), amniotic fluid pathology, mild pericardial 
effusion and/or single umbilical artery were not considered as significant extracardiac 
abnormalities and were not excluded. Multiple gestation, as well as cases with maternal 
pathology that could have an effect on fetal growth, i.e. pregnancy induced hypertension, 
preeclampsia, HELLP syndrome or signs of placental insufficiency by postnatal placental 
weight examination, were excluded.  Pre- and postnatal ultrasound data were reviewed. 
Postnatal follow-up regarding the definitive cardiac defect, genetic defects or syndromic 
diagnosis and neurodevelopment was distilled from clinical files, these were available 
until at least one year of age. Pre-existent maternal illnesses (such as pre-existent 
hypertension and thyroid disease), maternal smoking, maternal body mass index (BMI) and 
parity were distilled from clinical files. Gestational age (GA) was based on first-trimester 
ultrasound. Repeated prenatal ultrasound examinations were performed routinely to re-
evaluate the cardiac defect and to assess fetal wellbeing. At each examination, fetal 
biometrical data were measured routinely. Thus, head and abdominal circumference 
(HC and AC) were prospectively entered in patient files, and extracted from the fetal 
ultrasound databases for the purpose of this study. The measurements were performed 
according to the guidelines of the Dutch Society for Obstetrics and Gynecology30, which 
are the same as described by the International Society of Obstetrics and Gynecology. 
Clustering of CHDs
First, the CHDs were defined according to the postnatal diagnosis, made by postnatal 
ultrasound or postmortem examination. Second, CHDs were clustered based on two 
aspects: oxygen delivery and flow to the brain. The resulting clusters are depicted 
in table 2. As an indication for oxygen delivery to the brain, the heart defects were 
clustered by ascending aorta oxygen saturation as having either 1) low oxygen delivery 
to the brain (e.g. transposition of the great arteries; TGA), 2) intracardiac mixing of the 
oxygen-rich and oxygen-poor blood (e.g. atrioventricular septal defects, tetralogy of 
Fallot; TOF), or 3) normal oxygen delivery to the brain (e.g. congenitally corrected TGA 
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without additional cardiac defects, Ebstein’s anomaly with normal cardiac function). As 
an indication for cerebral blood flow, heart defects were labeled as having either a) 
reversed aortic arch flow (e.g. aortic atresia, hypoplastic left heart syndrome; HLHS), 
b) obstructed aortic arch flow (e.g. aortic stenosis or hypoplasia), or c) normal aortic 
arch flow (e.g. TOF, TGA). In some cases clustering was complex, for instance severe 
aortic stenosis (developing HLHS) can display forward flow in the aorta prenatally. For the 
subtypes of CHD in which the clustering was disputable, or in which the flow direction in 
the aorta was not described in the files, two researchers (FJ and MR) independently re-
evaluated all pre- and postnatal ultrasound and postmortem data to retrieve information 
about aortic arch flow and ascending aorta oxygen saturation in the prenatal period. In 
the supplementary material, the methods of clustering are clarified further and the types 
of CHD in the different clusters are listed. Our method of clustering shows similarities 
to the subclassification of Masoller et al28, and is based on theoretical hemodynamics. 
Actual in vivo measurement of cerebral oxygenation would be preferable21, but resources 
and expertise to do this are not widely available. Thus our approach is the most feasible 
and the most accessible for large groups, therewith minimizing selection bias. 
Data handling and statistical analysis
All biometrical data were compared to the growth charts of Verburg et al30, because 
these growth charts were produced from a large comparable Dutch population 
(n=3760), and constructed in approximately the same period as our own cohort with 
modern ultrasound machines. We constructed z-scores of HC and AC. The HC/AC 
ratio is not available in these growth charts. To account for the dependence between 
repeated measurements on the same fetus, we used a linear mixed regression model to 
study the effect of increasing gestational age (GA) on the z-scores. First, we analyzed 
the z-scores in a univariate regression model, to assess the difference with the normal 
values and estimate clinical relevance. Growth restriction of the fetal head was defined 
as a significant decrease in HC z-score with advancing GA (the slope of the regression). 
Secondary to this model we compared the effect of increasing GA on the z-scores 
between the clusters cerebral blood flow and ascending aorta oxygen saturation 
separately. Third, we used both clusterings, as well as known confounders, as covariates 
in a multivariate regression analysis. Variables of interest and confounders were only used 
as covariates if the univariate effect size was smaller than p=0.1. Obesity was defined as a 
BMI > 25 kg/m2.  Percentages of HC below -2 standard deviations (SD) within subgroups 
were compared with each other by Chi square test. Statistical analysis was performed 
using SPSS statistics version 20.0.0 (IBM, Armonk, NY, USA), data were displayed using 




With the above described criteria we identified 1089 fetuses. Cases with significant genetic 
anomalies and/or postnatal appearing syndromic abnormalities (n=254), extracardiac 
malformations/severe hydrops (n=340), primary arrhythmia (n=10), functional CHD 
(cardiomyopathy n=9), multiple gestation (n=18) or maternal pathology with possible 
effect on fetal growth (n=22) were excluded. This led to a total of 436 fetuses eligible 
for inclusion, of which 306 (70%) were live born; in 121 cases (28%) the pregnancy was 
terminated. Postnatal confirmation of the CHD by ultrasound was available in 99% of the 
live born cases;  lost to follow up due to birth outside the Netherlands occurred in 5 cases. 
Postnatal confirmation of the CHD was possible in 42% of the demised fetuses; in 58% 
the parents did not give permission for postmortem examination. Basic characteristics 
of the group, such as parity, BMI, pre-existent maternal illness and the presence and 
type of minor additional findings, as well as the CHD diagnoses are summarized in table 1. 
Table 1: Basic characteristics of the cohort
  N








ascites/pericardial- or pleural effusion 9
Arrhythmia
Other minor additional findings 
3
14
no additional findings 353





no maternal illness 380
nullipara 183 42%
multipara 252
live born 306 70%
termination of pregnancy 121
IUFD 9









hypoplastic left heart syndrome 76
transposition of the great arteries 38
aortic arch hypoplasia and/or aortic stenosis 29
tricuspid atresia or pulmonary atresia 29
Tetralogy of Fallot or Fallot-like defect 39
ventricular septal defect 28
other (see supplementary list) 197
hypoplastic left heart syndrome live born 26 34%
termination of pregnancy 49
IUFD 1
CHD congenital heart defect,  SUA single umbilical artery, BMI body mass index, IUFD intra uterine fetal demise
In 290 fetuses multiple biometrical measurements were present (available examinations: 
median 4 range 2-11) and in 146 fetuses only a single measurement was present, resulting 
in 1323 measurements in total (range 12+5 to 40+5 weeks+days). The clustering by aortic 
arch flow and ascending aorta oxygen saturation was possible in all included cases. The 
resulting clusters are depicted in table 2, with the corresponding number of fetuses. 
Table 2: Clustering of the types of congenital heart defect of the cohort
Ascending aorta oxygen saturation Total
low mixed normal
Aortic arch flow
reversed - 76 - 76
obstructed - 35 45 80
normal 38 150 92 280
Total 38 261 137 436
All CHDs combined
Compared to the growth charts, the HC z-score of the whole CHD group diminished 
with advancing GA (slope of -0.017 per day, univariate regression analysis, table S1). The 
HC had a mean z-score of +0.02 (95% CI -0.09;+0.12) at 20 weeks of gestation, reducing 
to a mean z-score of -0.23 (95% CI -0.35;-0.11) at 36 weeks of gestation. A HC < - 
2 SD at any point in pregnancy was encountered in 8.0 % (n=35/436, table S2). True 
microcephaly, defined as a HC < -3 SD, in the presence of normal overall fetal growth31, 




The results of univariate regression analyses of HC z-score in specific types of CHD 
compared to growth charts are shown in figure 1 and table S1. Fetuses with TGA showed 
normal HC z-score at 20 weeks of gestation (-0.14, 95% CI -0.44; 0.16), and a statistically 
significant HC restriction with advancing GA (HC z-score at 36 weeks of gestation -0.35, 
95% CI -0.63; -0.07). Fetuses with isolated tetralogy of Fallot (TOF) showed a smaller HC 
z-score at 20 weeks of gestation (-0.67; 95% CI -1.16; -0.18) but showed no statistically 
significant HC restriction with advancing GA. No statistically significant differences 
compared to growth charts were found in fetuses with HLHS (n=76), Ebstein’s anomaly 
(n=12), tricuspid atresia (n=16), persistent left vena cava superior (PLVCS) without left 
ventricle obstruction (n=15), coarctation of the aorta (n=20) or ventricular septal defect 
(n=28) separately. The other types of CHD (all n < 12)  were not separately analyzed, 
because numbers were too small to perform a reliable regression analysis. 
Figure 1: HC z-score throughout pregnancy in different types of CHD †
HLHS, hypoplastic left heart syndrome; TGA, transposition of the great arteries; Ebstein’s anomaly; TA tricuspid 
atresia; CoAo, coarctation of the aorta; VSD, ventricular septal defect; TOF, tetralogy of Fallot.
† only TOF showed statistically significant smaller HC Z-score at 20 weeks of gestation compared to growth charts; 
HC growth throughout pregnancy did not significantly decrease/increase in any of the types of CHD separately.
In the combined group of CHD with normal brain oxygenation and normal aortic flow 
(such as rhabdomyomata (without tuberous sclerosis), congenitally corrected TGA, 
Ebstein’s anomaly without hydrops and PLVCS without left ventricle inflow obstruction) 
we found a statistically significant higher HC z-score at 20 weeks of gestation compared 
to the population mean (+0.31, 95% CI 0.08; 0.53), but a significant decrease in HC 
growth with advancing GA (slope -0.024, table S1). 
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Ascending aorta oxygen saturation 
Intergroup analysis 
We observed a lower mean HC z-score (-0.47, 95% CI -0.88; -0.06) in the low oxygen 
group (TGA), compared to the normal oxygen group (reference value) at GA 20 (table 3 
and figure 2).  The intracardiac mixing group showed a lower z-score as well  (-0.41, 95% 
CI -0.64; -0.17). There were no statistically significant differences in HC growth between 
the low, mixed and normal ascending aorta oxygen saturation groups, although the TGA 
(low) group tended to have a slightly shallower slope. 









slope of HC 
z-score* p
normal ascending aorta oxygen 
saturation
137 456 ref ǂ ref
intracardiac mixing 261 729 -0.41† 0.001ǂ +0.004 0.7
TGA (low ascending aorta oxygen 
saturation) 
38 137 -0.47† 0.03ǂ +0.012 0.4
normal aortic arch flow 280 902 ref ǂ ref
obstructed aortic arch flow 80 258 +0.10 0.5ǂ +0.006 0.6
HLHS (reversed aortic arch flow) 76 162 -0.25 0.09ǂ +0.010 0.5
BMI >25 kg/m2 (obesity) 81 301 -0.13 0.4 +0.035† 0.002ǂ
BMI<25 kg/m2 167 567 ref ref ǂ
smoking 34 100 -0.4† 0.046ǂ +0.01 0.6
no smoking 336 1064 ref ref
Minor additional findings present 83 307 +0.08 0.6 +0.01 0.3
no additional findings 353 1015 ref ref
maternal illness 32 126 +0.01 0.9 -0.01 0.6
no maternal illness 380 1165 ref ref
nullipara 183 553 -0.22† 0.04ǂ +0.013 0.2
multipara 252 757 ref ǂ ref
live born 306 1119 ref ǂ ref
termination of pregnancy 121 138 -0.27† 0.02ǂ -0.05 0.1
IUFD 9 20 +0.17 0.7ǂ -0.01 0.8
HC head circumference, BMI body mass index, HLHS hypoplastic left heart syndrome, IUFD intra uterine fetal 
demise; ref reference category; †statistically significant; *comparing to Verburg; ǂ included in multivariate model
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left: clinical interpretation    right: zoomed in with 95% CI’s plotted
Figure 2: Influence of ascending aorta oxygen saturation on HC z-score throughout pregnancy
Bivariate regression analysis  was performed to assess the influence of ascending aorta oxygen 
saturation (clustering) on HC z-score throughout pregnancy.
Dashed line (green)--- normal ascending aorta oxygen saturation
Dotted line (blue) ... low ascending aorta oxygen saturation (TGA)
Continuous line (red) _ intracardiac mixing
Comparison with growth curves of a normal population
Compared to the normal growth charts, fetuses with low or reduced ascending aorta 
oxygen saturation (clusters TGA and intracardiac mixing) did not have a significantly 
smaller HC at 20 weeks of gestation (table S1, HC z-score TGA -0.14, 95% CI -0.44; 0.16, 
resp. intracardiac mixing -0.11, 95% CI -0.25; 0.03). At 36 weeks of gestation however, 
both groups displayed a significantly lower HC z-score when compared to normal fetuses 
(TGA -0.35, 95% CI -0.63; -0.07, resp. intracardiac mixing -0.33, 95%CI -0.50; -0.17). 
There were no significant differences in percentages of HC < -2 SD between the groups 
(table S2), which -at any point in pregnancy- was observed in 5.3% of fetuses with TGA, 
9.6% of fetuses with intracardiac mixing, and in 5.8% of fetuses with normal oxygen 
saturation. 
Aortic arch flow 
Intergroup analysis
Compared to the group of fetuses with normal aortic flow, the mean HC z-score at 
GA 20 tended to be slightly lower in the group with reversed aortic arch flow (HLHS), 
but the differences were not statistically significant (table 3 and figure 3). There were 
no significant differences in the slope between all subgroups. Of the cases with HLHS 
(reversed flow), termination of pregnancy was performed in 65%, resulting in 26 cases 
for regression analysis in this subgroup.
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left: clinical interpretation         right: zoomed in with 95% CI’s plotted
Figure 3: Influence of aortic arch flow on HC z-score throughout pregnancy
Bivariate regression analysis  was performed to assess the influence of aortic arch flow (clustering) 
on HC z-score throughout pregnancy.
Dotted line green. . .  normal flow
Continuous line purple __ obstructed flow
Dashed line pink - - - reversed flow (HLHS) 
Comparison with growth curves of a normal population
Compared to the normal growth charts, fetuses with reversed aortic arch flow tended to 
have a smaller HC at 20 weeks of gestation (−0.20, 95% CI, −0.44 to 0.04) and fetuses with 
obstructed aortic flow tended to have a slightly larger HC (0.14, 95% CI, −0.12 to 0.40); 
however, these differences were non-significant (table S1). At 36 weeks of gestation, the 
normal flow group had a smaller HC z-score when compared to growth charts (-0.26, 
95%CI -0.41; -0.12). Even though HC < -2 SD was observed in 9.2% of HLHS fetuses at 
any point in pregnancy in our cohort (table S2), there were no significant differences in 
percentages of HC < -2 SD between the normal and abnormal flow in aortic arch groups. 
HC < -2 SD was also observed in 8.5% of fetuses with normal aortic arch flow and 5.0% 
of fetuses with obstructed aortic arch flow.
Confounders and multivariate analysis
Besides the variables of interest, the influence of possible confounders, such as 
parity and smoking, are displayed in table 3 in a univariate analysis. Cases in which the 
pregnancy was terminated, and fetuses from nulliparous women, showed a significantly 
smaller HC at midgestation. Maternal obesity resulted in larger HC with advancing GA. 
Variables of interest and possible confounders used as covariates in a multivariate linear 
mixed regression model are marked in table 3. In the multivariate model (table 4) no 
statistically significant influence of ascending aorta oxygen saturation and aortic flow on 
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the midgestational HC z-score was found. Of the possible confounders, only BMI above 
25kg/m2 remained significantly correlated with increasing HC growth (slope). 
Abdominal circumference
The AC z-score regression analyses in the overall group is summarized in table S3. The AC 
displayed a mean z-score of -0.05 (95% CI -0.15;+0.06) at 20 weeks of gestation, with 
a slight but not significant increase to a mean of +0.11 (95% CI -0.02;+0.24) at 36 weeks 
of gestation. Clustering of the cases according to ascending aorta oxygen saturation or 
aortic flow had no effect on the mean AC z-score at GA 20 or on the AC z-score slope 
with advancing GA (data not shown). 
Table 4: Multivariate effect estimations of influence on HC Z-score
Variables of interest
Influence on midtrimester HC      
 z-score (95% CI)
p
Overall estimation in all CHD 0.33† (0.04; 0.62)
Ascending aorta oxygen saturation 0.07
 Normal ref
 Mixed -0.32† (-0.63; -0.003)
 Low (TGA) -0.43 (-0.90; 0.03)
Aortic arch flow 0.6
 Normal ref
 Obstructed -0.14 (-0.48; 0.21)
 Reversed (HLHS) +0.11 (-0.31; 0.52)
Advancing GA (slope) ǂ -0.023† (-0.036; -0.010)
Confounders
Influence on midtrimester HC      
 z-score (95% CI) p
Smoking -0.31 (-0.73; 0.11) 0.1
Nulliparity -0.12 (-0.38; 0.15) 0.4
Pregnancy outcome 0.2
 Live born ref
 Termination of pregnancy -0.24 (-0.60; 0.11)
 Intrauterine fetal demise -0.76 (-2.15; 0.64)
Obesity on advancing GAǂ +0.03† (0.01; 0.05)
Type III Tests of Fixed Effects and estimates; Dependent Variable: z-score HC Verburg.
† statistically significant ǂ other variables, besides obesity, with possible effect on the advancing GA were not 
included in the multivariate analysis because the univariate effect size was bigger than p=0.1. 
GA gestational age; HC head circumference
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DISCUSSION 
This study shows that all fetuses with prenatally detected isolated CHD show a decline in 
head circumference (HC) growth with advancing GA, irrespective of aortic flow or oxygen 
saturation. However, the clinical relevance of this decrease is small, as the effect size 
compared to the HC growth charts of normal populations is small (mean HC z- score 
in all CHD combined -0.23, representing the 41st percentile, at GA 36 weeks). The most 
important finding of this study is that differences in the HC z-score growth slopes between 
the various CHD clusters were absent. Interestingly, fetuses with normal aortic flow and 
oxygen saturation (such as Ebstein’s anomaly, persistent left caval vein and ventricular 
septal defects(VSDs)) showed the same HC growth decline as fetuses with obstructed or 
reversed flow (such as HLHS) or low or intracardiac mixing (such as TGA and TOF). 
Our study confirms the reported smaller HC at birth in infants with severe CHD17-20, and 
recently a large population based study also reported smaller neonatal HC in less severe 
CHD32. Our data indicate that especially fetuses with TOF present with a smaller HC, 
which is already present at midgestation (z-score -0.67; 25th percentile). A midgestational 
smaller HC was nót evidently present in fetuses with reversed flow in the aortic arch 
(HLHS) and TGA, nor in the other types of CHD in our cohort. 
Strengths of our cohort are the consecutive, non-selective inclusion of all cases with 
prenatally identified CHD in 3 centers. The repeated measurements facilitated linear 
regression analysis of the prenatal growth, from 20 weeks of gestation until birth. The 
size of the cohort made it possible to analyze some specific types of CHD for the first 
time prenatally. Our clustering into various subgroups is very accurate due to high rates 
of postnatal or postmortem confirmation. 
Our study demonstrates fetal growth patterns in isolated CHD, irrespective of the severity 
of the defect. Up to date only nine studies assessed fetal biometrics, all with different 
case mixes, various methods of subclassification and heterogeneous findings13;16;23-28;33. 
Most authors reported smaller HC at midgestation23;27;28 or in the third trimester16;24;27;33. 
Subtypes of CHD such as TGA and TOF are rarely reported separately, and less severe 
CHD have never been reported solely. The differences with our study can be explained 
by the fact that reports might have included pre-selected, non-consecutive, severe 
CHD cases and were dominated by specific CHD such as TOF. Some reports may not have 
excluded all IUGR cases and follow-up after birth was not always available. Three of the 
studies focus on cohorts of fetuses with (developing) HLHS only12;23;26. In an MRI study of 
18 fetuses with HLHS, delay in cerebral development and volume growth was noted in the 
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third trimester, hypothesized to precede HC growth restriction34. Our study comprises 
the largest cohort of consecutive HLHS cases so far (n=76). We found a smaller HC at 
midgestation in fetuses with HLHS, but statistical significance was absent. The HC growth 
restriction (slope) with advancing GA appeared even less severe compared to other 
types of CHD. 
Our findings underline the uncertainty regarding the etiology of the smaller HC in fetuses 
with CHD. A direct relationship between aortic flow or oxygen saturation and small HC 
could not be established clearly. Our results point towards an influence of type of CHD 
on HC growth, but sample sizes are nonetheless too small to establish a direct relation. 
We postulate that the smaller HC in certain types of CHD may be caused by certain 
genetic or embryological developmental pathways. CHDs develop through multifactorial 
pathways35;36 and some of these factors might also influence fetal HC growth and brain 
development26;30. By excluding known genetic syndromes by postnatal examination or 
standard antenatal genetic analysis in our study, this influence has been corrected 
maximally. We are however limited by the discriminating power of the used diagnostic 
methods used. 
Placental dysfunction and smaller fetal weight could also play a role in smaller HC sizes 
of fetuses with isolated CHD. Suggestions for this mechanism have also been found by 
Sun et al., who described lower oxygen levels in the umbilical vein with MRI in fetuses 
with severe CHD21. Fetuses with CHD however do not appear to have smaller placental 
volumes37. In our study we excluded pregnancies complicated by placental dysfunction 
and found no evidence that AC growth is restricted in fetuses with severe CHD, nor that 
AC growth is influenced by the type of CHD. 
An important limitation is that data on long-term neurodevelopmental outcome are 
not available in our cohort. With regard to implications for parental counselling, this 
data would be highly informative.  It is known that children with severe CHD are at risk 
for ND, and previous studies suggest that prenatal (head) growth restriction in CHD 
fetuses might be associated with ND21;25. In our opinion, a clear relationship of the 
prenatal (neurodevelopmental) factors with long-term neurodevelopmental outcome 
has, however, not been firmly established so far27;33;38;39. Large case control studies with 
prenatal factors correlating to neurodevelopmental outcome are necessary.  
In conclusion, fetuses with diminished ascending aorta oxygen saturation, but mainly 
fetuses with TOF, appear to have a slightly smaller HC at GA 20 weeks, and HC growth 
is restricted in all types of CHD with advancing GA. The cause of these findings remains 
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elusive. In the instances where there were (statistically) significant differences in 
HC, measurements were still within normal range – raising the question of its clinical 
significance. Based on our findings, we propose to refrain from including possible 
prenatal indicators, such as reduced HC, in parental counselling for neurodevelopmental 





Supplemental data available online
Supplement 1: List of primary diagnoses per group 
Table S1: univariate comparison of HC with population means in different CHD groups
Table S2: percentages of HC below the 2.3rd  percentile (z-score <-2) in the various types 
of CHD
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Reply to: Head growth in fetuses with isolated congenital heart defects: lack 
of influence of aortic arch flow and ascending aorta oxygen saturation. 
J. S. Carvalho 
Ultrasound in Obstetrics and Gynecology 2016; 48: 282–284
Congenital heart disease (CHD) and long-term neurodevelopmental delay is currently 
one of the hottest topics in fetal cardiology, generating much interest among many 
specialists. A link between the two was first suggested some years ago, but its etiological 
basis seemed multifactorial. However, since shifting the focus of this link to fetal life, 
there is growing evidence that in-utero circulatory changes, caused by the heart defect 
itself, may be responsible for abnormal fetal brain development and perhaps long-term 
brain function. Accepting this causation is a tall order and caution is needed. An intuitive, 
yet simplistic, concept is that smaller heads contain smaller brains and perhaps this may 
be the starting point for some of the neurodevelopmental abnormalities reported in 
children and adults with CHD. Reports of a smaller head size in fetuses and neonates with 
CHD have often been interpreted to mean possible neurodevelopmental abnormalities. 
As a pediatric cardiologist, it was refreshing to read in the paper by Jansen et al. that the 
‘status quo’ can, and should, be questioned. Jansen’s is a well-conducted retrospective 
study of a relatively large cohort of fetuses with isolated mixed type of CHD. Fetal 
head circumference (HC) in mid-gestation and HC growth pattern were examined and 
compared with those in a normal population. Cases of CHD were clustered according 
to perceived characteristics of aortic blood flow (normal, obstructed, reversed) and 
ascending aorta saturation (normal, low, mixed). Briefly, the study showed a statistically 
significant decrease in HC growth with advancing gestational age in all groups of CHD, 
resulting in reduced head size in the third trimester (and at birth). Interestingly this 
was irrespective of aortic flow or saturation. At 20 weeks’ gestation, however, HC in 
CHD fetuses was not statistically different from that of the normal population, with the 
exception of those with tetralogy of Fallot. This is at variance with findings of other 
studies. The questions remain: do statistically significantly smaller heads at birth matter 
if absolute measurements fall within the normal range and is a slightly smaller HC 
clinically significant? Statistically smaller HC should not necessarily equate to abnormal 
brain development.
Naturally, there are inherent limitations to any retrospective study. Two methodological 
strengths should, however, be highlighted. The first one relates to the likely certainty 
that CHDs were actually ‘isolated’. Absence of other ultrasound abnormalities at the 
20-week scan and normal fetal karyotype offer no such guarantee but, in this study, 
which had a 70% live-birth rate, minimum follow-up time was 1 year, thus reducing the 
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likelihood of including syndromic CHD. Second, the growth charts used as the standard 
reference were derived from a similar Dutch population that was evaluated over a similar 
timeframe as that of the CHD cohort. However, the lack of long-term neurodevelopmental 
follow-up prevents firm conclusions from being drawn about clinical significance of 
the findings. This of course calls for larger, prospective controlled trials. But will these 
ever be possible? It is therefore important that we continue to explore retrospective 
data obtained and analysed in a sound manner. I look forward to reviewing a follow-on 
paper by the same group, comparing HC in this cohort with that of a cohort with non-
isolated CHD. Lastly, interpreting results goes beyond their statistical significance. Whilst 
small differences may influence future research on mechanisms that lead to altered 
fetal growth in cases of CHD, the long-term implications for the individual fetus that is 
diagnosed antenatally with isolated CHD are far from clear.
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Fetuses with isolated congenital heart 
defects show normal cerebral and 
extracerebral fluid volume growth: 
a 3D sonographic study in the second 
and third trimester
Fetal Diagnosis and Therapy 2019 Jan 17:1-9.
F.A.R. Jansen 









The aim of our study is to explore whether the cerebral growth is delayed in fetuses with 
CHD in the second and early third trimester.
 
Methods
A prospective cohort study was conducted in 77 CHD cases, with 75 healthy controls. 
3D cerebral volume acquisition was performed sequentially. The volumes of the fetal 
hemicerebrum and extracerebral fluid were compared by linear regression analysis, and 
the Sylvian fissure was measured.
 
Results
Between 19 and 32 weeks of gestation, 158 measurements in cases and 183 measurements 
in controls were performed (mean 2.2/subject). The volume growth of the hemicerebrum 
(R2=0.95vs0.95; p=0.9) and the extracerebral fluid (R2=0.84vs0.82, p=0.9) were similar. 
Fetuses with abnormal oxygen delivery to the brain have a slightly smaller brain at 20 
weeks of gestation (p=0.02), but this difference disappeared with advancing gestation. 




Our study shows no differences in cerebral growth, studied in an unselected cohort, 
with successive cases of isolated CHD. Even in the severest CHD cases, cerebral size is 
similar in the early third trimester. The cause and meaning of a shallower Sylvian fissure 
is unclear, possibly it is a marker for delayed cerebral maturation or it might be an 
expression of decreasing amount of extracerebral fluid.
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INTRODUCTION
 
Congenital heart defects (CHD) are associated with cerebral abnormalities and 
neurodevelopmental delay (ND), even in the absence of chromosomal or syndromic 
anomalies1;2. Neonatal ultrasound imaging studies demonstrate cerebral abnormalities in 
15-75% of neonates with CHD prior to surgery3-7. Most cerebral findings in CHD newborns 
are mild, such as asymmetrical widened ventricles and increased extracerebral fluid. 
Neonatal MRI studies report delayed brain maturation and signs of cerebral atrophy8. 
These findings led to the hypothesis that cerebral damage or altered cerebral 
development in fetuses with CHD already starts in the prenatal period, due to abnormal 
flow and oxygenation patterns9.
Imaging studies in fetuses with CHD also report brain abnormalities, such as delay 
in head growth and brainsparing in subgroups of CHD10-15. The prenatal studies are 
however dominated by series of severe CHD and left-sided CHD13,16,17, and some studies 
also included cases with non-isolated CHD18,19. The reported variables, such as head 
circumference and flow indices, are very heterogeneous and were assessed at different 
gestational ages15. Studies that perform multiple measurements per fetus, to assess 
changes over time, are very scarce. Furthermore, the methods to report the data vary 
between studies, hindering comparison and making general conclusion drawing difficult. 
Previous studies mainly focus on the third trimester, as this might be the period in which 
cortical folding and development accelerates. However, several studies show that at 
midgestation fetal head circumference might already be delayed in certain CHD, possibly 
even predicting developmental delay20-22.
The purpose of this study was to investigate fetal brain volume and volume growth with 
ultrasound, in fetuses with CHD in the second and early third trimester. Additionally, 
extracerebral fluid space was studied, and the total cranial volume was compared as 
well. We aimed to assess an unselected consecutive cohort of isolated CHD fetuses and 
compare them with healthy control fetuses. We hypothesized to find smaller fetal brain 
volume and higher extracerebral fluid levels in CHD.
METHODS
All women diagnosed with isolated fetal CHD referred to the LUMC between September 
2013 and May 2016 were enrolled in this study after informed consent. All consecutive 
cases, detected before 32 weeks of gestation, were included. Healthy controls were 
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recruited after a normal 20 weeks’ standard anomaly scan in a low-risk community 
practice, after informed consent. The research protocols were evaluated and approved 
by the local ethical committee. Exclusion criteria were ultrasound anomalies other than 
the CHD, coinciding genetic or syndromic defects (prenatally diagnosed or postnatally 
apparent) and multiple gestation. Minor additional findings were not excluded, such as 
single umbilical artery, enlarged nuchal translucency without chromosomal defects, and 
small for gestational age without signs of placental insufficiency. Gestational age was 
based on first-trimester ultrasound. In both groups, detailed sonography was performed 
after inclusion and repeated sequentially, after two to five weeks. The examinations 
were performed by experienced sonographers (FJ/AT/SE), using a Voluson E8 or E10 
(GE Healthcare ultrasound, Milwaukee, WI, USA) with a RAB 6-D probe. The examination 
included the measurement of the depth of the Sylvian fissure (see supplement 1). A 3D 
volume recording of the fetal brain was acquired at the plane of the head circumference 
measurement. 
Offline postprocessing was performed using GE 4D viewer version 16. Ext. 1. The 
observer was blinded to the clinical characteristics (presence or absence of CHD and 
gestational age). The Virtual Organ Computer-aided AnaLysis software tool (VOCAL, GE 
Healthcare) was used to manually trace the outline of the cerebral hemisphere, as well 
as the cavity of the hemicranium, excluding the infratentorial space and cerebellum. 
To achieve maximum visibility, we used the hemisphere furthest from the ultrasound 
probe (figure 1).  The detailed description of the tracing methods and the intra- and 
interobserver reproducibility analysis are described in supplement 1. The volumes of the 
cerebral hemisphere, extracerebral fluid spaces (including the lateral ventricle) and total 
hemicranial cavity were calculated in cm3.
The various heart defects (see supplement 3) were labelled according to the postnatal 
diagnosis (postnatal ultrasound). Major heart defects were defined as requiring surgery 
in the first year of life. Heart defects were grouped together for summary purposes 
as listed in table 1. For the statistical analysis CHD were clustered based on two 
aspects: oxygen delivery and flow to the brain. This method was previously described 
by our group21. For instance, the group with low or reduced oxygen delivery to the 
brain included transposition of the great arteries (TGA, low oxygen) and univentricular 
CHD (mixed oxygen), and normal oxygen group included pulmonary or aortic stenosis 
(AoS) and persistent left caval vein with small LV (PLVCS). The group with reversed or 
diminished aortic arch flow included aortic hypoplasia or coarctation (diminished flow) 
and hypoplastic left heart syndrome (HLHS, reversed flow), and the normal aortic arch 
flow group tetralogy of Fallot (TOF), TGA and double outlet right ventricle (DORV) – in the 
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absence of aortic obstruction. Irrespective of the other defects, several CHD can have 
left sided/aortic obstruction. When for example a DORV TGA case álso has a small aortic 
arch, they are categorized in group 2 diminished flow.
A
B
Figure 1: Tracing example of the hemicranium (A)  and hemicerebrum (B)
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Statistical analysis and data handling
Using the 3D measurements of the hemicerebral volume, extracerebral fluid volume and 
hemicranial volume, the extracerebral fluid-to-brain volume ratio was calculated, as well 
as the percentage of the hemicranium consisting of fluid (ventricular and extracerebral). 
The hemicerebral volume to estimated fetal weight ratio was calculated (brain-weight 
ratio). The depth of the Sylvian fissure was displayed as ratio of the inner biparietal 
diameter (BPD). To account for fetal growth, the relation of various variables with the 
advancing gestation was evaluated with scatterplots, and the linearity of the data was 
assessed. Volume measurements underwent a logistic transformation to facilitate linear 
regression (exponential growth model), and the natural logarithm (ln) of the measurements 
were used for further statistical analysis. Comparison of (ln of) measurements at 
various gestational ages (GA) was performed by comparing linear correlations (equality 
of regression) in different subgroups, using a linear mixed regression model. Data are 
presented as R2 or mean +/- SD. Group means are compared by independent-sample 
T-Test and percentages are compared by Chi2 analysis. P<0.05 was considered statistical 
significant. The sample size was reached as follows: at least 60 patients per group were 
required for the unpaired t-test to have 90% chance of detecting a difference in mean 
cerebral volume of 2 weeks (SD assumed 3 weeks) at the 1.7% level of significance. All 
analyses were performed in SPSS version 23.0.0.0 (IBM, Armonk, NY, USA).
RESULTS
Isolated CHD was diagnosed in 92 fetuses in the study period. Of these, 15 cases were 
excluded because of multiple gestation (n=3), postnatal genetic abnormalities (n=8) or 
a normal heart on postnatal ultrasound (these fetuses were suspected for coarctation; 
n=4). Thus, 77 cases were included for neurosonographic analysis. Postnatal confirmation 
was not possible in 12 cases (16%) in which pregnancy termination was chosen, because 
parents did not give consent for post-mortem examination. The type of CHD and the 
clustering with regard to cerebral oxygen delivery and aortic flow of the included cases 
are summarized in table 1, and a detailed description is available in supplement 3. Most 
CHD were major, and we included 8 minor CHD cases (10%). Secondly, we enrolled 75 
control cases. All control infants received a neonatal cranial ultrasound in the first week 
of life and showed normal postnatal development until at least 1 month postpartum. 
In total, 158 examinations in 77 cases (mean 2.1 measurements per case) and 183 examinations 
in 75 controls (mean 2.4 measurements per control) were performed between GA 19+0 and 
GA 31+4 (mean GA at inclusion in cases 24+2 and in controls 24+1; ns). In 13 recordings (4%), 
the volume measurements were not possible due to poor quality.
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Table 1: Types of included congenital heart defects and clustering on oxygen and flow
type of CHD number %
Hypoplastic left heart syndrome (HLHS) 9 12%
(other) Left ventricular outflow tract obstructions* 12 16%
Transposition of the great arteries (TGA) 13 17%
Hypoplastic right heart syndrome (HRHS) 8 10%
Tetralogy of Fallot/double outlet right ventricle – Fallot type 12 16%
Double outlet right ventricle - TGA type 6 8%
(un)balanced atrioventricular septal defect 4 5%
other major CHD** 5 6%
minor CHD*** 8 10%
 TOTAL 77
oxygen delivery  




reversed (HLHS) 9 12%
obstructed 17 22%
normal 51 66%
* includes aortic stenosis, shone syndrome, aortic arch hypoplasia or coarctatio, interrupted aortic arch.
** includes congenitally corrected TGA, complex defects with tricuspid atresia and TGA, and truncus arteriosus.
*** includes persistent left superior caval vein, (small) ventricular septal defect, (mild) pulmonary stenosis, right 
aortic arch and restrictive foramen ovale.
The results of the hemicerebral volumes and extracerebral fluid volumes are summarized 
in table 2. The mean volume of the hemicerebrum (32.9 vs 32.9 cm3, p=0.9) and 
hemicranium (49.9 vs 50.8 cm3, p= 0.7) were equal in cases compared to controls. The 
linear mixed regression model revealed no difference in hemicerebral volume growth 
(table 2, figure 2), nor in the hemicranial volume and the extracerebral fluid space (table 
2). The hemicerebral volumes and growth velocity were assessed by type of CHD.  The 
cluster with low or mixed oxygen delivery to the brain (grouped together as ‘abnormal’ 
oxygen) appeared to have a smaller hemicerebral volume at midgestation, compared 
to CHD with normal oxygen delivery to the brain (ln of hemicerebrum 2.69 vs 2.56; 
p=0.02). This difference disappeared with advancing gestation (at 28 weeks of gestation: 
ln of hemicerebrum 4.01 vs 3.97; p=0.3). Linear growth per week was slightly -but not 
significantly- different (abnormal oxygen +0.18 vs normal oxygen +0.16; p=0.07, figure 3). 
There were no differences in the hemicerebral volume or growth velocity between CHD 
cases with normal or abnormal aortic flow (linear growth per week +0.17 vs +0.17; p=0.9).
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Table 2: results of fetal hemicerebral and extracerebral fluid growth; cases versus controls
variable CHD controls
number 160   183    
3D measurement not possible 4   9    
  mean(SD)  R2 mean(SD)  R2 p-value 
GA at ultrasound (w+d) 24+2 (22d)   24+1 (21d)   0.9
estimated fetal weight (g) 732 (348)   741 (357)   0.8
volume hemicerebrum (cm3) 32.9 (17.3)   32.9 (17.0)   0.9
linear growth* per week +0.17 0.95 +0.17 0.95 0.2
volume hemicranium (cm3) 49.9 (24.6)   50.8 (25.3)   0.7
linear growth* per week +0.16 0.94 +0.16 0.95 0.3
extracerebral fluid volume**  (cm3) 16.9 (7.6)   17.1 (8.0)   0.6
linear growth* per week +0.14 0.89 +0.14 0.87 0.6
% ECF (of hemicranium) 35 (3.9)   35 (3.5)   0.6
linear decline per week -0.7 0.34 -0.6 0.24 0.1
fluid-brain ratio 0.54 (0.10)   0.54 (0.09)   0.6
linear decline per week -0.018 0.34 -0.014 0.24 0.2
brain-weight ratio 0.44 (0.05)   0.45 (0.05)   0.7
linear growth per week +0.001 0.26 +0.001 0.18 0.2
Sylvian-BPD ratio 0.146 (0.023)   0.153 (0.021)   0.004
linear growth per week +0.005 0.42 +0.004 0.40 0.5
* logarithmic transformation
** including lateral ventricles
CHD congenital heart defect; GA gestational age; w+d weeks+days; ECF extracerebral fluid; BPD biparietal diam-
eter; EFW estimated fetal weight
The extracerebral fluid volume, as well as the various ratios, were not significantly 
different, comparing cases to controls (table 2). The percentage of the hemicranium 
occupied by fluid trended towards diminishing with advancing gestation, as well as the 
fluid-to-brain-ratio. In the supplemental figures S1-S5, this trend can also be identified 
in the ventricular volume growth, sinocortical distance, ventricular index and lateral 
ventricle size measurements. These trends were, however, not statistically significant. 
The difference in relative depth of the Sylvian fissure (Sylvian-BPD ratio) between cases 
and controls reached statistical significance. CHD cases demonstrated a slightly shallower 
Sylvian fissure (mean ratio 0.146 vs 0.153; p=0.004, table 2); there was no significant 
change with advancing gestational age on this ratio (linear growth per week in cases 
+0.005 vs controls +0.004; p=0.5, figure 4).
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Figure 2: Linear regression of the volume growth of the hemicerebrum; cases vs controls
Linear regression of the logarithmic transformation of the hemicerebrum measurements. No statis-
tical differences were found (linear growth per week +0.17 vs +0.17; p=0.2)
Figure 3: Linear regression of the volume of the hemicerebrum; normal versus abnormal cere-
bral oxygen delivery
Linear regression of the logarithmic transformation of the hemicerebrum measurements. No statis-
tical differences were found (linear growth per week +0.16 vs +0.18; p=0.07)
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Figure 4: Linear regression of the Sylvian fissure depth
Linear regression of the relative Sylvian fissure depth (Sylvian-biparietal diameter ratio), a smaller 
ratio implicating a shallower Sylvian fissure. The mean ratio in cases was 0.146 vs 0.153 in controls; 
p=0.004. Linear growth per week did not differ between cases (+0.005) vs controls (+0.004; p=0.5).
DISCUSSION
In this prospective study of consecutive isolated CHD cases compared to controls, a 
significant difference in hemicerebral volume and volume growth was absent in the 
second and early third trimester. CHD cases with reduced cerebral oxygen delivery such 
as tetralogy of Fallot (TOF), double outlet right ventricle (DORV), transposition of the 
great arteries (TGA) and hypoplastic left heart syndrome (HLHS) show a slightly smaller 
hemicerebral volume at 20 weeks of gestation, but this effect disappears with advancing 
gestation. 
Previous MRI studies on brain volume or brain weight only report on third-trimester 
measurements, which makes comparison with our results difficult11,18,19,22-26. Smaller brain 
volumes are previously demonstrated in mixed CHD types in third trimester, but these 
studies comprise small cohorts and most importantly they report on selected (severe), 
non-consecutive cases, and some even included chromosomal abnormalities18,19. 
Smaller brain volumes in isolated HLHS cases in the third trimester have been reported, 
confirming the widely-accepted hypothesis that HLHS fetuses demonstrate prenatal 
cerebral developmental and growth delay25-27. Our study included only 6 cases of HLHS 
with repeated measurements, because termination of the pregnancy was frequently 
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chosen in cases with HLHS. In a retrospective cohort with 26 ongoing HLHS cases, we 
however did not find a deflecting head growth in this group21. When clustering our results 
on cerebral oxygenation or flow, no significant differences were identified either. 
To put our results in perspective further, in our previous retrospective study regarding 
head circumference (HC) in CHD, we also found that especially fetuses with TOF appear 
to have a small HC at midgestation21. This finding has also been reported in an MRI study 
in TOF fetuses22. The hypothesis that the specific type of heart defect, such as HLHS and 
TOF, might play an important role in fetal cerebral development has been suggested in an 
increasing number of studies10,13,26,28,29. When specific types of CHD are studied in depth, 
it was furthermore found that neonates with minor CHDs such as ventricular septal 
defects also demonstrate altered brain growth30, which was the rationale for us to include 
minor CHD in our current study. Also, in minor lesion PLVCS, with an enlarged coronary 
sinus and small left ventricle, it is generally accepted that there might be diminished 
flow in the aortic arch, therefore we decided not to exclude these lesions as well. The 
fact however that minor CHD and CHD that do nót influence cerebral oxygenation or 
aortic flow also show altered brain growth, indicates that factors other than flow and 
oxygenation might play a role in the pathophysiology of cerebral developmental variations 
in CHD. Focusing on severe CHD and theoretical oxygen delivery to the brain is therefore 
insufficient. Genetic or epigenetic factors may also be responsible, as CHD such as VSD, 
TOF and DORV are known to be specifically present in children with genetic syndromes. 
Another finding that supports this hypothesis is the fact that in TOF submicroscopic 
chromosomal aberrations with known and unknown significance are frequently found31,32. 
Our cohort is unfortunately too small to evaluate the data according to specific type of 
CHD. Larger, multicenter studies, focusing on specific cardiac lesions, with adequate 
genetic and postnatal neurodevelopmental follow-up, are needed to avoid case mix 
bias and/or selection bias, which are common methodological problems in the previous 
studies. The exploration of the role of small genetic aberrations is needed, such as small 
microarray variants and possibly whole exome sequencing variants.
Although we acknowledge that there is debate whether MRI or ultrasound is the most 
sensitive to detect brain abnormalities33-35, we deliberately chose to perform our study 
with ultrasound, because ultrasound is cheap and widely available. Therewith it allows 
sequentially repeated measurements in a growing fetus36-38. We chose to perform the 
measurements by hand, as the volume data were not suitable for (semi-) automatic 
volume calculation. Although manually tracing can be prone to interobserver error, our 
reliability analysis demonstrated excellent inter- and intraobserver variation, possibly 
because we chose to examine the easily visible distal hemisphere only. Examining the 
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distal hemicerebrum only might seem insufficient, due to asymmetry in the brain, 
however the fact that we randomly measured left and right hemispheres in cases and 
controls justifies this strategy. Our assessment of the brain volumes by VOCAL is slightly 
comparable to a study in 2015 by Zeng et al, studying complete intracranial volumes in 73 
CHD cases, in which a smaller cerebral volume in CHD in the third trimester was found39. 
However, Zeng et al. only included severe CHD with only a single measurement per case, 
did not report postnatal follow-up nor inter- and intraobserver variation analyses, and 
our VOCAL measurement rotation angle was more detailed (6 to 9 degree steps vs 30 
degree). Furthermore, in our experience, measuring the cerebral volume after GA 32 
becomes less reliable with ultrasound because of extensive shadowing. The latter can 
also be regarded as a drawback of our study, but we deliberately chose to assess the 
second and early third trimester, even though previous research has focused on the 
third trimester, as studies have demonstrated that in certain types of CHD, the possible 
delay in head growth is already visible at midgestation20-22.
Our report also includes various extracerebral fluid-to-brain ratio’s and basic assessment 
of cerebral gyrification in the Sylvian fissure40. Firstly, there appears to be a more rapid 
decrease in relative amount of extracerebral fluid in CHD fetuses, however this effect 
was not statistically significant. The Sylvian fissure furthermore is significantly shallower 
in fetuses with CHD. The clinical significance of these findings has yet to be unveiled. 
Possibly they are early markers of delayed cerebral maturation, delayed cortical folding 
or impending cerebral volume growth deflection. The Sylvian fissure has previously 
been reported to be shallower in CHD, when measured in a comparable manner as our 
method, but only in the third trimester41. However, these results should be interpreted 
with caution, as the depth of the Sylvian fissure - measured in this manner - partly 
depends on the extracerebral fluid shell around the cortex. Thus, the difference possibly 
is an expression of a smaller amount of extracerebral fluid in fetal CHD.  The depth of the 
Sylvian fissure maybe of predictive value regarding further neurodevelopment, but this 
finding has not been correlated to postnatal outcome yet and normal values in healthy 
fetuses have not been established either. Ultrasound has also been proven capable to 
analyze cerebral maturation with high detail42, but to our knowledge this has not been 
investigated in fetal CHD yet. Currently, our cohort is being analyzed further to report 
on more detailed cerebral maturation variables in the future.
Strengths of our study are multiple measurements per case, and reduction of selection 
bias by including all consecutive cases referred to our unit, deliberately including minor 
CHD cases as well.  Also, we excluded cases and controls with extracardiac abnormalities 
and/or genetic or syndromic anomalies, even if this was only apparent postnatally. The 
132
7
PART II: BRAIN DEVELOPMENT
inter- and intraobserver variation analysis demonstrated high concordance. Unfortunately, 
long-term neurodevelopmental outcome parameters are not available in our cohort yet. 
Also, brain volume analysis after GA 32 was deemed unreliable due to high levels of 
acoustic shadowing. This might be the period in which fetal cerebral growth is mostly 
affected. In our opinion however, neonatal studies so far cannot exclude that hypoxia in 
the first days of life in prenatally undetected cases are an important cause for the pre-
operative cerebral abnormalities. We state that a prenatal origin for neurodevelopmental 
delay in later life has not been irrefutably proven, especially in other CHD types than 
HLHS. Therapies like maternal hyperoxygenation should be used with caution, as it is not 
yet proven beneficial and might even cause less flow to the brain as it causes increased 
flow towards the pulmonary arteries, leading to a possible steal effect in the brain43-45.
In conclusion, our study shows no significant difference in hemicerebral volume, 
extracerebral fluid space and volume growth between fetuses with isolated CHD and 
controls. Only fetuses with specific lesions such as TOF, DORV and HLHS might have a 
slightly smaller brain volume at 20 weeks of gestation, but the effect-size is very small 
and wanes with advancing gestation. Fetuses with CHD do have a shallower Sylvian fissure. 
The etiology and consequences of these findings are unknown. Unfortunately, there are 
no known fetal ultrasound parameters available in the second trimester for prediction of 
neurodevelopmental outcome yet. 
Supplemental data available online
Supplement 1: Neurosonography and 3D assessment; reliability measurements.
Supplement 2: assessment of additional intracranial fluid measurements.
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A low incidence of preoperative 
neurosonographic abnormalities in 
neonates with prenatally detected 
congenital heart defects – 












To investigate whether neonates with prenatally detected congenital heart defects (CHD) 
demonstrate cerebral abnormalities on early preoperative cranial ultrasound (CUS)
scans, compared to healthy neonates, and to measure several brain structures to assess 
brain growth and development. 
 
Study design
Prospective cohort study. Between September 2013 and May 2016 all consecutive cases 
of prenatally detected severe isolated CHD were included. Neonatal CUS was performed 
within two weeks after birth, before surgery and in a healthy unmatched control group. 
Blinded images were reviewed for brain abnormalities and various measurements of 
intracranial structures were compared.
 
Results 
CUS was performed in 59 healthy controls and 50 CHD cases. Physiological CUS variants 
were present in 54% of controls and in 52% of CHD cases. Abnormalities requiring 
additional monitoring (both significant and minor) were identified in four controls (7%) 
and five CHD neonates (10%). Significant abnormalities were only identified in four 
CHD neonates (8%) and never in controls (p=0.04). A separate analysis of 8 additional 
CHD neonates after endovascular interventions demonstrated that arterial stroke 
was diagnosed in two cases that underwent balloon atrioseptostomy (BAS). Cerebral 
measurements were smaller in CHD, except for the cerebrospinal fluid measurements, 
which were similar to the controls.
 
Implications and relevance
The prevalence of significant preoperative CUS abnormalities in CHD cases was lower 
than previously reported, which may be caused by a guarding effect of a prenatal 
diagnosis. Arterial stroke occurred only in cases after BAS. As expected, neonates with 
CHD display slightly smaller head size and cerebral growth.
8
140 PART II: BRAIN DEVELOPMENT
INTRODUCTION
Congenital heart defects (CHD) occur in 7-8 per 1000 newborns and are responsible 
for significant morbidity and mortality1. Survival has increased over the last decades, 
but these infants remain at increased risk for neurodevelopmental delay (NDD)2-6. 
Until recently, this was assumed to result from perioperative cerebral injury, caused 
by hypoxia or thrombo-embolic events7;8. Abnormalities on neonatal MRI or cranial 
ultrasound (CUS) are also reported before surgery in 36% of CHD neonates, and include 
ischemic lesions, hemorrhage and delayed maturation9-20. It has been suggested that 
part of these abnormalities are caused by abnormal prenatal development of the brain, 
resulting from altered prenatal hemodynamics in CHD21. Several of the CUS studies are, 
however, hampered by selection bias caused by the inclusion of selected types of CHD 
and some included syndromic cases17-19. Furthermore, most studies assessed cases in 
which CHD was diagnosed after birth14,16,17,20. In severe CHD without a prenatal diagnosis, 
neonates may experience a period of hemodynamic collapse and hypoxia, which can 
cause damage to the brain, This could influence previous reported findings. Comparison 
with a control group was only reported in one of the seven preoperative CUS studies15 
and CUS was frequently performed weeks or months after birth16-18. Therefore the results 
of these studies cannot be applied to fetuses with a prenatally detected CHD.
We performed a prospective CUS study in prenatally detected, isolated CHD and 
compared the findings to a group of healthy controls. The primary aim was to investigate 
whether neonates with prenatally detected CHD demonstrate cerebral abnormalities on 
early preoperative CUS. The secondary aim was to measure several brain structures to 
assess brain growth and development in both groups. Our hypothesis was that neonates 
with CHD more frequently display CUS abnormalities and present with smaller brain 
structures and wider cerebrospinal fluid (CSF) compartments.
METHODS
We performed a prospective cohort study with controls. The institutional ethical 
committee approved the study protocol. Consecutive cases of neonates with prenatally 
detected and postnatally confirmed CHD, born between September 2013 and May 2016 in 
the Leiden University Medical Centre (LUMC) were included. Severe CHD was defined as 
the need of a therapeutic catheter intervention or cardiac surgery in the first year of life. 
An unmatched healthy control group with a normal second trimester anomaly scan was 
recruited in midwifery practices between August 2014 and May 2016. Exclusion criteria 
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were additional structural or genetic anomalies, birth before 35 weeks gestational age 
(GA), small for GA (birth weight below the 2.3rd percentile), maternal illnesses influencing 
placental function (pre-eclampsia, hypertension) and perinatal complications (such 
as perinatal asphyxia, hypoglycemia and congenital/neonatal infection). Besides the 
postnatal CUS, both groups had monthly prenatal neurosonography (up to 36 weeks 
of GA) which revealed no suspected abnormalities. Additional maternal and perinatal 
data were collected, including mode of delivery, GA at birth, head circumference (HC) 
and birth weight (BW, both expressed in z-scores), type of CHD and type of surgery or 
endovascular intervention. Follow-up data regarding neurodevelopment were distilled 
from clinical charts. The sample size was a result of the prenatal inclusion of the CHD 
cases necessary for chapter 7.  
Postnatal CUS was performed within 14 days after birth, preferably in the first postnatal 
week, but not on the first day of life, to allow the ventricles to open22. All scans were 
assessed for various ultrasound findings as listed below. All noted ultrasound findings 
were categorized in three categories: as a significant abnormality, a minor abnormality, 
or as a physiological variant (described in box 1). CUS was always performed before 
surgery. Because the aim was to study the intrauterine effects on the brain in CHD, 
cases in which CUS was performed after early endovascular interventions, such as 
balloon atrioseptostomy (BAS), were excluded from the primary analysis, and analyzed 
separately.
Box 1: Categorization of ultrasound findings
Significant abnormalities were defined as: any grade of P/IVH, persistent grade 2 PVE, cPVL, 
intraparenchymal lesions suspect for stroke and structural brain abnormalities.
Minor abnormalities were defined as: any variant or combination of variants with need for further 
assessment or CUS follow up, not included in the significant abnormalities group, such as a com-
bination of large/ multiple pseudocysts suspected for (congenital) infection or transient lesions 
(cysts, focal echodensities) with spontaneous regression.
Physiological variants were defined as: LSV, subependymal and choroid plexus cysts, grade 1 PVE 
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CUS assessment and -findings
All scans were assessed for the presence of: periventricular echogenicity (PVE) of the 
white matter; cystic periventricular leucomalacia (cPVL)23; peri- and intraventricular 
hemorrhage (P/IVH)24;38 non-physiologic echogenicity in the deep grey matter; suspected 
stroke; changes in echogenicity in the cerebellum and supra- and infratentorial congenital 
malformations. Lenticulostriate vasculopathy (LSV) and subependymal or choroid plexus 
cysts (CPC) were also noted. For the classification of PVE we used grade 1 (moderately 
increased echogenicity, (almost) as bright as the choroid plexus) and grade 2 ((smaller 
areas of) increased echogenicity, being obviously brighter than the choroid plexus)38. 
CUS was performed with an Aloka α 10 ultrasound system (Hitachi Medical Systems 
Holding AG, Switzerland) or a Toshiba Aplio 400 system (Toshiba Medical Systems B.V., the 
Netherlands). Scanning was performed routinely by the attending neonatologist or one 
of the investigators (FJ/SS), according to a standardized protocol through the anterior 
and mastoid fontanelles39. Images were digitally stored (Clinical Assistant, RVC B.V., the 
Netherlands) and reviewed at least 2 months after the initial recording by two separate 
investigators (FJ/SS), blinded to the patients’ names and the presence or absence of 
CHD. Discrepancies were solved by consensus. 
Cerebral measurements were performed offline (see supplement 1) and included the 
lateral ventricles, interhemispheric fissure, sinocortical and cavum septum pellucidum 
width, corpus callosum length, corpus callosum to fastigium distance, transcerebellar 
diameter and basal ganglia dimensions. An estimated intracranial volume was calculated 
according to the method of Graca25).The volume of the basal ganglia area was calculated 
according to the same method (see supplement 1).
Data management and statistical analysis
Categorical variables were summarized with frequency counts and percentages 
and compared using a Chi-square or Fischer’s exact test. Continuous variables were 
summarized with means/SD and compared using t-test or one-way ANOVA. To check 
for normality, we plotted outcome measures in a histogram. If data were not distributed 
normally we performed a Mann-Whitney-U non-parametrical test. In case of a linear 
correlation of a measurement with age, regression coefficients were compared in a 
generalized linear model. In these models we included the postmenstrual age (PMA) at 
CUS and the presence of CHD as covariates, as well as the interaction between age 
and CHD. Using a generalized linear model, the mean+SD at the PMA of 40 weeks was 
calculated. The inter- and intra-observer variations of the measurements were estimated 
with the interclass correlation coefficient. Analyses were performed with SPSS (version 




Isolated severe fetal CHD was suspected in 100 healthy women in the mentioned time 
period. The exclusion process is shown in the flow diagram, resulting in 58 infants with 
prenatally detected CHD and an early postnatal pre-operative CUS in which data were 
available for analysis. There were no neonates with CHD excluded due to low birth weight. 
The types of CHD are listed in table 1. The CHD group included 4 neonates which were 
part of a twin pregnancy: all were term born dichorionic twins with otherwise uneventful 
pregnancies. Eight CHD cases underwent (emergency) endovascular intervention before 
CUS was performed. These cases were analyzed separately, resulting in 50 CHD cases 
to be compared with controls. In the control group of 65 healthy singleton pregnancies, 
6 neonates were excluded due to maternal morbidity (hypertension/HELLP syndrome, 
n=2) or neonatal factors (small for GA n=1, GA at birth <35wks n=2, pneumonia n=1), 
resulting in 59 healthy controls. The characteristics of cases and controls are displayed 
in table 1. CHD cases were younger at birth and at CUS and had a significantly lower HC 
z-score. 
Flow diagram of inclusion process of CHD neonates
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Table 1: basic characteristics of study population
Controls n=59 CHD n=58 p-value
Neonatal characteristics
Male gender, n (%) 25 (42%) 34 (58%) 0.06
GA weeks at birth, mean ± SD 39.7 ± 1.3 39.0 ± 1.4 0.02
Range GA at birth, weeks+days 35+6 to 42+0 35+3 to 41+5
PMA weeks at CUS, mean ± SD 40.3 ± 1.3 39.3 ± 1.4 0.000
Range PMA at CUS, weeks+days 36+1 to 43+2 35+4 to 43+2
Postnatal age at CUS*, mean days ± SD 3.5 ± 2.5 2.1 ± 2.0 0.000
Range postnatal age, days 1-11 0-13
CUS after endovascular intervention‡, n (%) n/a 8 (14%)
HC cm,  mean± SD 35.2 ± 1.1 34.1 ± 1.5 0.000
HC z-score, mean ± SD 0.18 ± 0.84 -0.33 ± 0.96 0.02
BW grams, mean ± SD 3479 ± 415 3166 ± 524 0.000
BW z-score, mean ± SD -0.03 ± 0.87 -0.33 ± 1.06 0.1
Maternal characteristics
Age years,  mean ± SD 31.8 ± 4.6 30.9 ± 4.6 0.3
Smoking, n (%) 2 (4%) 5 (9%) 0.1
Induced labor, n (%) 19 (32%) 32 (55%) 0.006
Vaginal unassisted delivery, n (%) 47 (80%) 39 (67%) 0.07
First line/home delivery (midwife), n (%) 19 (32%) n/a
Type of CHD N Intervention‡
Left sided: AS / Ao hypoplasia /small left heart /CoAo/PLVCS with small LV 18 (31%) 1
Left sided: hypoplastic left heart syndrome 4 (7%) -
Tetralogy of Fallot or DORV-Fallot type 6 (10%) -
TGA 17 (29%) 6
Right sided: Ebstein’s anomaly / PS / PA-IVS / tricuspid atresia 5 (9%) -
Other: common arterial trunk, ccTGA, AVSD, DORV 8 (14%) 1
*Mann Whitney nonparametric test
Abbreviations: GA gestational age; PMA postmenstrual age; HC head circumference; BW birth weight; CHD con-
genital heart defects; CUS cranial ultrasound; CS caesarian section; AS aortic stenosis; Ao aorta; CoAo Coarcta-
tion;  DORV double outlet right ventricle; LV left ventricle; PS pulmonary stenosis; PA-IVS pulmonary atresia with 
intact ventricular septum; PLVCS persistent left vena cava superior; ccTGA congenitally corrected TGA; AVSD 
atrioventricular septal defect.
Frequencies of CUS findings are listed in table 2. No differences were found between the two 
groups regarding physiological variants. Abnormal CUS findings were present in 5 neonates 
with CHD (10%) (all singletons) and in 4 of controls (7%) (p=0.1). Of these, in 1 neonate 
with CHD (2%) and in 4 controls (7%) the CUS finding was considered a minor abnormality. 
Significant abnormalities were considered in 4 CHD cases (8%), but not in controls (p=0.04). 
Table 3 describes the patient and ultrasound characteristics of neonates with abnormal CUS 
findings. Two CHD cases (aortic arch hypoplasia, double outlet right ventricle (DORV)-Fallot 
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type) displayed persistent grade 2 PVE and 2 left-sided CHD cases displayed grade 1 IVH. 
In table 4, CUS findings of the 50 neonates before intervention, are compared to 8 CHD 
neonates who underwent CUS after an endovascular intervention, showing a (not statistically 
significant) higher prevalence of CUS abnormalities after endovascular intervention (10% vs 
37%, p=0.07). Arterial stroke, confirmed by MRI, only occurred in the post-intervention 
group (p=0.02). The two cases with stroke had a transposition of the great arteries (TGA) 
and underwent emergency BAS on their first postnatal day. 
For the analysis of measurements of the intracranial and basal ganglia area volumes we 
used 54 singleton CHD cases and 59 controls, see table 5. Most cerebral structures were 
smaller in neonates with CHD, when corrected for age at CUS. However, the TCD and CSF 
measurements did not differ significantly. To assess the influence of postnatal age at CUS 
and re-opening of the ventricles22, measurements of the CSF compartments were also 
corrected for postnatal day at CUS. These analyses (data not shown) did not differ from 
the results shown in table 5, and the measurements did not show a change with advancing 
(postnatal or postmenstrual) age, thus no statistical correction was performed.
Table 2: Frequencies (numbers  and percentages) of CUS findings in cases and controls.
Controls n=59 CHD n=50 p-value
Abnormal CUS finding 4 (7%) 5 (10%) 0.4
- Significant CUS abnormality - 4 (8%) 0.04
- Minor CUS finding 4 (7%) 1 (2%) 0.1
No variations *) 23 (39%) 19 (38%) 0.5
Physiological variants total */ 32 (54%) 26 (52%) 0.5
- Grade 1 PVE 12 (20%) 12 (24%) 0.4
- Lenticulostriate vasculopathy 16 (27%) 14 (28%) 0.5
- Choroid plexus cyst(s) 12 (20%) 10 (20%) 0.6
- Subependymal cyst(s) 8 (14%) 8 (16%) 0.5
- Any cyst(s) 16 (27%) 18 (36%) 0.3
- 2 or more variations present 13 (22%) 11 (22%) 0.6
Wide/plump ventricles ** 1 (2%) 4 (7%) 0.1
Asymmetric ventricles ** - 3 (6%) 0.09
Wide extra-axial spaces ** 3 (5%) 5 (10%) 0.3
*) normal CUS; 
*/ including cases with variants coinciding with CUS abnormalities; 
** subjective finding as interpreted by the reviewer; categorised as normal CUS variant
CUS cranial ultrasound; CHD congenital heart defects; PVE periventricular echogenicity
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age at CUS 
(days)
CUS physiological 
variants CUS finding + follow up
CHD cases
11 M Borderline HLHS 35+6 2 LSV
significant: grade 1 IVH, no major 
NDD (4 years old)
57 M
Aortic arch 
hypoplasia 37+0 4 SEP, grade 1 PVE
significant: grade 1 IVH, no major 
NDD (2 years old)
93 F
Aortic arch 
hypoplasia 41+0 2 LSV (bilateral), SEP
significant: persistent grade 2 
PVE, no cPVL on follow up CUS, 
loss to follow up.
65 M
DORV - Fallot 
type 40+5 1 -
significant: persistent grade 2 
PVE, no c PVL on follow up CUS, 
no major NDD (1,5 years old).
43 M Aortic stenosis 39+3 2 CPC, SEP
minor: multiple (large) CPCs/
SEP, CMV excluded. 
Deceased when 2 months old 
after perisurgical cardiac arrest 
with severe neurological damage.
Controls
4 F - 40+1 3 CPC, SEP, LSV
minor: multiple CPCs/SEP/
LSV, CMV excluded, no further 
follow up.
19 M - 39+4 1 SEP, LSV
minor: small (transient) focal 
abnormality in the basal ganglia, 
suspect for stroke, but normal 
on follow up CUS, no further 
follow up.
26 M - 41+1 2
large pericerebral 
CSF spaces
minor: mildly dilated lateral ven-
tricles and possible IVH, but no 
pathological findings on follow 
up CUS.
42 M - 37+1 4
large pericerebral 
CSF spaces
minor: cavum velum interposi-
tum cyst (12mm), spontaneous 
regression after 6 weeks, no 
further follow up.




immediate BAS. 38+5 1 -
significant: stroke in basal ganglia 
(MRI confirmation). Second inci-
dent: asphyxia after perisurgical 
cardiac arrest when 3 months 
old. Has global NDD (3 years old).
24 M
TGA. Postpartum 
immediate BAS. 36+4 1
large pericerebral 
CSF spaces
significant: middle cerebral 
artery stroke, persistent grade 2 





immediate BAS 39+1 3 LSV (bilateral)
minor: small (transient) focal 
abnormality in  the basal ganglia, 
suspect for stroke but normal on 
follow up. No NDD (2 years old).
Abbreviations: BAS balloon atrioseptostomy; CUS cranial ultrasound; DORV double outlet right ventricle; FO fo-
ramen ovale; GA gestational age *(weeks +days); HLHS hypoplastic left heart syndrome; TGA transposition of the 
great arteries; CMV cytomegalovirus; CPC choroid plexus cyst; CSF cerebrospinal fluid; SEP subependymal cyst; 
LSV lenticulostriate vasculopathy; PVE periventricular echodensity, grade 1 or 2; NDD neurodevelopmental delay.
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Significant CUS abnormality total 4 (8%) 2 (25%) 0.2
- Intraventricular hemorrhage 2 (4%) - 0.7
- Grade 2 PVE 2 (4%) 1** (13%) 0.4
- Stroke - 2** (25%) 0.02
Abnormal CUS finding (including minor) 5 (10%) 3 (37%) 0.06
** one case had both grade 2 PVE and stroke; 
CUS cranial ultrasound; CHD congenital heart defects; PVE periventricular echogenicity
Table 5: CUS measurements and estimations of intracranial and basal ganglia volumes.  
Controls n= 59 CHD n=54
mean SD mean SD p-value
Cerebrospinal fluid assessment
Sinocortical width (mm) 0.4 ± 0.4 0.3 ± 0.4 0.2*
Interhemispheric fissure (mm) 0.8 ± 0.5 0.7 ± 0.6 0.3*
Cavum septum pellucidum width (mm)** 1.7 ± 2.0 2.4 ± 1.5 0.8**
Ventricular index (mm)** 12.3 ± 2.1 12.6 ± 1.5 0.3**
Anterior horn width (mm) 0.8 ± 0.5 0.7 ± 0.5 0.1*
Thalamo-occipital distance (mm) 14.4 ± 2.2 14.3 ± 2.6 0.7†
Cerebral growth assessment
Basal ganglia volume (cm3)** 10.1 ± 1.7 9.6 ± 1.2 0.00**
Cranial volume (cm3)** 437 ± 67 398 ± 48 0.00**
CC length (mm)** 44.0 ± 4.3 42.5 ± 3.1 0.01**
CC to fastigium length (mm)** 50.3 ± 3.6 49.1 ± 2.5 0.01**
Pons diameter (mm)** 17.1 ± 2.1 16.5 ± 1.5 0.05**
Vermis height (mm)** 24.0 ± 3.0 23.1 ± 2.0 0.01**
TCD (mm)** 54.6 ± 3.6 54.0 ± 2.5 0.2**
CUS cranial ultrasound; CHD congenital heart defects; SD standard deviation; CC corpus callosum; TCD transcer-
ebellar diameter
* Mann Whitney nonparametric test
† independent sample t-test
** at 40 weeks of postmenstrual age; linear correlation; estimated with generalized linear regression model
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DISCUSSION
This study is the first to prospectively assess early neonatal, preoperative CUS findings 
in a cohort of neonates with prenatally detected CHD, and to compare the findings with 
CUS in healthy term born neonates. Significant CUS abnormalities, including IVH and 
grade 2 PVE, occurred in 8% of CHD neonates. The prevalence of CUS abnormalities in 
our study is much lower than the previously reported rates of 15-59%14-18. This can be 
explained by our strict definition of pathological findings, excluding physiological and 
minor variants. Another reason may be that we only included prenatally detected isolated 
CHD, (near) term born, without additional (genetic) pathology, and the separate analysis 
of cases with CUS after endovascular interventions. This avoids the inclusion of cases 
with possible neurological injury, for instance due to hypoxia after birth in undetected 
cases. We therefore state that prenatal detection of CHD might have a positive effect of 
the postnatal (neurodevelopmental) outcome26. Strengthening this statement is the fact 
that our cohort had a favorable ND outcome. 
The timing of the identified significant CUS abnormalities remains difficult to determine. 
In all cases extensive prenatal CUS up to 36 weeks of gestation revealed no abnormalities, 
but abnormalities were already visible within 1-4 days after birth. The neonates with 
grade 2 PVE had CHD with different hemodynamic effects (aortic hypoplasia, DORV), 
and the sample size is too small to establish an effect of the specific type of CHD. The 
two cases with grade 1 IVH both had a left sided CHD. Both cases were stable during 
transition and the early postnatal period. A higher prevalence of low grade IVH in 
newborns with various types of CHD has recently been described, and may be explained 
by a combination of cerebral immaturity and hypoxia and/or impaired perfusion27. 
Arterial stroke was diagnosed in two neonates that underwent BAS; an association that 
has been reported previously28,29.
Physiological variants and minor CUS abnormalities occurred as frequently in CHD 
neonates as in healthy controls. Examples of physiological variants are CPC, LSV and 
homogeneous grade 1 PVE within the first postnatal week. Previous studies found similar 
or lower frequencies of physiological variants in high-risk neonates, admitted to the 
neonatal ward for various reasons: Shin et al. found 22% LSV (vs 27% in our healthy 
cohort) and Norton et al found 12% CPC (vs 20% in our healthy cohort)30;31. Our slightly 
higher prevalence of physiological CUS variants may be due to the fact that we specifically 
searched for these findings, and to the use of new CUS equipment with high resolution. 




With respect to the cerebral measurements, we found a slightly smaller head 
circumference, a smaller intracranial volume and a smaller size of several brain structures 
in CHD neonates, when corrected for age, as found in previous studies10,17,32,33. In contrast 
to previous reports we did not find wider CSF spaces in CHD neonates. This may be 
explained by the fact that we scanned the CHD cases closer to birth and included 
prenatally detected CHD only. A longer interval between birth and surgery and lower 
oxygenation levels after birth are associated with cerebral lesions just before surgery29, 
34; the same (hemodynamic) factors might also affect the development of cerebral 
atrophy and widened CSF spaces. 
Previous authors have suggested that hemodynamic factors in fetal life already cause 
susceptibility for cerebral damage in CHD21. Our findings neither confirm nor deny this. 
Left sided CHD are overrepresented in our group with abnormal CUS findings (cases 11, 
57 and 93), indicating a possible effect of prenatal aortic flow. However, in our cohort, 
grade 2 PVE also occurred in DORV with uncompromised fetal and neonatal aortic flow. 
Previous studies could not identify a possible effect of prenatal cerebral oxygenation or 
aortic flow on fetal head circumference growth35;36. We therefore are not convinced that 
prenatal hemodynamics are a major cause for fetal or early neonatal cerebral damage. 
Other factors, such as (epi)genetic changes, might also be involved in the susceptibility 
for cerebral damage and/or NDD.
Strengths of our study are the prospective inclusion of unselected, consecutive, isolated, 
prenatally detected CHD cases, and the comparison with healthy controls, recruited in a 
non-clinical midwifery practices. The most important CUS abnormalities were confirmed 
by MRI. Furthermore, we used regression models to correct for age.
An important limitation of our study is that we were not always able to perform 
(structured and ND) follow-up. The evolution of several CUS findings, including PVE grade 
1 in the first postnatal week, is unknown in most cases. However, in cases with (possible) 
significant abnormalities, we did perform CUS follow-up to see whether these abnormalities 
persisted. Secondly, our study design resulted in a slightly younger postnatal age of the CHD 
group, which could result in an overestimation of cerebral abnormalities in the CHD group. 
As described before, we  corrected cerebral measurements for gestational age at CUS to 
correct for the age difference. Finally, CUS may not be the optimal tool to detect all types of 
cerebral  injury, such as maturational delay or diffuse mild white matter injury13,16,18. However, 
CUS is a cheap, non-invasive and bedside method to detect clinically relevant abnormalities 
and perform growth measurements37. The use of CUS instead of MRI in our study made it 
possible to perform very early postnatal imaging in healthy controls and in CHD neonates 
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who were often too unstable to leave the neonatal intensive care unit. 
In conclusion, neonates with prenatally detected CHD display CUS abnormalities 
more frequently, and have smaller cerebral volume, compared to healthy neonates. 
The prevalence of significant cerebral abnormalities in our cohort is much lower than 
previously reported in mixed pre- and postnatally detected CHD groups. Therefore, 
abnormal neurodevelopment may only partly be explained by pre-operative cerebral 
injury in CHD. Acute severe hypoxia and/or chronic mild hypoxia in the period between 
birth and surgery may be important factors as well, and prenatal diagnosis of CHD may 
have a guarding effect.
Figure 1: Intraventricular hemorrhage in case 57
The arrow marks the place of the grade 1 IVH in CHD case 57.
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Figure 2: Example of lenticulostriate vasculopathy
The arrows mark the places of LSV in one of the control cases.
Figure 3: Example of various measurements performed through the anterior fontanelle
These measurements are performed in the third coronal plane at the level of the foramen of Monro. 
A sinocortical width; B interhemispheric fissure width; C width of cavum septum pellucidum.
Supplemental data available upon request: 
Supplement 1 - measurements performed.
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When future parents are confronted with a suspected fetal congenital heart defect within 
the severe spectrum, they will have many questions and fears. In the initial phase these 
questions focus often on the abnormal anatomy and the surgical procedures to correct 
those. Mortality risks are nowadays low in the majority of cases, but always leading to 
parental anxiety. After receiving information about the early postnatal outcome, follow 
up questions concern the uncertainty about the quality of life: Will our child be healthy, 
besides the scar on the chest? Will it be able to walk, talk, see, hear and function, 
comparable to its peers? Can it play sports? Will it be able to go to a normal school? 
The prognosis for a fetus with a congenital heart defect depends on several factors. 
First of all the severity of the defect plays an important role. Heart defects which need 
univentricular palliation surgery carry high mortality rates and subsequent morbidity 
during life. But most other defects have mortality risks below 10%. In these cases the 
outcome is largely determined by three factors: first is the type of surgical intervention(s) 
needed, the cardiopulmonary bypass time, and the risk of perioperative complications 
like hypoxia and thrombo-embolism, which can cause cerebral damage. Secondly, the 
outcome is determined largely by the presence of a genetic syndromes, which can be 
associated with neurodevelopmental delay and extracardiac malformations. Thirdly, even 
in children without genetic syndromes or perioperative complications, it is known that 
there is a chance of neurological injury and abnormal neurodevelopment. This might be 
already visible before or shortly after birth. This thesis is focused on the last two factors: 
the genes and the developing brain.
GENETIC ANOMALIES IN FETAL CONGENITAL HEART DISEASE
In the prenatal phase, on a case-by-case level, the presence of a syndromic abnormality 
may be suspected in the detection of additional malformations on ultrasound. Examples 
are a co-existing renal defect like renal dysplasia or a skeletal defect like hemivertebra 
or polydactyly. Some specific types of CHD are known to be highly associated with 
syndromic abnormalities, even in the absence of obvious additional defects. For instance, 
the complete atrioventricular septum defect (cAVSD) is associated with trisomy 21 (Down 
syndrome) in approximately 50% of the liveborn cases, and conotruncal heart defects 
such as tetralogy of Fallot (TOF) or truncus arteriosus are associated with 22q11.2 
microdeletion (Di George syndrome) in approximately 50% of the liveborn cases. 
Other types of CHD are more often seen as purely isolated lesions; in transposition of the 
great arteries (TGA) genetic syndromes are identified sporadically (<1%) and hypoplastic 




If there is a genetic syndrome, this often results in ND impairments, depending on the 
type and size of the genetic defect. In this thesis we investigated the frequency of 
submicroscopic genetic abnormalities in isolated CHD cases with a normal karyogram (in 
the absence large deletions/duplications and aneuploidies, such as trisomy 21), and we 
tried to specify which CHD are most affected by submicroscopic genetic abnormalities.
The data presented in this thesis indicate that clinically relevant genetic abnormalities 
can be found in all types of CHD using aCGH. New techniques, such as aCGH, offer the 
possibility to increase the diagnostic yield of genetic testing in CHD. The routine use of 
aCGH in the prenatal phase is leading to a paradigm shift, in which all types of CHD can 
be considered part of an associated genetic syndrome until proven otherwise. As a major 
benefit over karyotyping, the yield of aCGH expands beyond known genetic syndromes, 
and also includes susceptibility factors for ND delay or neurobehavioral disorders. 
Our recommendation is to offer detailed genetic testing, like aCGH, in all types of fetal 
CHD, even if the lesion is apparently isolated based on prenatal imaging, and even when 
the type of defect is usually not associated with syndromes. The outcome of detailed 
genetic testing is essential when estimating the likely outcome with regard to surgical 
prognosis, ND functioning and co-existing morbidities. Parents should always be offered 
this option. Detailed genetic testing should be preceded by rapid aneuploidy detection 
(RAD) to rule out large chromosomal aberrations first, as the most frequent genetic 
syndromes associated with CHD are aneuploidies, such as trisomy 21. Performing 
RAD first can save time and reduce health care cost; when the results are abnormal, 
submicroscopic testing can be omitted. Parents should be counseled about the slight 
risk of amniocentesis (rupture of membranes, infection and/or miscarriage) versus the 
possible yield of genetic testing. With the advancing options of non-invasive prenatal 
testing (NIPT), in the future amniocentesis might even be unnecessary.
In the period around the publication of chapters 2,3 and 4, aCGH has indeed been 
increasingly used in cases of prenatal structural anomalies, and it became the new 
standard in many fetal medicine units. A drawback of aCGH is, however, that single-gene 
disorders such as CHARGE, Kabuki and Noonan – which are also associated with CHD – 
will not be detected. In the Heart And NeuroDevelopment study cohort, up to 2016, we 
found two cases with a postnatal diagnose of CHARGE syndrome (in 90 live born children 
with apparently isolated CHD) in the absence of any signs prenatally. This diagnosis can 
be made by whole exome sequencing (WES), which at this moment is still time consuming 
and costly. If future parents consider termination of pregnancy, the genetic work-up 
must be ready before 24 weeks of gestation, the legal limit to perform pregnancy 
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termination in the Netherlands. Turnover time of WES can be reduced to several days, 
yielding it possible to use in prenatal medicine. At this moment WES gradually finds its 
way into the daily practice of prenatal diagnosis. We recommend to reserve WES to 
cases in which there are suspicions there might be a single gene disorder, for instance by 
the combination of a CHD with other (subtle) ultrasound variations. WES is relatively new 
in prenatal practice and has not proven its value in large clinical trials yet. 
The implementation of new techniques like aCGH and now WES in the prenatal setting 
has many advantages. The opportunity to identify syndromic cases prenatally, and 
therewith offering an estimation of ND functioning on the long term, greatly influences 
parental counselling and expectation management. However, implementation of these 
new techniques can also include some relevant downsides. New ethical dilemmas arise, 
for example around decisions to terminate a pregnancy or refusal for surgical repair. 
For some parents even a minimal genetic aberration might lead to the consideration 
of pregnancy termination, even when the phenotype is mild or uncertain. In other 
situations the refusal of genetic testing by parents, in cases that obviously appear to be 
syndromic with a dismal survival rate, might lead to the feeling of healthcare workers 
that some postnatal interventions might be disproportionate when the genetic syndrome 
is confirmed some weeks after birth. This can lead to conflicts between patients and 
healthcare workers, when patient demands collide with personal or institutional moral 
codes, financial constraints, cultural differences, and ideological divides. Guidance by an 
ethicist will increasingly be necessary when the advances of medical possibilities lead to 
an expansion of the morally grey areas.
Performing WES in a prenatal setting, under pressure of time, implies rapid and targeted 
exome analyses of panels of genes with known cardiac and/or syndromic involvement. 
In a short time a magnitude of data regarding genetic variations is produced which 
has to be categorised and valued. Comparable to the first experiences with aCGH in 
the prenatal setting, questions regarding the optimal WES platform and the method 
of categorization into (likely) benign and pathogenic remain important. It can be a 
challenging task for the clinical geneticist to decide which genetic variations to report. 
Genetic variants often display variable expressivity and genetic abnormalities might show 
decreased penetrance. Also, genetic syndromes have a wide spectrum of phenotypes 
varying from normal function to severely disabled. In the prenatal phase, the described 
phenotype is different and less complete than the postnatal phenotype because 
information about organ function, neurodevelopment and external features are missing. 
The clinical geneticist therefor does not have the complete picture yet to interpret the 




that prenatal detailed genetic analysis might not always render straightforward answers 
regarding the expected outcome, which results in challenges in subsequent parental 
counselling. 
Another difficulty of the introduction of aCGH and WES is the additional yield of 
unexpected secondary findings unrelated to the initial phenotype (such as BRCA mutation 
or susceptibility factors for autism) and polymorphisms with unknown significance, 
which could lead to parental anxiety and ethical dilemmas. Regarding the first, in some 
cases it can be disputable whether the fetus/child will benefit on the long term from 
the knowledge of carrying certain genetic variations; knowing may cause emotional, 
psychological or social harm. With respect to the second aspect, the frequency and 
clinical ambiguity of polymorphisms with unknown significance is fortunately decreasing 
rapidly with advancing experience. In our opinion, fear of polymorphisms with unknown 
significance and unexpected secondary findings should not be a reason to refrain from 
genetic testing from a clinical perspective. Parents, however, must be informed about 
this possibility, as they should be able to make a well-informed choice about whether 
to perform genetic testing or not. Counselling by a geneticist is crucial to interpret 
and explain abnormal findings. Future research regarding WES findings in fetal CHD will 
have to lead to the development of gene panels with known cardiac and/or syndromic 
involvement, to avoid secondary findings.
DEVELOPMENT OF THE BRAIN IN FETUSES AND CHILDREN 
WITH ISOLATED SEVERE CONGENITAL HEART DISEASE
In the absence of genetic syndromes, isolated CHD also show ND delays on the long term. 
This is presumed to be the result of cerebral injury. Cerebral damage can be sustained 
in the obviously risky and possible unstable period before and around cardiothoracic 
surgical repair. As stated in the introduction of this thesis, results from postnatal 
research indicate that the brain might already be at risk in the prenatal phase in CHD. 
In this thesis we assessed fetuses with apparently isolated CHD for signs of impeding 
cerebral impairment in the prenatal phase and very shortly after birth.
We conclude that it is indisputable that fetuses with certain types of CHD display 
cerebral variations more frequently than healthy controls. In our systematic review 
(chapter 5) we found higher incidences of abnormal cerebral flow and smaller HC, but 
these data are biased towards left sided CHD. Our study of HC growth as a proxy for 
brain development in CHD (chapter 6) points towards an influence of specific types of 
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CHD – such as HLHS and TOF. The clinical relevance as well as a pathogenesis of  these 
abnormalities remain to be determined, but there are several possible explanations. In 
this thesis we explored the possible pathogenic mechanism of altered hemodynamics, 
which is described hereafter. However, concomitant placental insufficiency seems to 
play an important role. An underlying common genetic pathway seems to be a logical 
explanation for the combination CHD, small fetal growth and cerebral variations.
As mentioned in the introduction of this thesis, a correlation between cerebral 
hemodynamics and fetal neurodevelopment in CHD has been suggested, referred to 
as the ‘altered hemodynamics theory’. It has been reasoned that the fetal brain in 
CHD suffers from a decreased flow to the carotid arteries (in cases of left ventricle 
obstruction with reversed aortic arch flow such as HLHS) and/or decreased oxygen 
delivery (in TGA, DORV and TOF). These phenomena might induce vasodilatation in the 
cerebral circulatory system, to facilitate transport of oxygen and nutrients. A lower 
middle cerebral artery (MCA) pulsatility index when compared to the umbilical artery 
(brainsparing) is a phenomenon observed in growth restricted fetuses. Some authors 
state that the same mechanism is present in CHD. This is not proven in an in-vivo setting, 
the cerebro-placental ratio (CPR) in blood flow has rarely been investigated in CHD, 
and data from the various studies as reported in chapter 5 are highly heterogeneous. 
There are reports of a lower MCA pulsatility index in left sided CHD, but this could also 
be attributed to a higher prevalence of growth restriction and placental insufficiency in 
CHD, which has not been clearly investigated yet. Brainsparing is correlated with worse 
ND outcome in growth restricted fetuses, but in CHD (irrespective of the presence or 
absence of growth restriction), a correlation of brainsparing with long-term outcome 
has not been established yet. On the contrary, it has even been suggested that it is 
associated with more favorable ND outcome in CHD. In a prospective cohort of 72 
single ventricle CHD cases, a low MCA pulsatility index was associated with higher scores 
on psychomotor assessment of ND at 14 months of age1.There are limitations to this 
conclusion, considering the small sample size of this particular study. 
To look for an effect of a theoretically decreased flow to the carotid arteries or a 
theoretical oxygen deficiency in the brain we investigated whether CHD clusters based 
on these aspects displayed variations in HC growth in the second or third trimester 
(chapter 6 ). We found no sign that cerebral oxygen deficiency or reduced cerebral flow 
results in a smaller HC or a deflecting HC growth. 
Following the altered cerebral hemodynamics theory, some centers actively advocate 




these measures should be applied with caution, as it is not yet proven beneficial and 
the underlying rationale is not robust. Hyperoxygenation might even cause less flow to 
the brain, as it causes vasodilatation in the pulmonary vasculature, leading to increased 
flow towards the pulmonary arteries, possibly leading to a steal effect in the brain2. As 
the etiology of ND damage in CHD is still a subject of debate, experimental therapies like 
these should not be advocated, as it might cause harm instead of benefit. 
As second possible explanation for smaller HC and abnormal flows in CHD is the known 
association of CHD with placental insufficiency. Children with CHD show growth restriction 
in a higher frequency than the general population, or do not reach the size which, 
according to the familial background, would be expected. In fetal growth parameters 
this would imply a similarly small - or an even smaller - abdominal circumference (AC) 
compared to HC, a common phenomenon in dysmaturity. This HC-AC ratio has been 
rarely investigated prenatally in CHD. Recent evidence has emerged that the smaller HC 
found in CHD is correlated to smaller fetal weight and fetal AC3. A new study performed by 
our own group demonstrated that the decrease in HC throughout gestation (as identified 
in chapter 6 in CHD in general) is most prominent amongst subjects with concomitant 
placental pathology, and we speculate that this is the most important attributor for 
reduced head size in CHD populations6. In our cohort (chapter 6) HC was within normal 
limits when cases with obvious placental pathology and syndromic cases were excluded. 
The discrepancy between our findings and other studies reporting a higher incidence of 
microcephaly in CHD could be explained by the fact that these other studies have not 
corrected for concomitant placental insufficiency.
The relationship between a reduced fetal HC and ND outcome in CHD has been studied, 
but it was never proven that fetal HC alone could predict ND delay in CHD. In a large 
follow up study of univentricular CHD, authors stated that decreased somatic overall 
growth might be an important predictor for ND impairment4. Postnatal studies have 
indicated that most of the neonates with CHD and smaller HC, implicating TOF and HLHS 
predominantly, are also small for gestational age (SGA) at birth. It is known that growth 
restriction (in the absence of CHD) is a risk factor for ND delay. 
A third possible explanation for cerebral variations in children with CHD could be a 
common genetic pathway causing fetal CHD combined with ND delay. This might also 
explain the association of fetal CHD with placental insufficiency. TOF is a defect which 
is highly associated with syndromic abnormalities and submicroscopical aberrations in 
array-profiles in many previous studies. In this thesis TOF has been identified to be at 
higher risk for smaller HC and cerebral volume - already at midgestation (chapters 6 
and 7). This strengthens our hypothesis that factors besides aortic flow and cerebral 
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oxygen saturation attribute to cerebral injury and ND delay. With the implementation of 
advanced techniques such as WES to perform a thorough genetic assessment in fetal 
CHD studies we will gradually gain more knowledge about the underlying genetic factors 
in CHD an concurrent ND delay. 
The fact that fetuses and neonates with types of CHD that do not have a significant 
effect on fetal hemodynamics (minor CHD), also demonstrate cerebral anomalies and a 
smaller HC supports our theory of underlying common genetic pathways. In our cohort, 
we deliberately included minor CHD, such as ventricular septal defects, besides severe 
CHD. Our analyses support findings in a large Danish postnatal cohort5 and indicate that 
these minor CHD show abnormalities in HC growth as well. The meaning for long-term 
ND outcome is however unclear. The further development of the fetal brain in less 
severe CHD and the correlation to ND outcome unfortunately has not been reported 
separately. 
Besides ultrasound data regarding HC and cerebral flows, there are surprisingly few 
studies performed with ultrasound to examine the developing brain in fetuses with CHD. 
Our cerebral volume study in chapter 7 included the assessment of the sylvian fissure. We 
found it to be more shallow in our CHD cohort. There are only a few comparable analyses 
in literature, which also implicate several gyri and sulci to be abnormal in CHD. Again, 
no relation to long-term ND outcome has been made yet, and the effect size of these 
findings (the extent of the actual delay of brain maturation) is unknown. Our HAND study 
group has yet to publish the results of neurosonographic assessment of cortical folding 
up to 36 weeks of gestation. It is important to already emphasize that we did not identify 
any significant cerebral lesions in the total prenatal cohort. We were therefore slightly 
taken aback that in our postnatal study (chapter 8) several significant cerebral lesions 
were identified by CUS in the CHD neonates. The timing and the origin of these lesions 
is debatable. Whether they were late prenatal or early postnatal cannot be deduced. 
The lesion types could implicate cerebral immaturity (prenatal origin) or hypoxic damage 
(presumably postnatal origin). Fetal ultrasound is less reliable in the late third trimester, 
as a result from the engaged head and acoustic shadowing. This might be the period in 
which fetal cerebral development, maturation and growth is affected in CHD.
As reviewed in chapter 5, several prenatal MRI studies have been performed in CHD 
fetuses, up to the later third trimester as well, but we found no statistical proof that there 
is a higher prevalence of cerebral MRI abnormalities or cerebral maturation delay in CHD. 
Important to note is that prenatal MRI studies included in our review, as well as postnatal 
ultrasound studies, differ in their definition of cerebral abnormality. Mild physiological 




our postnatal ultrasound study in chapter 8 we did not consider these minor variants as 
clinically relevant. We therefore conclude that in a prenatally detected group of CHD of 
various types (severe and minor), cerebral abnormalities are much less frequent then 
suggested in earlier literature. Previous literature has (unintendedly) greatly exaggerated 
the impact of prenatal cerebral ‘damage’. This leads to much debate on how to address 
these issues in prenatal counseling, how to be honest and clear about the reported 
associations with ND delay, but avoiding disproportionate parental anxiety. 
Whether MRI or ultrasound is the most sensitive modality to detect fetal brain 
abnormalities is disputable. Although MRI is capable of distinguishing white brain matter 
and abnormal gyration patterns, it has the disadvantage of high costs, less availability and 
large slice thickness. Just as in ultrasound, MRI is operator dependent. In experienced 
hands, ultrasound has also been proven capable to analyze cerebral maturation with 
high detail, and in our opinion it is not inferior to MRI. Reports of fetal neurosonography 
studies in fetal CHD are gradually emerging. Currently, the HAND-cohort is being analyzed 
further. Gyration patterns and the extent of the developmental delay are subjects under 
study. We are aiming to relate these data to the actual ND outcome on school age. 
CONCLUSION 
In short, in this thesis we found that clinically relevant genetic abnormalities can be 
detected in all types of CHD with aCGH. The yield of new genetic techniques expands 
beyond known genetic syndromes and can also include susceptibility factors for adverse 
ND outcome. With detailed prenatal genetic analyses we will increasingly be able to 
identify those at risk for ND delay. Second, certain types of CHD display fetal and early 
postnatal cerebral variations more frequently than healthy controls. We demonstrated 
that altered hemodynamics is unlikely to be the underlying pathogenic mechanism. Co-
existing factors like genetic variations, placental insufficiency and growth restriction 
underly the vulnerability of the brain in CHD to be damaged, which ultimately may 
predispose for ND delay. Thus far there are no known ways to influence or treat these 
co-existing factors. We consider hypoxia after birth, in the first hours and days of life, as 
a far more plausible cause of the found pre-operative cerebral abnormalities. Prenatal 
detection of CHD will ensure adequate postnatal care, that reduces acute severe or 
chronic mild hypoxia after birth to a minimum, thus prenatal detection will have a 
positive effect of the postnatal (ND) outcome.
The data in this thesis underline the importance of fetal neurological evaluation in all 
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CHD cases. However, it is too early to conclude that variations revealed by prenatal 
neuroimaging involve a high risk of ND delay. Parental counselling regarding ND outcome 
should be tailored, focussed on the type of CHD that has been identified. Genetic 
analysis must be offered to all parents, which should be performed with the option 
to obtain the highest available resolution. To define the clinical implication of prenatal 
cerebral variations in CHD, prospective large and long-term cohort studies are required, 
combining pre- and postnatal data, genetic analysis, and correcting for confounding 
factors. This will only be possible in multicentre multinational studies, leading to large 
cohorts. Whether there will be a role for prenatal neuroprotective measures, such 
as maternal treatment with hyperoxygenation, erythropoietin, acetylsalicylic acid or 
allopurinol, or peripartum measures such as early term induction of labor or postponed 
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Congenital heart defects (CHD) are associated with syndromal abnormalities and/or 
neurodevelopmental delay. The aim of this thesis was to analyze whether prenatally 
appearing isolated CHD are as a matter of fact really isolated, without postnatally 
apparent syndromes or neurological damage.
Firstly, in part I, this was done by assessing the additional value of a array comparative 
genomic hybridization (aCGH) and the potential value of whole exome sequencing (WES) 
in CHD. The main goal of these detailed genotyping modalities is to identify fetuses that 
are at high risk for a more severe phenotype, including long term neurological delay, 
additional abnormalities, other organ system involvement and dysmorphic features. This 
provides prognostic information for clinical outcome and could also inform the family 
about genetic reproductive risks. 
In chapter 2, a systematic review and meta-analysis of the literature up to September 2014 
on aCGH in fetal CHD is presented. aCGH yielded additional clinically valuable information 
in 7.0% of fetal CHD cases, even after karyotyping ànd 22q11 microdeletion analysis 
(with fluorescent in situ hybridization(FISH)) were normal. There were particularly more 
pathogenic copy number variants (9.3% CNV) when extracardiac defects were visible on 
prenatal ultrasound. This yield is lower when compared with published reports of aCGH 
in the postnatal setting of non-isolated CHD. When analyzing fetal CHD that appear 
isolated, an additional yield of aCGH of 3.4% CNV was found. There is no specific type 
of CHD  associated with aCGH anomalies, as the reported types of CHD with anomalies 
are heterogeneous. Ventricular septal defects (VSDs) with extracardiac malformations, 
conotruncal malformations (tetralogy of Fallot (ToF), interrupted arch) and left ventricle 
outflow tract malformations are common in prenatal cases which yield pathogenic aCGH 
results. However, also transposition of the great arteries (TGA) and cardiac heterotaxy, 
which are generally not considered to be associated with genetic syndromes, were found 
to have pathogenic aCGH results. 
We advise to perform aCGH as a replacement of FISH and karyotyping, since it has 
benefits over both. It should be preceded by rapid aneuploidy detection (RAD) - and 
only be performed if RAD is normal- to reduce healthcare utilization and costs. 
In chapter 3 the additional value of prenatal aCGH was investigated in a subgroup of 
left sided CHD. Left sided CHD as a group - end stage developmental defects including 




are generally considered nót to be associated with genetic syndromes, if they appear 
isolated on prenatal ultrasound. Therefore physicians may be reluctant to stress 
the need for fetal genetic sampling in prenatal counseling. Our study shows that in - 
apparently isolated - left sided CHD cases, in euploid fetuses (with normal karyotyping), 
aCGH can yield clinically significant abnormalities in 7%. 22q11 microdeletion is included 
in this yield. This risk of 7% appears to be unrelated to the presence of minor additional 
malformations such as enlarged nuchal translucency. With detail we elaborate on our 
abnormal findings, and the variants of unknown significance, and the way they may have 
affected the subsequent phenotype.  Our data serve as guide in focused prenatal 
counselling when genetic analysis is offered in left sided CHDs. 
Counselling parents whether or not to perform genetic testing in fetal CHD will always 
remain colored by the type of defect and the presences of additional anomalies. Our 
recommendation however is to offer aCGH in all types of fetal CHD, even if the lesion 
is apparently isolated based on prenatal imaging, and even when the type of defect is 
usually not associated with syndromes. The yield of array expands beyond known genetic 
syndromes, and also includes susceptibility factors for neurodevelopmental delay or 
behavioural disorders, for instance.
In chapter 4 an extraordinary case of a coinciding mitochondrial disease – identified 
with whole exome sequencing (WES) -  in a fetus with a small VSD is described. A 
VSD is a frequently occurring, usually mild (minor) type of CHD. However, in this case, 
fetal ultrasound also revealed polyhydramnios, periventricular cysts and cerebral 
hypoplasia. The neonate was born in a poor condition and the child died as a result 
of a severe metabolic disease. Targeted WES using a mitochondrial gene panel proved 
its benefit by revealing mutations in the FBXL4 gene, causing recessive mitochondrial 
encephalomyopathy, which was the cause of death. Prenatal testing was successfully 
carried out in the subsequent pregnancy to rule out recurrence. 
In part II, prenatal cerebral development in CHD is investigated. In chapter 5, a systematic 
review and meta-analysis of the literature up to November 2015 on this matter is 
presented, focusing on imaging of cerebral development in a very broad definition: fetal 
cerebral ultrasound and fetal brain magnetic resonance imaging (MRI). We conclude 
that the studies with abnormal cerebral findings mainly evolve around left sided CHD. 
The most studied ultrasound parameter is the middle cerebral artery (MCA; studied in 
1412 fetuses), which demonstrates a slightly increased end-diastolic blood flow in CHD. 
This means that there might be cerebral dilatation of the blood vessels, increasing the 
volume of blood flowing to the brain. This effect appears to be predominantly present 
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in left sided CHD. The MCA-flow appears not to be altered in TGA or right sided CHD. In 
the ultrasonographic head growth studies (753 fetuses), combining all types of CHD, a 
smaller head circumference (HC) throughout gestation is encountered, but, again, severe 
CHD - and especially left sided CHD - are overrepresented in these data. In postnatal 
studies, small HC has also been identified in less severe CHD, such as VSDs, which was 
not confirmed in prenatal studies yet. We did not encounter any fetal ultrasound studies 
assessing detailed neurodevelopment, such as cortical thickness, cerebral maturation 
or spinal fluid amount, even though neonatal studies report delayed brain maturation 
and cerebral atrophy in newborns with CHD and dedicated neurosonography has the 
capacity to detect most of the reported anomalies. 
Fetal brain development is increasingly being studied in CHD using fetal MRI (445 
fetuses). Reports on this topic are emerging rapidly, but the analysis of fetal cerebral 
volume, metabolism and maturation appears to be limited to research settings and have 
not have not yet been implemented in daily clinical practice. A summarizing conclusion 
cannot be drawn, due to variations in methods of measurement and analysis. Another big 
issue is that the definition of (the pathogenicity of) MRI lesions varies between studies, 
resulting in an overestimation of the prevalence of brain anomalies. We present a table 
to demonstrate the variation in reported cerebral anomalies. The total prevalence of 
reported anomalies might be 18%, but the 95% confidence interval ranges from -6 to 
42%. This means that there is high heterogeneity, much uncertainty and no statistical 
proof that there is a higher prevalence of cerebral MRI abnormalities in CHD. Fluid 
compartment (lateral ventricular) ‘anomalies’ do seem to be present in 4-19% of fetuses 
with CHD, but this includes asymmetrical lateral ventricles with normal sizes and mild 
dilation of the lateral ventricles, which can also be perceived as normal variants.
Eight studies (including 331 fetuses) correlated the fetal imaging modalities to postnatal 
neurodevelopmental outcome, but no solid conclusion can be drawn. Therefore, it is 
too early to conclude that aberrations revealed by neuroimaging, such as a higher MCA 
pulsatility index or a slightly smaller HC,  involve a high risk of neurodevelopmental delay.
In short, left sided CHD are associated with fetal cerebral abnormalities. In other CHD 
types, the groups are either too small or no significant difference with healthy controls 
is found.
Chapter 6 shows the results of a large retrospective analysis of HC growth in fetal 
CHD. We included the fetal biometrical data (1322 measurements) of 436 cases 
with a severe isolated CHD from 2002-2014. It has been hypothesized that in CHD 




neurodevelopmental delay. Our aim was to evaluate the effect of cerebral oxygenation 
and aortic arch flow on HC growth. This study was the first to demonstrate fetal growth 
patterns in isolated CHD, showing that all fetuses with prenatally detected isolated CHD 
demonstrate a decline in HC  growth with advancing GA, irrespective of aortic flow or 
oxygen saturation, irrespective of the severity of the CHD. Our study thus confirms the 
reported smaller HC at birth in infants with CHD, not only the severe types, but now 
also in minor CHD. The clinical relevance of this decrease is small, as the effect size 
compared to the HC growth charts of normal populations is small. Interestingly, fetuses 
with normal aortic flow and oxygen saturation (such as Ebstein’s anomaly, persistent left 
caval vein and VSDs) showed the same HC growth decline as fetuses with obstructed or 
reversed flow (such as HLHS) or low or intracardiac mixing (such as TGA and ToF). Our 
data also indicate that fetuses with ToF already demonstrate a smaller HC at 20 weeks 
of gestation. 
We conclude that variations in cerebral oxygenation or flow, caused by the hemodynamic 
changes in certain CHD types, cannot be the only explanation of the deflecting HC growth 
in CHD. Other causes such as concomitant placental insufficiency have to considered. An 
underlying common genetic pathway seems to be a logical explanation.
Chapters 7 and 8 describe analyses of the Heart and NeuroDevelopment (HAND) study, 
a prospective cohort of isolated CHD cases in which we performed extensive monthly 
neurosonography, compared to healthy controls. We aimed to avoid selection bias by 
including all cases with prenatally detected CHD when they appear isolated on fetal 
ultrasound. We deliberately chose to include minor, less severe types of CHD in this 
study as well, as previous studies have implied these to be at risk for deflecting HC and 
cerebral abnormalities as well. We started this HAND study cohort in 2013, and still have 
an ongoing inclusion up to date. In this thesis, we analyzed the data up to March 2017. 
We have added a group of healthy control fetuses, in which we performed the same 
measurements for comparison, between 2014 and 2016. 
In chapter 7  the results of the volume measurements of the brain in the second and early 
third trimester of the HAND study are shown, exploring the prenatal cerebral growth 
and evolution of the extracerebral fluid compartments. 77 consecutive fetuses with 
CHD and 75 healthy fetuses were analyzed, with multiple measurements per subject. 
We performed reproduceable, detailed 3D measurements of the (hemi)cerebral volume 
and extracerebral fluid spaces. Our study shows no significant difference in volume, 
extracerebral fluid and volume growth between fetuses with isolated CHD and controls. 
Only fetuses with specific lesions such as ToF, DORV and HLHS might have a slightly 
smaller brain volume at 20 weeks of gestation, but the effect-size is very small and 
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wanes with advancing gestation. Again, our results point towards the direction of an 
influence of CHD type, and not of cerebral flow or oxygenation.
Our report also includes various extracerebral fluid-to-brain ratios and assessment 
of cerebral gyrification in the Sylvian fissure. Firstly, there appears to be a more rapid 
decrease in relative amount of extracerebral fluid in CHD fetuses, however this effect 
was not statistically significant. Secondly, the Sylvian fissure is significantly shallower 
in fetuses with CHD. Possibly these are early markers of delayed cerebral maturation, 
delayed cortical folding, or impending cerebral volume growth deflection, but the clinical 
significance of these findings has yet to be unveiled. They might also be associated to 
extracerebral fluid compartment differences.
In chapter 8 the results of early postnatal and preoperative cranial ultrasounds 
(CUS) are compared between 50 neonates of the HAND study cohort and 59 healthy 
controls. Significant CUS abnormalities, such as intraventricular hemorrhage (IVH) and 
periventricular leukomalacia (PVL), occurred only in CHD neonates (8%). The prevalence 
of significant CUS abnormalities in our study was much lower than previously reported, 
in mixed pre- and postnatally detected CHD groups (up to 59%). This is probably due 
to our strict definition of pathological findings, excluding minor abnormalities (such as 
spontaneously resolving small cysts or transient echogenic white matter) as significant. 
Also we avoided to include cases with possible pre-existing neurological injury, for instance 
due to hypoxia after birth in undetected cases, or in cases that underwent a balloon 
atrioseptostomy (BAS) directly after birth. We therefore state that prenatal detection 
of CHD might have a positive effect of the postnatal (neurodevelopmental) outcome. 
A separate analysis of 8 CHD neonates after endovascular interventions demonstrated 
that arterial stroke was indeed associated with BAS. As expected, neonates with CHD 
display slightly smaller head size and cerebral growth. The cerebrospinal fluid (CSF) 
measurements however were similar in cases and controls. This may be caused by our 
short interval between birth and CUS - within the first week of life -, thus preceding the 
effect of chronic mild hypoxia, which might cause cerebral atrophy and widened CSF 
spaces.
This thesis is finalized by chapter 9, which provides a general discussion with summarizing 





Aangeboren hartafwijkingen als groep zijn de meest voorkomende aangeboren afwijking; 
ongeveer 0,8% van alle pasgeborenen heeft een hartafwijking. Ongeveer 75% van 
alle ernstige hartafwijkingen wordt prenataal opgespoord bij de 20 weken echo. Als 
toekomstige ouders worden geconfronteerd met het vermoeden op een ernstige 
aangeboren hartafwijking, zullen ze uiteraard veel vragen en angsten hebben. 
Initieel gaan deze vragen voornamelijk over de chirurgische procedures om het hart 
te corrigeren en de bijbehorende kans op sterfte. Gelukkig zijn de sterftecijfers van 
kinderen met aangeboren hartafwijkingen de laatste jaren steeds verder dalende. 
Vervolgens vragen veel ouders zich derhalve af wat de kwaliteit van leven van hun kind 
zal zijn: zal ons kind gezond zijn, naast het litteken op de borst? Zal hij of zij kunnen lopen, 
praten, zien, horen en functioneren, vergelijkbaar met zijn of haar leeftijdsgenoten? Kan 
hij of zij sporten? Zal hij of zij naar een normale school kunnen gaan?
In de prenatale fase kan de prognose van een aangeboren hartafwijking ingeschat worden 
aan de hand van verschillende factoren. Allereerst speelt de ernst van het defect een 
belangrijke rol. Kinderen die slechts één functionele hartkamer over zullen houden 
(univentriculaire harten), hebben een hoog sterftecijfer en een grote kans op ernstige 
ziekte tijdens het leven. Maar de meeste andere aangeboren hartafwijkingen hebben 
een sterftecijfer van minder dan 10%. In deze gevallen wordt de lange termijn uitkomst 
grotendeels bepaald door drie factoren. Ten eerste speelt het type chirurgische ingreep 
dat nodig is een rol, inclusief de duur aan de hart-longmachine. Bij elke ingreep is er een 
bepaald risico op complicaties rondom de ingreep - zoals zuurstofgebrek en de vorming 
van bloedpropjes in de hersenen - die hersenbeschadigingen kunnen veroorzaken. Ten 
tweede wordt de uitkomst grotendeels bepaald door de aanwezigheid van genetische 
syndromen, die veelal gepaard gaan met neurologische ontwikkelingsachterstanden. 
Bekende syndromen die vaak samengaan met hartafwijkingen zijn het syndroom van 
Down (trisomie 21) en het Di-George syndroom (22q11 microdeletie). Ten derde is het, 
zelfs bij kinderen zonder genetische syndromen of complicaties rondom de operatie, 
bekend dat er een kans is op neurologische schade en afwijkende ontwikkeling. Dit kan al 
zichtbaar zijn vóór of kort na de geboorte.
Dit proefschrift richt zich op de laatste twee factoren: de genetische afwijkingen en de 
zich ontwikkelende hersenen.
In het eerste deel van dit proefschrift wordt de potentiele additionele waarde van 
twee gedetailleerde genetische testen bij aangeboren hartafwijkingen onderzocht: 
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‘array comperative genomic hybridisation’ (aCGH) en ‘whole exome sequencing’ (WES). 
Het belangrijkste doel van deze tests is het vóór de geboorte reeds identificeren 
van kinderen die na de geboorte bijkomende problemen kunnen ontwikkelen, 
zoals ontwikkelingsachterstanden, bijkomende afwijkingen buiten het hart (andere 
orgaanbetrokkenheid) of een afwijkend uiterlijk. Dit biedt prognostische informatie voor 
zowel toekomstige ouders als zorgprofessionals om rekening mee te houden.
 
In hoofdstuk 2 wordt een systematische review en meta-analyse over aCGH in de 
prenatale fase van aangeboren hartafwijkingen gepresenteerd. Uit de vergelijking van 
diverse artikelen kan samengevat worden dat aCGH klinisch waardevolle bijkomende 
informatie oplevert in 7.0% van de gevallen, zelfs nadat syndromen zoals Down en Di-
George uitgesloten waren. Er waren met name meer aCGH afwijkingen (9,3%) wanneer 
naast het hart ook andere defecten zichtbaar waren op prenatale echografie. Ook als 
er naast het hart geen afwijkingen gezien werden, leverde aCGH in 3.4% van de gevallen 
een bijdrage. Er is geen specifiek type hartafwijking geassocieerd met afwijkende 
aCGH resultaten; eigenlijk bij alle typen werd wel een of meerdere keren een aCGH 
afwijking gevonden. Zelfs bij transpositie van de grote vaten (TGA) en hypoplastisch 
linkerhartsyndroom (HLHS), waar dit vaak niet bij verwacht wordt.
Wij adviseren om a CGH aan te bieden aan alle toekomstige ouders waarbij een hartafwijking 
bij de foetus vermoed wordt. De ‘oude’ genetische tests zoals FISH en karyotypering 
zouden hierdoor vervangen moeten worden. Om eerst grove chromosoomafwijkingen - 
zoals trisomie 21 - uit te sluiten, zou alvorens een aCGH verricht wordt ook een ‘rapid 
aneuploidy detection’ test gedaan kunnen worden, om tijd en kosten te besparen.
In hoofdstuk 3 wordt de toegevoegde waarde van prenatale aCGH onderzocht in 
een subgroep - linkszijdige hartafwijkingen zoals HLHS en aortastenose. Linkszijdige 
hartafwijkingen worden in het algemeen niet geassocieerd met genetische syndromen. 
Daarom zijn artsen vaak terughoudend om prenatale genetische tests te adviseren. 
Onze studie laat echter zien dat in schijnbaar geïsoleerde linkszijdige hartafwijkingen, 
bij euploïde foetussen (met normale karyotypering), aCGH in 7% van de gevallen toch 
relevante afwijkingen kan opleveren (inclusief 22q11 microdeletie/Di-George syndroom). 
Dit risico van 7% lijkt niet gerelateerd te zijn aan de aanwezigheid van kleine extra echo-
varianten, zoals een verdikte nekplooi (NT) of een navelstreng met een slagader tekort 
(SUA). 
Overkoepelend kan gezegd worden dat informatie over de kans op genetische afwijkingen 
bij hartafwijkingen altijd gekleurd zal blijven door het type defect, en de eventuele 




aCGH aan te bieden in alle gevallen van aangeboren hartafwijkingen, zelfs als er naast 
de hartafwijking geen bijkomende afwijkingen gezien worden op echografie, en zelfs als 
het type defect meestal niet geassocieerd wordt met genetische syndromen (zoals TGA 
en HLHS). De klinische relevantie van aCGH gaat verder dan de ‘bekende’ genetische 
syndromen, en omvat ook gevoeligheidsfactoren (susceptibility loci) voor bijvoorbeeld 
ontwikkelingsachterstanden en gedragsproblematiek.
In hoofdstuk 4 wordt een bijzonder geval beschreven van een foetus met een hartafwijking 
(ventrikel septum defect; VSD), die tevens een mitochondriale ziekte bleek te hebben. 
Een VSD is een vaak voorkomende, mild type aangeboren hartafwijking. In dit geval was 
er met foetale echografie echter ook te veel vruchtwater te zien (polyhydramnion), 
alsmede afwijkingen in de hersenen (periventriculaire cysten en cerebellaire hypoplasie). 
De pasgeborene werd in een slechte conditie geboren en stierf als gevolg van een 
ernstige stofwisselingsziekte. Gerichte ‘whole exome sequencing’ (WES) - met behulp 
van een gericht mitochondrieel gen-panel - onthulde mutaties in het ‘FBXL4-gen’, die 
de letale recessieve mitochondriële encefalomyopathie veroorzaakten. In de volgende 
zwangerschap kon een gerichte genetische test worden uitgevoerd om herhaling in een 
vroeg stadium uit te sluiten.
In het tweede deel van dit proefschrift wordt de hersenontwikkeling van foetussen met 
een aangeboren hartafwijking onderzocht.
Hoofdstuk 5 omhelst een systematische literatuurstudie en meta-analyse, gericht 
op beeldvorming van de ontwikkeling van de hersenen in een brede zin: foetale 
neurosonografie (echo) en magnetische resonantie (MRI). We concluderen dat met name 
ernstige, specifiek vooral linkszijdige, hartafwijkingen onderzocht zijn in deze studies. De 
meest bestudeerde echo-parameter is de doorbloeding van de arteria cerebri media 
(MCA; bestudeerd bij 1412 foetussen). Hieruit blijkt dat er bij hartafwijkingen vaker wordt 
gezien dat er een lage weerstand is in de cerebrale bloedvaten (cerebrale vasodilatatie), 
waardoor het volume van het bloed dat naar de hersenen stroomt mogelijk toeneemt. 
Dit effect lijkt voornamelijk aanwezig te zijn bij linkszijdige hartafwijkingen, en niet bij 
TGA of rechtszijdige hartafwijkingen zoals tetralogie van Fallot (TOF). In de echografische 
studies naar de hoofdomtrek (753 foetussen) wordt gezien dat bij aangeboren 
hartafwijkingen de prenatale hoofdomtrek gemiddeld kleiner is dan normaal. Opnieuw 
zijn ernstige hartafwijkingen - en vooral linkszijdige - oververtegenwoordigd in deze data. 
In postnatale studies werd gezien dat minder ernstige hartafwijkingen, zoals VSD’s, een 
kleinere hoofdomtrek bij geboorte hebben, maar dit is nog niet bevestigd in prenatale 
onderzoeken. Er werden geen prenatale echo-studies gevonden die gedetailleerde 
hersenrijping hebben bestudeerd, zoals corticale dikte, maturatie van de hersenplooien 
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of spinale vloeistofhoeveelheid. Foetale hersenontwikkeling wordt in toenemende 
mate wel nader bestudeerd met behulp van foetale MRI (445 foetussen). De analyse 
van foetaal cerebraal volume, metabolisme en rijping lijkt echter beperkt te zijn tot 
gespecialiseerde onderzoeksinstellingen en is nog niet doordrongen van de dagelijkse 
klinische praktijk. Een overkoepelende conclusie kan derhalve niet getrokken worden, 
vanwege grote variatie in onderzoeksmethoden. In de vergelijking van de MRI studies 
valt verder op dat ook de indeling van MRI-laesies flink verschilt tussen onderzoeken, 
en dat vele studies ook milde varianten meerekenen als afwijkend. Dit resulteert in 
een overschatting van het voorkomen van MRI afwijkingen. In totaal lijken foetale MRI 
afwijkingen gemiddeld bij 18% van de hartafwijkingen voor te komen, maar het 95% 
betrouwbaarheidsinterval van deze schatting varieert van -6 tot 42%. Dit betekent dat er 
een grote heterogeniteit, veel onzekerheid en geen statistisch bewijs is dat er überhaupt 
cerebrale MRI afwijkingen bij aangeboren hartafwijkingen voorkomen. Afwijkingen in de 
wijdte van de hersenvochtkamers (laterale ventrikel) lijken wel vaker voor te komen, bij 
4-19% van de foetussen met hartafwijkingen, maar deze afwijkingen zouden grotendeels 
ook als normale varianten kunnen worden waargenomen in een gezonde groep.
Acht studies (331 foetussen) correleerden de foetale beeldvorming aan de postnatale 
neurologische uitkomst, maar hier kan geen solide conclusie uit worden getrokken. Er is 
onvoldoende bewijs om te concluderen dat variaties gezien op MRI of echografie, zoals 
een hogere MCA doorbloeding of een iets kleinere hoofdomtrek, een verhoogd risico op 
neurologische ontwikkelingsachterstand met zich meebrengen.
Hoofdstuk 6 toont de resultaten van een grote retrospectieve analyse van de groei 
van de hoofdomtrek bij foetale hartafwijkingen. Onze studie was de eerste die foetale 
groeipatronen - met herhaalde metingen - bij geïsoleerde hartafwijkingen bestudeerde. 
We includeerden de foetale biometrie (1322 metingen) tussen 20 en 40 weken 
zwangerschap, van 436 foetussen met een ernstige geïsoleerde hartafwijking. Ons doel 
was om het effect van cerebrale oxygenatie en doorstroming op de groei van het hoofd 
te evalueren door de verschillende typen hartafwijkingen te clusteren in groepen met 
vergelijkbare hemodynamiek. In eerdere literatuur wordt immers verondersteld dat door 
de veranderde anatomie (afwijkingen in de ‘loodgieterij’) er afwijkende hemodynamiek 
ontstaat (verminderde cerebrale oxygenatie of flow) bij hartafwijkingen. Dit zou een 
oorzaak zijn van neurologische afwijkingen. Wij toonden aan dat álle foetussen met 
prenataal gedetecteerde geïsoleerde hartafwijkingen een afbuiging van de hoofdomtrek 
groei vertonen naarmate de zwangerschap vordert; ongeacht de cerebrale doorbloeding 
of zuurstofsaturatie. Onze studie bevestigt hiermee de gerapporteerde kleinere 




VSDs. De afbuiging is maar minimaal in vergelijking met de normale populatie, maar wel 
degelijk significant aanwezig. Interessant is dat foetussen met een “normale” aorta flow 
en zuurstofsaturatie (zoals Ebstein’s anomalie, persisterende linker vena cava en VSD’s) 
dezelfde groei-afbuiging vertoonden als foetussen met een geobstrueerde aorta (zoals 
HLHS) of theoretisch lagere zuurstofspanning in de hersenen (zoals TGA en TOF). Onze 
gegevens wijzen er ook op dat elk type hartafwijking zijn eigen groeipatroon lijkt te hebben; 
zo hebben foetussen met TOF al een kleinere hoofdomtrek vroeg in de zwangerschap, 
bij 20 weken al. We concluderen dat de variaties in cerebrale oxygenatie of doorbloeding 
dus niet de (enige) verklaring kunnen zijn voor de afbuigende hoofdomtrek groei in deze 
groep foetussen.
Hoofdstukken 7 en 8 beschrijven twee analyses van de Heart and NeuroDevelopment 
(HAND) studie, een prospectief cohort met geïsoleerde aangeboren hartafwijkingen, 
ontdekt bij 20 weken zwangerschap, waarbij we uitgebreide maandelijkse neurosonografie 
uitvoeren. We zijn dit HAND cohort in 2013 gestart, en includeren nog steeds nieuwe 
gevallen. In dit proefschrift hebben we de gegevens tot maart 2017 geanalyseerd. We 
hebben tussen 2014 en 2016 een gezonde controlegroep toegevoegd ter vergelijking.
In hoofdstuk 7 worden hersenvolumes vergeleken, gemeten in het tweede en vroege 
derde trimester.  De data van 77 opeenvolgende foetussen met een hartafwijking en 
75 gezonde foetussen werden geanalyseerd, met meerdere metingen per persoon om 
de groei over tijd te evalueren. We voerden gedetailleerde 3D-metingen uit van het 
(hemi)cerebrale volume en de extracerebrale vloeistofruimten (liquor). Onze vergelijking 
toont geen significant verschil in hersenvolume, extracerebrale vloeistof ruimte of 
hersenvolumegroei. Alleen foetussen met specifieke typen hartafwijking (TOF, DORV en 
HLHS) lijken een iets kleiner hersenvolume te hebben bij 20 weken zwangerschap, maar 
dit trekt weer bij met vorderende zwangerschapsduur. Ook in deze studie wijzen de 
resultaten meer in de richting van een invloed van het specifieke type hartafwijking, en 
niet op veranderde cerebrale doorbloeding of zuurstofspanning, net als in hoofdstuk 6.
Dit hoofdstuk bevat ook verschillende analyses met betrekking tot de verhoudingen tussen 
de extracerebrale vloeistof en het hersenvolume, en beoordeling van hersenplooiing in de 
fissuur van Sylvius. Er lijkt een afname van de relatieve hoeveelheid liquor te ontstaan bij 
foetussen met een hartafwijking, maar dit effect is niet statistisch significant. Ten tweede 
is de fissuur van Sylvius minder diep bij foetussen met een hartafwijking. Mogelijk zijn dit 
beide vroege markers van vertraagde hersenrijping, vertraagde hersenplooiing (corticale 
gyrering) of dreigende afbuiging van volumegroei van de hersenen. De betekenis hiervan 
is nog niet helemaal duidelijk.
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In hoofdstuk 8 worden de resultaten vergeleken van vroege postnatale en pre-operatieve 
craniale echografie (CUS), tussen 50 neonaten van het HAND-studiecohort en 59 gezonde 
controles. Ernstige CUS-afwijkingen, zoals bloedingen en witte stof schade, kwamen 
alleen voor bij 8% van de pasgeborenen met een hartafwijking. Dit percentage (8%) 
is echter veel lager dan eerder gerapporteerd (rapportages variëren van 15 tot 59%). 
Dit komt waarschijnlijk door onze strikte definitie van wat afwijkend genoemd wordt, 
waarbij we de fysiologische varianten en afwijkingen die spontaan weer verdwenen 
hebben geëxcludeerd. Ook hebben we kinderen niet meegenomen in de analyse als zij 
mogelijk reeds bestaand neurologisch letsel hadden, bijvoorbeeld als gevolg van acuut 
zuurstofgebrek na de geboorte (als de hartafwijking nog niet ontdekt was), of kinderen 
die direct na de geboorte een katheter-interventie (zoals de Rashkind procedure) 
ondergingen. Wij denken daarom dat prenatale detectie van hartafwijkingen een positief 
effect kan hebben op de postnatale (neurologische) uitkomst. Een afzonderlijke analyse 
van 8 kinderen die een katheter-interventie ondergingen toonde aan dat 2 gevallen een 
herseninfarct hadden gekregen hierna; in de andere groep kwamen herseninfarcten niet 
voor. Er werden nog een aantal aanvullende analyses verricht: zoals verwacht hebben 
pasgeborenen met een hartafwijking een iets kleinere hoofdomtrek en hersenvolume. 
De metingen van de cerebrospinale vloeistof (liquor ruimten) waren echter hetzelfde in 
beide groepen. Waarschijnlijk komt dit omdat we de CUS vroeg na de geboorte hebben 
gemaakt; op dat moment heeft chronisch mild zuurstofgebrek nog geen kans gekregen 
om hersenatrofie (en daarmee verwijde liquor ruimten) te veroorzaken. Wij denken 
dat dit laatste een van de belangrijkste verklaringen is dat wij een lager percentage 
hersenafwijkingen hebben gevonden dan eerdere literatuur.
Dit proefschrift wordt afgesloten door hoofdstuk 9, waarin de resultaten in het algemeen 
worden bediscussieerd, samenvattende conclusies worden getrokken, en aanbevelingen 
gedaan worden voor toekomstig onderzoek. Er worden adviezen gegeven hoe in de 
prenatale setting ‘in de spreekkamer’ om te gaan met de relatie tussen hersenafwijkingen 
en hartafwijkingen. Als onderliggende medeverklaring voor de neurologische variaties bij 
kinderen met hartafwijkingen wordt ingegaan op mogelijke placentaire afwijkingen en/
of gezamenlijke genetische variaties, die zowel een hartafwijking, een groeivertraging, 
als neurologische schade zouden kunnen veroorzaken. Er wordt gespeculeerd over de 
aanvullende waarde van ‘whole exome sequencing’ in grote groepen hartafwijkingen, en 
de mogelijke bijkomende ethische dilemma’s alsmede de uitdagingen bij de interpretatie 
van de resultaten. Afgesloten wordt met de statement dat het nog te vroeg is om 
‘hersenbeschermende maatregelen’ (zoals zuurstoftoediening of bepaalde medicatie 
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aCGH  array comperative genomic hybridization
CNV  copy number variation
SNP  single nucleotide polymorphism
WES  whole exome sequencing
VOUS  variant of unknown significance
RAD  rapid aneuploidy detection
FISH  fluorescent in situ hybridization
Mb  Mega basepair (*106)
Kb  Kilo basepair (*103)
Cardiac terms
AS  aortic stenosis (LSOL)
AVSD  atrioventricular septal defect
BAS  balloon atrioseptostomy (rashkind procedure)
CAT  common arterial trunk
CHD  congenital heart defect
CoA  coarctatio of the aorta (LSOL)
DORV  double outflow right ventricle
FO  foramen ovale
HLHS  hypoplastic left heart syndrome (LSOL)
HRHS   hypoplastic right heart syndrome (RSOL)
iAA  interrupted aortic arch (LSOL)
LSOL  left sided obstructive lesion
MA  mitral atresia (LSOL)
PA  pulmonary atresia (RSOL)
PLVCS  persistent left vena cava superior (sometimes considered LSOL)
PS  pulmonary stenosis (RSOL)
RSOL  right sided obstructive lesion
TA  tricuspid atresia (RSOL)
TI  tricuspid insufficiency
TGA  transposition of the great arteries
TOF  Tetralogy of Fallot (RSOL)





MCA  middle cerebral artery
PI  pulsatility index
MRI  magnetic resonance imaging
US  ultrasound
CUS  cranial ultrasound
VOCAL  Virtual Organ Computer-aided AnaLysis, tool to perform volume 
  calculation
CPC  choroid plexus cyst
LSV  lentriculostriate vasculopathy
BPD  biparietal diameter
HC  head circumference
AC  abdominal circumference
EFW  estimated fetal weight (usually based on HC, AC and FL)
FL  femur length
PVE  periventricular echogenicity
CSF  cerebrospinal fluid
Other
ND  neurodevelopmental
NDD  neurodevelopmental delay
GA  gestational age
PMA  postmenstrual age
SD  standard deviation
RE  random effects
Frequently used terms
z-score  the number of standard deviations from the mean (a z-score of -1 
  equals 1 standard deviation below the mean)
Isolated CHD without additional structural malformations and without apparent 
  genetic anomalies
Severe CHD Major CHD – requiring surgery or transcutaneous intervention when 
  <1 year of age. (examples: HLHS, TGA, TOF, CAT, etc)
Minor CHD mild CHD -  transient or without necessity of surgical or otherwise 
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